US Pat. No. 10,711,300

METHODS AND COMPOSITIONS FOR DELIVERY OF MOLECULES AND COMPLEXES TO REACTION SITES

Pacific Biosciences of Ca...

1. A method of delivering polymerase enzyme complexes to nanoscale wells, the method comprising:(a) providing a substrate comprising an array of nanoscale wells;
(b) coating the top surface of the substrate between the nanoscale wells with a positively charged molecule to form a coated surface;
(c) applying a composition comprising polymerase enzyme complexes to the coated surface such that at least a portion of the polymerase enzyme complexes attach to the positively charged molecules, wherein the polymerase enzyme complexes comprise template nucleic acids complexed with polymerase enzymes; and
(d) after step c), releasing the polymerase enzyme complexes from the positively charged molecules to allow the polymerase enzyme complexes to passively diffuse into the nanoscale wells,thereby delivering polymerase enzyme complexes to the nanoscale wells.

US Pat. No. 10,711,296

DIRECTIONAL AMPLIFICATION OF RNA

Sigma-Aldrich Co. LLC, S...

1. A process for directionally amplifying RNA, the process comprising:(a) reverse transcribing at least one RNA molecule in the presence of a plurality of first synthesis primers to generate a plurality of first strands of complementary DNA (cDNA), each of the first synthesis primers comprising a 3? sequence having complementarity to a portion of the RNA molecule, a 5? sequence corresponding to one or more methylated amplification primers, and optionally an internal tag sequence comprising a first tag sequence;
(b) replicating the plurality of first strands of cDNA in the presence of a plurality of second synthesis primers to generate a plurality of double-stranded cDNA products, each of the second synthesis primers comprising a 3? sequence having complementarity to a portion of the first strands of cDNA, a 5? sequence corresponding to the one or more methylated amplification primers, and optionally an internal tag sequence comprising a second tag sequence, provided that either one or both of the pluralities of first and second synthesis primers comprises the internal tag sequence such that each double-stranded cDNA product is flanked by either the first or second tag sequence or both the first and second tag sequences; and
(c) amplifying the plurality of double-stranded cDNA products in the presence of the one or more methylated amplification primers to generate an amplified library of cDNA products;
wherein the 5? sequence of the first and second synthesis primers further comprises at least one binding element for a methylation-dependent restriction enzyme, and
wherein the amplified library of cDNA products is contacted with the methylation-dependent restriction enzyme.

US Pat. No. 10,711,294

NUCLEIC ACID ANALYSIS DEVICE

HITACHI HIGH-TECH CORPORA...

1. A nucleic acid analysis device comprising:a flow cell for use in analysis of nucleic acid having a substrate,
the substrate having a plurality of analysis areas partitioned on the substrate,
each of the analysis areas having a plurality of absorbent portions capable of absorbing a DNA fragment or a vector where the DNA fragment is borne,
at least one of the analysis areas having the plurality of absorbent portions and a non-absorbent portion other than the absorbent portions, and at least a part of the non-absorbent portion defines a first marker portion having a predetermined shape disposed at a center of the respective analysis area and plural second marker portions each having respective predetermined shapes and disposed at corners of the respective analysis area;
a piping connected to the flow cell to pass a fluid through a flow passage of the flow cell;
a temperature control device that controls a reactive temperature of the flow cell;
a light source that irradiates excitation light onto the at least one of the analysis areas serving as an analysis target;
a detection unit including a detector that detects fluorescence emitted from the analysis target by irradiating the excitation light thereon; and
a stage configured to support the flow cell and a driving motor configured to move the stage,
wherein, in each of the at least one of the analysis areas, straight lines obtained by linking the respective second marker portions are separated from the respective first marker portion by a same distance.

US Pat. No. 10,711,290

TRANSFORMED FUNGUS HAVING ENHANCED ERGOTHIONEINE PRODUCTIVITY AND METHOD FOR PRODUCING ERGOTHIONEINE

KIKKOMAN CORPORATION, No...

1. A transformed filamentous fungus comprising a gene encoding an enzyme (1) or genes encoding enzymes (1) and (2) inserted therein and can overexpress the inserted gene or genes,wherein the gene encoding the enzyme (1) is a gene having the base sequence set forth in SEQ ID NO: 1, 23 or 33, or the enzyme (1) is an enzyme having the amino acid sequence set forth in SEQ ID NO: 4, 26 or 34, and
wherein the gene encoding the enzyme (2) is a gene having the base sequence set forth in SEQ ID NO: 2, 3, 24 or 25, or the enzyme (2) is the enzyme having the amino acid sequence set forth in SEQ ID NO: 5, 6, 27 or 28, wherein the enzyme (1) catalyzes the reaction in which hercynyl cysteine sulfoxide represented by the following formula (I)

is produced from histidine and cysteine in the presence of S-adenosylmethionine, iron (II), and oxygen; and wherein the enzyme (2) catalyzes the reaction in which ergothioneine is produced from hercynyl cysteine sulfoxide using pyridoxal 5?-phosphate as a coenzyme.

US Pat. No. 10,711,269

METHOD FOR MAKING AN ASYMMETRICALLY-TAGGED SEQUENCING LIBRARY

Agilent Technologies, Inc...

1. A method for making an asymmetrically-tagged sequencing library, comprising:(a) obtaining a symmetrically-tagged library of cDNA or genomic DNA fragments, wherein at least some of the members of the library comprise a top strand comprising a 5? sequence tag and a 3? sequence tag, wherein the 5? and 3? sequence tags comprise complementary sequences;
(b) hybridizing a first primer to a region of the 3? sequence tag of the library, wherein the first primer comprises a 3? region which is complementary to said region of the 3? sequence tag of the library, and a 5? non-complementary tail;
(c) extending the first primer to produce primer extension products that comprise, from 5? to 3?, the sequence of the first primer, a sequence of a fragment, and the complement of a 5? sequence tag of (a); and
(d) amplifying the primer extension products of (c) using:
i. a forward primer comprising sequence A4; and
ii. a reverse primer of formula A5-A2, wherein sequence A5 is a 5? tail and sequence A2 is contained in the 5? sequence tag of (a);
to produce an asymmetrically-tagged library in which at least some of the members comprise a top strand comprising i. a first end comprising sequence A5, ii. the sequence of a fragment, and iii. a second end comprising the complement of sequence A4.

US Pat. No. 10,711,268

METHOD FOR PRODUCING PEPTIDE LIBRARY, PEPTIDE LIBRARY, AND SCREENING METHOD

The University of Tokyo, ...

1. A method for producing a peptide library including 1×106 or more peptides containing amino acids encoded by N1N2N3, comprising:a step of preparing an mRNA library including mRNAs which encode peptides of the peptide library, respectively, and each contain a plurality of N1N2N3s; and
a step of translating each of the mRNAs of the mRNA library in a cell-free translation system added with a tRNA containing an anticodon to any of N1N2N3 codons and charged with an amino acid corresponding to the codon,
wherein N1, N2, and N3 are each independently selected from adenine (A), guanine (G), cytosine (C), and uracil (U); and an arbitrary amino acid is reassigned to each N1N2N3 and N1N2U codons are reassigned to non-proteinogenic amino acids, and
wherein the amino acids encoded by N1N2N3 contain a non-proteinogenic amino acid selected from cyclic N-alkyl amino acids represented by chemical structures 2 to 22:

US Pat. No. 10,711,265

ELECTROPHORESIS ASSISTED METHOD FOR PURIFYING A TARGET NUCLEIC ACID USING A DELAYED ELUTION APPROACH

Qiagen GmbH, Hilden (DE)...

1. An electrophoresis assisted method for purifying a target nucleic acid from a nucleic acid containing sample, comprising(a) binding the target nucleic acid to a solid phase;
(b) placing the solid phase with the bound target nucleic acid into a loading chamber of a device, wherein the device comprises a passage which comprises the loading chamber and a liquid permeable collection matrix and wherein the solid phase with the bound target nucleic acid is present in the loading chamber in a liquid medium comprising at least one water-miscible organic solvent and wherein the target nucleic acid remains bound to the solid phase in said liquid medium;
(c) generating an electric field between a cathode and an anode and using a running solution that conducts the electric current, wherein the running solution dilutes the liquid medium comprised in the loading chamber resulting in elution of the bound target nucleic acid, and wherein the eluted target nucleic acid migrates according to its charge in the electric field and is retained by the collection matrix;
(d) collecting the purified target nucleic acid.

US Pat. No. 10,711,263

METHOD FOR EXTRACTING POLYHYDROXYALKANOATES (PHAS)

NATIONAL CHI NAN UNIVERSI...

1. A method for extracting polyhydroxyalkanoates (PHAs), comprising the following steps:a pre-process step: removing water from waste sludge containing microorganisms so that the waste sludge containing microorganisms has a water content of less than 40%; and
an extraction step: by utilizing a electroporation, applying a high-voltage pulsed electric field to the waste sludge to destroy the microorganisms and release polyhydroxyalkanoates (PHAs), wherein the high-voltage pulsed electric field is between 50 volts and 400 volts, an application time of the high-voltage pulsed electric field is between 5 seconds and 90 seconds, and an application frequency of the high-voltage pulsed electric field is between 500 Hz and 1000 Hz.

US Pat. No. 10,711,261

TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES

Brandeis University, Wal...

1. A stabilized analogue comprising a first Protein X and a second Protein X cross-linked to one another by a compound of Formula I or a compound of Formula II, whereinthe first Protein X comprises a first cysteine residue and has at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to CAC88866.1;
the second Protein X comprises a second cysteine residue and has at least 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to CAC88866.1;
the compound of Formula I is

wherein
Y is S, S?O, or S(?O)2;
n is 0, 1, 2, 3, or 4; and
R is independently selected from the group consisting of —H, —OH, —NH2, —NHR?, —N(R?)2, alkyl, —OMs, —OTs, —OTf, and —CO2H; or any two geminal R groups, taken together, form an imine; or any two vicinal R groups, taken together, form a ring;
wherein any alkyl or imine may be substituted with a carbamide, a carboxylate, or a hydroxyl; and
R? is alkyl or aryl; and
the compound of Formula II is

wherein
R? is —H, alkyl, or aryl, or both R?, taken together, form a ring; wherein any alkyl, aryl, or ring may be substituted with —OH, alkyl, or halo.

US Pat. No. 10,711,242

APPARATUS AND METHODS FOR CONTROLLING CELLULAR DEVELOPMENT

The Board of Trustees of ...

1. A method for selectively controlling growth and development of a mammalian stem cell in vivo or in a tissue in vitro, the method comprising:a) genetically modifying a selected type of stem cell to express a microbial opsin;
b) stimulating the genetically modified stem cell with a light-based activation signal, wherein the light-based activation signal is generated by a system comprising:
i) a light source;
ii) a pulse generator that is configured to send signals to and control the light source;
iii) a signal receiver that is configured to receive response signals from the genetically modified stem cell; and
iv) a computer that is configured to modulate signals sent by the pulse generator based on the response signals;
c) receiving one or more response signals from the genetically modified stem cell; and
d) modulating the light-based activation signal based on the response signals, thereby selectively controlling growth and development of the genetically modified stem cell.

US Pat. No. 10,711,239

ADIPOSE TISSUE CENTRIFUGE AND METHOD OF USE

DSM IP ASSETS B.V., Te H...

1. A method for processing a biologic mixture and selectively concentrating constituents of the biologic mixture, the constituents having differing specific gravities and being stratifiable in a centrifugal field, said method comprising:a. introducing a biologic mixture comprising adipose tissue into a chamber of a centrifuge, said chamber comprising a sidewall with a tapered inner surface, a base, an annular screen having an inner surface, and a first port; and
b. rotating said chamber about an axis to pass at least a substantial portion of said adipose tissue through said annular screen, thereby morselizing the substantial portion of said adipose tissue; and causing the biologic mixture to stratify in said chamber into at least two concentric stratified constituent layers.

US Pat. No. 10,711,238

METHOD FOR PROLIFERATION OF CELLS WITHIN A BIOREACTOR USING A DISPOSABLE PUMPHEAD AND FILTER ASSEMBLY

Repligen Corporation, Wa...

1. A method of assembling a system for tangential flow perfusion filtering, the system comprising(a) a bioreactor vessel containing bioreactor fluid, the bioreactor fluid comprising cells residing in the bioreactor vessel, the cells including cells produced in the bioreactor vessel and additional material residing in the bioreactor vessel including at least one of waste material, expressed proteins, and viruses of interest,
(b) a first bioreactor fluid flow tubing in fluid communication with the bioreactor vessel,
(c) bioreactor return tubing in fluid communication with the bioreactor vessel,
(d) a disposable pumphead and tangential flow filter unit wherein the pumphead and tangential flow filter unit are assembled and pre-sterilized, configured for attachment to the bioreactor vessel and comprising in serial order of flow:
a first aseptic connector sealed by a first cap;
a second bioreactor fluid flow tubing connected to the first aseptic connector;
the disposable pumphead connected to the second bioreactor fluid flow tubing;
a third bioreactor fluid flow tubing connected to the disposable pumphead;
the tangential flow filter unit connected to the third bioreactor fluid flow tubing;
permeate tubing connected to a permeate port of the tangential flow filter unit;
a retentate return tubing connected to a retentate port of the tangential flow filter unit; and
a second disposable aseptic connector connected to the retentate return tubing and sealed by a second cap, and
(e) a reusable control system including a reusable pump motor configured for cooperation with the disposable pumphead;
the method of assembling the system consisting of:
attaching the assembled, pre-sterilized pumphead and tangential flow filter unit to the bioreactor vessel, wherein the assembled, pre-sterilized pumphead and tangential flow filter unit includes said first aseptic connector and said second aseptic connector, by:
removing the first cap from the first aseptic connector;
aseptically connecting the first bioreactor fluid flow tubing to the first aseptic connector;
removing the second cap from the second aseptic connector;
aseptically connecting the bioreactor return tubing to the second aseptic connector;
engaging the disposable pumphead with the reusable pump motor;
the disposable pumphead circulating the bioreactor fluid through the tangential flow filter; thereby separating the bioreactor fluid into a retentate flow comprising the cells that is returned from the tangential flow filter unit through the retentate return tubing to the bioreactor vessel and a permeate flow comprising the additional material that is removed from the tangential flow filter unit through the permeate tubing; and
optionally, connecting a permeate pump to the permeate tubing to draw the permeate flow from the tangential flow filter unit.

US Pat. No. 10,711,237

APPARATUS AND METHODS FOR BIOPROCESSES AND OTHER PROCESSES

1. A single use module for analysis of a bioprocess, comprising:a housing having a plurality of inlet ports and a plurality of outlet ports, wherein said housing has a flow cell therein or extending at least partially from one side thereof, a valve located at least partially in said housing, a guard column and a column located in said housing, wherein said housing is adapted to receive a biological sample through a sample inlet port in one side thereof, and, when a solvent is pumped under pressure into said housing, move through the valve, the guard column, the column, and then the flow cell, and wherein the flow cell is adapted to determine a characteristic of the sample, wherein the characteristic of the sample comprises:
protein concentration, spectral information, fluorescence, or a combination thereof.

US Pat. No. 10,711,236

CARBON SEQUESTRATION METHODS AND SYSTEMS, AND COMPOSITIONS PRODUCED THEREBY

Blue Planet, Ltd., Los G...

1. A system for removing CO2 from a CO2 containing gas, the system comprising:a source of the CO2 containing gas, wherein the source of the CO2 containing gas is an industrial plant;
an aqueous medium source;
an alkaline earth metal cation source that is distinct from the aqueous medium source; and
a single reactor configured to:
contact the CO2 containing gas with the aqueous medium under conditions sufficient to produce a bicarbonate rich product; and
contact the bicarbonate rich product with alkaline earth metal cations from the alkaline earth metal cation source to produce a solid carbonate from the bicarbonate rich product and the alkaline earth metal cations in a continuous process.

US Pat. No. 10,711,234

MICROFLUIDIC PLATFORM FOR INVESTIGATING CELL-BASED INTERACTIONS

AIM BIOTECH PTE. LTD., S...

1. A microfluidic platform for investigating cell-based interactions, the platform comprising:a chip base comprising a plurality of ports in fluid communication with a microfluidic channel for containing a fluid culture medium in which cells are held, each port comprising:
an internal inlet, connecting the port with the microfluidic channel,
a trough for containing a small reservoir of culture medium fluid adjacent to the inlet, and
an upper reservoir above said trough and said internal inlet,
wherein, in use, the fluid culture medium can be aspirated from the microfluidic channel via the trough rather than directly via the internal inlet.

US Pat. No. 10,711,233

HEAT EXCHANGER SYSTEM WITH FLEXIBLE BAG

Life Technologies Corpora...

1. A bag assembly for use with a heat exchanger, the bag assembly comprising:a flexible bag comprised of one or more sheets of polymeric material, the bag having a first end that bounds a first compartment and an opposing second end that bounds a second compartment, a support structure being disposed between the first compartment and the second compartment so that the first compartment is separated and isolated from the second compartment, wherein the one or more sheets of polymeric material comprise a first sheet of polymeric film overlaying and secured to a second sheet of polymeric film so that the first compartment and the second compartment are bounded between the first sheet and the second sheet, the first sheet and the second sheet each comprise a single, integral, continuous sheet that extends from the first end to the second end;
a first inlet port, a first outlet port, and a first drain port being coupled with the flexible bag so as to communicate with the first compartment; and
a second inlet port, a second outlet port, and a second drain port being coupled with the flexible bag so as to communicate with the second compartment;
wherein the first compartment is bounded by an upper edge disposed toward the support structure and an opposing lower edge, the lower edge comprising a portion of the first sheet and the second sheet where the first sheet and the second sheet are directly secured together, opposing ends of the lower edge being sloped toward a central location, the first drain port being disposed at the central location.

US Pat. No. 10,711,231

CLARIFIED FERMENTED BEVERAGES, AND A METHOD THEREOF

Mark Anthony Internationa...

1. A method of producing a clarified fermented beverage having a reduced or negligible level of organic acids, by neutralizing and removing organic acidic contaminants from a fermented beverage solution, comprising the steps of:a. providing a fermented beverage solution comprising at least one organic acidic contaminant;
b. treating the fermented beverage solution by neutralizing the at least one organic acidic contaminant, by adding into the fermented beverage solution a sufficient amount of an alkaline treating agent to convert within the fermented beverage solution substantially all of the at least one organic acidic contaminant within the fermented beverage solution into a salt of the at least one organic acid contaminant, and forming a treated fermented beverage comprising the salt of the at least one organic acid contaminant; and
c. separating the salt of the at least one organic acid contaminant formed in step (b) from the treated fermented beverage solution, thereby producing a clarified fermented beverage having a reduced or negligible level of organic acids.

US Pat. No. 10,711,229

DETERGENT COMPOSITION IN EFFERVESCENT TABLET FORM

WASH TO GO. Unipessoal Ld...

1. An effervescent detergent tablet, comprising:a) from 1% to 2% of calcium carbonate;
b) from 10% to 1.5% of sodium laureth sulfate;
c) from 10% to 15% of citric acid;
d) from 15% to 25% of tartaric acid;
e) from 30% to 40% of sodium bicarbonate;
f) less than 0.1% of enzyme mix;
g) from 1.5% to 4% of fragrance;
h) from 0.7% to 1.5% of Methyl bis[ethyl (tallowate)]-2-hydroxyethyl ammonium methyl sulfate;
i) from 0.1% to 0.4% of polyhexamethylene biguanide;
j) from 0.5% to 1.4% of stearic acid;
k) from 3% to 4.5% of silicon dioxide;
l) from 0.1% to 0.4% of Disodium Distyrylbiphenyl Disulfonate;
m) from 1% to 3% of Magnesium Stearate;
n) from 3% to 5% of Polyvinylpyrrolidone, crosslinked;
o) from 0% to 1.8% of Chlorhexidine Hydrochloride; and
p) from 0% to 1.8% of calcium carbonate and sodium disilicate mix.

US Pat. No. 10,711,228

SUBSTRATE TREATING APPARATUS AND SUBSTRATE TREATING METHOD

SEMES CO., LTD., Chungch...

1. A substrate treating apparatus comprising:a support member configured to support a substrate;
a treatment liquid discharging member configured to discharge a treatment liquid containing a monomeric substance to the substrate located in the support member;
a light irradiator configured to irradiate light to the treatment liquid discharged to the substrate; and
cleaning film removers configured to remove a cleaning film formed when the treatment liquid is cured by the light from the substrate,
wherein the cleaning film removers are clips arranged at locations corresponding to an outer circumference of the substrate.

US Pat. No. 10,711,227

TIN HARD MASK AND ETCH RESIDUE REMOVAL

VERSUM MATERIALS US, LLC,...

1. A composition for selectively removing PVD titanium nitride (TiN or TiNxOy; where x=0 to 1.3 and y=0 to 2) from a semiconductor device comprising the PVD titanium nitride and a second material selected from the group consisting of Cu, Co, CVD titanium nitride, dielectric material, low-k dielectric material, and combinations thereof, the composition comprising:1 to 20 wt % peroxide;
1-5 wt % base;
0.1-1 wt % carboxylic acid selected from the group consisting of citric acid, oxalic acid, malonic acid, lactic acid, adipic acid, acetic acid, iminodiacetic acid, and combinations thereof;
ammonium salt selected from the group consisting of ammonium citrate, ammonium acetate, ammonium malonate, ammonium adipate, ammonium lactate, ammonium iminodiacetate, ammonium chloride, ammonium bromide, ammonium fluoride, ammonium bifluoride, ammonium sulfate, and combinations thereof;
corrosion inhibitor, or 1-15 wt % of a long chain or mixed alkylammonium hydroxide, and combinations thereof, wherein said long chain or mixed alkylammonium hydroxide is selected from the group consisting of tetrabutylammonium hydroxide and mixed tetraalkylammonium hydroxide, wherein the alkylammonium cation contains alkyl groups of at least two different chain lengths; and
Solvent;wherein the composition has a pH ranging from 7 to 11.5.

US Pat. No. 10,711,222

CLEANING LIQUID

Daido metal Co., Ltd., A...

1. A cleaning liquid comprisinga liquid,
a first fine gas bubble group included in the liquid and comprising a gas at a first temperature, and
a second fine gas bubble group included in the liquid and comprising a gas at a second temperature that is lower than the first temperature,
wherein the gas bubbles have a diameter of no greater than 1 ?m and a concentration of 1×106 or greater per ml.

US Pat. No. 10,711,221

METHOD OF REFINING A GRAIN OIL COMPOSITION TO MAKE ONE OR MORE GRAIN OIL PRODUCTS, AND RELATED SYSTEMS

POET Research, Inc., Sio...

1. A method of refining a grain oil composition to make one or more grain oil products, the method comprising:a) providing a grain oil composition obtained from a biorefinery, wherein the grain oil composition comprises a fatty acid alkyl ester component; and
b) exposing the grain oil composition to temperature and pressure conditions for a time period to evaporate at least a portion of the fatty acid alkyl ester component from the grain oil composition to form a first grain oil product and a second grain oil product, wherein the first grain oil product has a first concentration of fatty acid alkyl ester component and the second grain oil product has a second concentration of fatty acid alkyl ester component, and wherein the first concentration of fatty acid alkyl ester component is less than the second concentration of fatty acid alkyl ester component, wherein the temperature is in the range from 300 to 400° F., wherein the pressure is in the range from 10 to 5000 millitorr, and wherein the time period is in the range from 1 second to 30 minutes.

US Pat. No. 10,711,220

HIGH TEMPERATURE HEAT-RESISTANT OIL-BASED RELEASE AGENT, HIGH TEMPERATURE HEAT-RESISTANT ELECTROSTATIC APPLICATION-TYPE OIL-BASED RELEASE AGENT, AND APPLICATION METHOD THEREFOR

AOKI SCIENCE INSTITUTE CO...

1. An oil-based release agent comprisinga petroleum-based hydrocarbon solvent (a),
an adhesive (b), wherein adhesive (b) is dimethyl polysiloxane having a weight average molecular weight of 100,000 or more, and
a conductive modifier (f), wherein the conductive modifier (f) is at least one selected from the group consisting of
an imidazolium salt (f-1),
a pyrrolidinium salt (f-2),
a pyridinium salt (f-3),
a phosphonium salt (f-5), and
a sulfonium salt (f-6);
wherein the release agent contains 0% water.

US Pat. No. 10,711,219

AUTOMOTIVE TRANSMISSION FLUID COMPOSITIONS FOR IMPROVED ENERGY EFFICIENCY

Infineum International Li...

1. A method of improving the fuel economy of a vehicle equipped with an automatic transmission, the method comprising lubricating the automatic transmission with an automatic transmission fluid comprising a major amount of an oil of lubricating viscosity and minor amounts of(a) one or more oil-soluble or dispersible molybdenum-containing compounds selected from the group consisting of molybdenum dithiocarbamates, molybdenum dialkyldithiophosphates, molybdenum alkyl xanthates, molybdenum alkylthioxanthates, and mixtures thereof,
(b) a reaction product of an isomerized alkenyl-substituted succinic anhydride and a polyamine characterized by structure (II):
wherein x and y are independently zero or integers from 1 to 30, where x+y is from 1 to 30, and z is zero or an integer from 1 to 10,(c) an ashless dispersant, and
(d) a metal-containing detergent,
thereby improving fuel economy by at least 0.9% in an FTP-75 test cycle relative to a comparative automatic transmission fluid comprising a major amount of the oil of lubricating viscosity, a minor amount of the reaction product (b), a minor amount of ashless dispersant (c), and a minor amount of metal-containing detergent (d), but no oil-soluble or dispersible molybdenum-containing compound (a),
wherein the automatic transmission fluid further exhibits comparable paper-on-steel (POS) friction and significant reduction in steel-on-steel (SOS) friction, relative to the comparative automatic transmission fluid so as to satisfy one or both of the following:
no more than a 3% reduction in static POS friction, measured using a D600 fiber plate against an SAE1035 tumbled steel plate on a small scale Low Velocity Friction Apparatus (LVFA) at about 80° C., relative to the comparative automatic transmission fluid, and no less than a 12% reduction in dynamic SOS friction, measured on a Falex block-on-ring apparatus according to JASO M358-2005 at about 80° C. and at 0.025 to 1.00 m/s; and/or
no more than a 9% reduction in static POS friction, measured using a D600 fiber plate against an SAE1035 tumbled steel plate on a small scale LVFA at about 80° C., relative to the comparative automatic transmission fluid, and no less than a 17% reduction in dynamic SOS friction, measured on a Falex block-on-ring apparatus according to JASO M358-2005 at about 110° C. and at 0.025 to 1.00 m/s.

US Pat. No. 10,711,216

ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME

ExxonMobil Chemical Paten...

1. A compound having a formula (F-I) below:
wherein:
R1 and R2 are independently each a hydrocarbyl group comprising at least 2 carbon atoms; and
R3 is a substituted or unsubstituted hydrocarbyl group.

US Pat. No. 10,711,214

PRODUCTION OF A CARBONACEOUS FEEDSTOCK MATERIAL FROM A WASTE CARBON SOURCE

NORTH-WEST UNIVERSITY, P...

1. A process for producing a carbonaceous feedstock material from waste-containing carbon sources, the process including the steps consisting of:(i) introducing a source of a hydrothermal liquefaction biochar product to a source of discard coal fines to form a bio-coal mixture;
(ii) introducing a gasification catalyst additive selected from the group consisting of a source of an alkali metal or a source of an alkaline earth metal to the bio-coal mixture;
(iii) optionally, contacting the bio-coal mixture with a binder; and
(iv) compacting the resulting mixture of step (ii) or (iii) to form one or more carbonaceous feedstock briquettes, the size of said briquettes having a dimension of at least 5 mm.

US Pat. No. 10,711,213

METHOD AND SYSTEM FOR ENHANCING THE CARBON CONTENT OF CARBON-CONTAINING MATERIALS

1. A method of enhancing the carbon content of a carbon-containing material, the method comprising:subjecting a pre-determined amount of a carbon-containing material to a vacuum pressure of 0.1 atm or lower,
subjecting the carbon-containing material to an inert gas at a pressure of 1-5 atm,
heating the carbon-containing material to remove moisture and volatile components therefrom to enhance the carbon content, and
cooling and collecting the carbon-containing material thus treated, wherein the heating step is performed by sequentially heating the carbon-containing material to three or more different increasingly higher temperatures, each temperature being held for a predetermined duration of time such that the weight percentage of the carbon in the treated carbon-containing material is increased by 20% or higher, as compared to the untreated carbon-containing material.

US Pat. No. 10,711,212

PROCEDURE AND EQUIPMENT FOR THE PRODUCTION OF SOLID FUEL FROM WASTEWATER SLUDGE

1. A process for producing solid fuel from wastewater sludge, comprising removing water from the wastewater sludge, which contains 2-8 wt % dry material by mechanical water removal to provide wastewater sludge with a dry material content of 25-30 wt %, drying the wastewater sludge containing 25-30 wt % dry material to a dry material content of 50-55 wt % by heat from a flue gas of a furnace, wherein steam and gases are released from the wastewater sludge, extracting the steam and gases, which are optionally filtered, and are fed to the furnace, pelletizing the wastewater sludge containing 50-55 wt % dry material at a pressure of 800-900 bar, which provides a pellet product, drying the pellet product to a dry material content of 80-85 wt % by heat of said flue gas of the furnace, which forms a solid pellet final product, wherein 30-50 wt % of the solid pellet final product is fed to the furnace as fuel.

US Pat. No. 10,711,211

REDUCED TEMPERATURE GAS DEHYDRATION

Equitrans Gathering Holdi...

1. A natural gas dehydration system comprising:a heat exchanger having a first passage defining a first inlet and a first outlet, and second passage defining a second inlet and a second outlet, the first and second passages in thermal communication with each other and fluidly isolated from each other, the first inlet is coupled to receive a first stream of natural gas and water vapor having a first temperature and a first pressure;
a pressure reduction valve having an inlet coupled to receive the first stream from the first outlet of the heat exchanger, the pressure reduction valve operative for providing a reduced temperature and reduced pressure first stream at an outlet of the pressure reduction valve;
a separator having an inlet coupled to receive the first stream from the outlet of the pressure reduction valve, the separator operative for separating at least part of the water from the first stream to form a second stream of natural gas and water vapor having a lower water content than the first stream and for outputting the second stream via a first outlet of the separator to the second inlet of the heat exchanger, wherein the second outlet of the heat exchanger is coupled to a distribution pipeline or a storage system;
a valve coupled between the second inlet and the second outlet of the heat exchanger;
a temperature sensor for sensing a temperature of the first stream between the outlet of the pressure reduction valve and the inlet of the separator; and
a controller operative for controlling the valve to be in an open state for passage of at least part of the second stream therethrough or a closed state for blocking passage of the second stream therethrough based on temperature of the first stream determined via the temperature sensor.

US Pat. No. 10,711,210

METHOD OF PREPARING METAL DIBORIDE DISPERSIONS AND FILMS

Arizona Board of Regents ...

1. A method of producing metal diboride nanomaterials comprising:preparing a mixture of at least one metal diboride and a suspending solution, the suspending solution including at least one solvent;
at least partially exfoliating the at least one metal diboride by exposing the mixture to ultrasonic energy comprising ultrasonic vibrations;
centrifuging the mixture and forming at least a lower phase and an adjacent supernatant, the supernatant including a dispersion of exfoliated metal diborides; and
extracting at least a portion of the dispersion from the supernatant;
wherein the at least one solvent is selected from N-methyl-2-pyrrolidone, dimethylformamide, cyclopentanone, cyclohexanone, N-formyl piperidine, vinyl pyrrolidone, 1,3-dimethyl-2-imidazolidinone, bromobenzene, benzonitrile, benzyl benzoate, N,N?-dimethylpropylene urea, y-butrylactone, N-ethylpyrrolidone, dimethylacetamide, cyclohexylpyrrolidone, dimethyl sulfoxide, dibenzyl ether, chloroform, isopropylalcohol, cholobenzene, 1-octyl-2-pyrrolidone, 1-3 dioxolane, ethyl acetate, quinoline, benzaldehyde, ethanolamine, diethyl phthalate, NDodecyl-2-pyrrolidone, pyridine, dimethyl phthalate, formamide, ethanol, vinyl acetate, acetone, ethylene glycol, toluene, heptane, hexane, and pentane.

US Pat. No. 10,711,209

GASIFICATION CO-GENERATION PROCESS OF COAL POWDER IN A Y-TYPE ENTRAINED FLOW BED

CHINA UNIVERSITY OF PETRO...

1. A gasification co-generation process of coal powder in a Y-type entrained flow bed, comprising the following steps:(1) mixing coal with lime powder to obtain coal powder, or mixing the coal, lime powder and water to obtain coal water slurry; in the coal water slurry or coal powder, the weight ratio of calcium to aluminum is 2-4:1, the weight ratio of calcium to silicon is 1-4:1, and the weight ratio of calcium to iron is 1-3:1;
(2) introducing the coal water slurry or coal powder, gasification agent and water vapor into a gasification furnace of a Y-type entrained flow bed, and performing combustion and gasification at a temperature range of 1,300-2,000° C., so as to produce a crude syngas and slag at a temperature range of 1300-2000° C., the gasification furnace comprising a furnace wall;
wherein the coal water slurry or coal powder, gasification agent and water vapor are sprayed into the gasification furnace through a top nozzle and a plurality of side nozzles of the gasification furnace, and collide, ignite and turbulently mix with each other at a combustion chamber center of the gasification furnace, to form a rotational strike and high temperature reaction zone; the residence time of a residual ash generated by the combustion and gasification in the rotational strike and high temperature reaction zone is 10 s or more;
the residual ash is thrown toward the furnace wall of the gasification furnace and swirled downward, and solidified on the furnace wall of the gasification furnace to form a slag layer;
(3) introducing the crude syngas and slag into a chilling chamber to carry out chilling with water, wherein the slag is cooled and solidified into a solid slag with a temperature of 500-950° C.; the solid slag passes through a solid discharge pipe with a perforated segmented conical head and flows into a fluidized bed heat extractor, and then its temperature is reduced to 120-500° C. under the action of a fluidized vapor and an atomized water mist or a heat extraction sleeve to obtain gasification slag, in the meanwhile, the fluidized vapor carries a fine ash having a high content of residual carbon and flows upward to pass through a perforated conical head, so as to further fluidize and sort the fine ash in the solid slag, then obtained fluidized vapor containing fine ash mixes with the crude syngas; the gasification slag is discharged from the fluid bed heat extractor, and is further cooled to a temperature less than 80° C. and subjects to a dry method slagging to produce a cement clinker;
the crude syngas is cooled by the chilling with water to a temperature range of 500-950° C., and carries the fine ash and is discharged from the chilling chamber to separate the fine ash from the gasification slag;
(4) discharging the crude syngas carrying fine ash from the chilling chamber, and further performing a gas-solid separation by means of a gas-ash separator to obtain a separated and purified syngas, the separated and purified syngas enter into a convective waste pot for heat recovery and is then ready for use; a separated fine ash passes through an ash exhaust port and is discharged into a moving bed heat exchanger, and is cooled to a temperature less than 500° C. and discharged and then returned to step (1) and mixed into the coal.

US Pat. No. 10,711,208

PROCESS SCHEME FOR THE PRODUCTION OF OPTIMAL QUALITY DISTILLATE FOR OLEFIN PRODUCTION

Saudi Arabian Oil Company...

1. A method of producing a feedstock for olefin pyrolysis, comprising:hydrotreating a gasoil feed with a hydrotreating catalyst in the presence of hydrogen to produce an ultralow sulfur distillate (ULSD) stream comprising less than 10 parts-per-million weight (ppmw) sulfur, less than 10 ppmw nitrogen, and maximum aromatic saturation as compared to the gasoil feed such that greater than 95% by weight of the aromatics in the ULSD stream are monoaromatics;
separating, via a tray distillation column, the ULSD stream into a light distillate stream and a heavy bottom stream, wherein aromatics in the light distillate stream comprise at least 50% by weight monoaromatics and aromatics in the heavy bottom stream comprise no more than 15% by weight monoaromatics;
extracting, in an extraction section, an extract phase and a raffinate phase from the light distillate stream, the raffinate phase comprising at least 50% by weight saturated hydrocarbons and no more than 15% by weight aromatics, the extraction section comprising a liquid-liquid extraction (LLE) column, secondary re-extract column, an extract and raffinate wash column, a distillation column, and a solvent recovery column; and
mixing the raffinate phase with the heavy bottom stream produced from the separation of the ULSD stream to produce the feedstock for olefin pyrolysis, wherein a Bureau of Mines Correlation Index (BMCI) of the feedstock for olefin pyrolysis is less than the BMCI of the gasoil feed and the BMCI of the ULSD stream.

US Pat. No. 10,711,207

INTEGRATED HYDROTREATING AND SLURRY HYDROCRACKING PROCESS

UOP LLC, Des Plaines, IL...

12. A slurry hydrocracking process comprising:hydrotreating a fresh, heavy residual, asphaltene-containing hydrocarbon feed in a fixed bed reactor, hydrotreating zone under hydrotreating conditions including a temperature in a range of about 330° C. to about 440° C., a pressure of about 13 MPa to about 28 MPa, a liquid hourly space velocity of about 0.1 hr?1 to about 2 hr?1, and a gas to oil ratio of 4,000-10,000 SCFB to provide a conversion of 975+° F. hydrocarbons of from about 20 to about 50 wt % in the presence of a hydrotreating catalyst to hydrogenate multi-ring aromatics including asphaltenes and form a hydrotreated effluent, wherein the hydrotreating catalyst comprises at least one Group VIII metal selected from cobalt and nickel and at least one Group VI metal selected from molybdenum and tungsten on an alumina support;
separating the hydrotreated effluent in a first separator to form an overhead vapor stream and a bottoms liquid stream;
hydrocracking the bottoms liquid stream directly from the first separator in a slurry hydrocracking zone under slurry hydrocracking conditions including a temperature of about 432° C. (810° F.) to about 476° C. (890° F.) and a pressure in a range of about 10 MPa to about 25 MPa in the presence of a slurry hydrocracking catalyst;
fractionating at least a portion of the effluent from the slurry hydrocracking zone in a fractionation zone into at least two streams; and
wherein an overall conversion of 975+° F. hydrocarbons in the heavy residual, asphaltene-containing hydrocarbon feed is at least about 93%.

US Pat. No. 10,711,206

METHOD FOR STARTING UP A METHOD FOR PRODUCING KEROSENE AND DIESEL FUEL FROM HYDROCARBON COMPOUNDS PRODUCED BY FISCHER-TROPSCH SYNTHESIS

IFP Energies Nouvelles, ...

1. A method for starting up a method for producing kerosene and diesel fuel from hydrocarbon compounds produced by Fischer-Tropsch synthesis, comprising:a) catalytic Fischer-Tropsch synthesis with a synthesis gas to produce a heavy hydrocarbon fraction and a light hydrocarbon fraction,
b) reduction of a hydrotreatment catalyst by ensuring contact with a gas comprising hydrogen, and then c) is carried out,
c) contacting the heavy hydrocarbon fraction with the hydrotreatment catalyst,
d) during c), the temperature of the hydrotreatment catalyst is increased to a temperature of 260° C. to 360° C., and then e) is carried out,
e) contacting a mixture comprising the heavy hydrocarbon fraction and the light hydrocarbon fraction with the hydrotreatment catalyst.

US Pat. No. 10,711,200

NANOBUBBLE AIDED BITUMEN EXTRACTION FROM OIL SAND

SYNCRUDE CANADA LTD. in t...

1. A process for extracting bitumen from mined oil sands, comprising:mixing slurry water and mined oil sands in a slurry preparation unit to form an oil sand slurry containing bitumen droplets;
conditioning the oil sand slurry to promote bitumen liberation from sand grains, bitumen droplet coalescence and aeration to form a conditioned oil sand slurry, conditioning forming microbubbles having a diameter of greater than 5,000 nm due to natural entrainment of air and mechanical agitation;
subjecting the conditioned oil sand slurry to gravity separation to form a bitumen froth, a middlings stream and coarse tailings;
optionally adding flood water to the conditioned oil sand slurry prior to subjecting it to gravity separation; and
introducing nanobubbles having a diameter of less than 5,000 nm to the slurry water, the flood water, the oil sand slurry, the conditioned oil sand slurry, or combinations thereof.

US Pat. No. 10,711,199

PROCESSING APPARATUS

NOV DOWNHOLE EURASIA LIMI...

1. A processing apparatus, comprising:a microwave processing chamber;
a rigid, vertically oriented rotatable feed wheel having a horizontally oriented axis of rotation, wherein a part of the feed wheel is located within the processing chamber;
a feed device configured to deposit materials to be processed onto a radially outer surface of the feed wheel; and
an output configured to receive processed materials that fail from the radially outer surface of the feed wheel after the processed materials have passed through the processing chamber.

US Pat. No. 10,711,198

CATALYTIC UPGRADING OF PYROLYTIC VAPORS

Valmet Technologies Oy, ...

1. A method for producing crude condensate from pyrolyzable material comprising:burning fuel in a fluidized bed boiler to produce flue gas and heat,
heating a first particulate material comprised by a fluidized bed of the fluidized bed boiler with said heat,
optionally, heating a second particulate material using the heated first particulate material,
transferring at least a portion of the heated first particulate material or at least a portion of the heated second particulate material to a pyrolysis reactor,
conveying the pyrolyzable material into the pyrolysis reactor,
pyrolyzing the pyrolyzable material in the pyrolysis reactor by contacting the pyrolyzable material with the heated first particulate material or the heated second particulate material to produce at least raw pyrolytic vapor comprising non-condensable gases, oxygenated condensable hydrocarbons, and char,
cleaning at least a portion of the raw pyrolytic vapor to produce a clean pyrolytic vapor and char,
transferring a portion of the char back into the fluidized bed boiler or into a char burner, burning the char in the fluidized bed boiler or in the char burner to produce heat, and transferring the heat back to the pyrolysis reactor,
deoxygenating at least part of the clean pyrolytic vapor in the presence of a catalyst bed comprising catalyst material and at a partial pressure of hydrogen in the catalyst bed of less than 0.5 bar to produce a treated pyrolyticvapor product, and
separating at least a portion of the treated pyrolytic vapor product into a crude condensate comprising bio-crude and non-condensable gas comprising carbon oxides, hydrogen, and methane.

US Pat. No. 10,711,197

LIQUID-CRYSTALLINE MEDIUM AND HIGH-FREQUENCY COMPONENTS COMPRISING SAME

MERCK PATENT GMBH, Darms...

1. A liquid-crystal medium comprising:one or more compounds selected from formulae I-3a to I-3d:

in which
R1 denotes H, unfluorinated alkyl or unfluorinated alkoxy having 1 to 17 C atoms or unfluorinated alkenyl, unfluorinated alkenyloxy or unfluorinated alkoxyalkyl having 2 to 15 C atoms;
one or more compounds selected from formula II:

in which
R2 denotes H, unfluorinated alkyl or unfluorinated alkoxy having 1 to 17 C atoms or unfluorinated alkenyl, unfluorinated alkenyloxy or unfluorinated alkoxyalkyl having 2 to 15 C atoms,
Z21 denotes trans-CH?CH—, trans-CF?CF— or —C?C—, and

independently of one another, denote

and one or more compounds selected from formula III-1b:

in which
R3 denotes H, unfluorinated alkyl or unfluorinated alkoxy having 1 to 17 C atoms or unfluorinated alkenyl, unfluorinated alkenyloxy or unfluorinated alkoxyalkyl having 2 to 15 C atoms,
wherein the amount of compounds of formula III-1b in said medium is in the range from 5 to 45 wt. %,
wherein the liquid-crystal medium has a clearing point of 90° C. or more,
wherein the medium has a material quality, ?, of 20 or more at 20° C. and 19 GHz, and
wherein the total concentration of compounds of formulae I-3a to I-3d, II, and III-1b is 90% to 100%.

US Pat. No. 10,711,196

BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA

Merck Patent GmbH, Darms...

1. A bimesogenic compound of formula I
wherein
R11 is F, CN, NCS or a straight-chain or branched alkyl group with 1 to 25 C atoms which are unsubstituted, mono- or polysubstituted by halogen or CN, wherein optionally one or more non-adjacent CH2 groups are replaced, in each occurrence independently from one another, by —O—, —S—, —NH—, —N(CH3)—, —CO—, —COO—, —OCO—, —O—CO—O—, —S—CO—, —CO—S—, —CH?CH—, —CH?CF—, —CF?CF— or —C?C— in such a manner that oxygen atoms are not linked directly to one another,
R12 is F, Cl, CN, NCS or a straight-chain or branched alkyl group with 1 to 25 C atoms which are unsubstituted, mono- or polysubstituted by halogen or CN, wherein optionally one or more non-adjacent CH2 groups are replaced, in each occurrence independently from one another, by —O—, —S—, —NH—, —N(CH3)—, —CO—, —COO—, —OCO—, —O—CO—O—, —S—CO—, —CO—S—, —CH?CH—, —CH?CF—, —CF?CF— or —C?C— in such a manner that oxygen atoms are not linked directly to one another,
Sp1 is a spacer group containing 5 to 40 C atoms, wherein one or more non-adjacent and non-terminal CH2 groups are optionally replaced by —O—, —S—, —NH—, —N(CH3)—, —CO—, —O—CO—, —S—CO—, —O—COO—, —CO—S—, —CO—O—, —CH(halogen)-, —CH(CN)—, —CH?CH— or in such a way that no two O-atoms are adjacent to one another, no two —CH?CH— groups are adjacent to each other and no two groups selected from the group consisting of —O—CO—, —S—CO—, —O—COO—, —CO—S—, —CO—O— and —CH?CH— are adjacent to each other, wherein one or more H atoms in CH2 groups are independently of each other optionally replaced by F or CH3,
X11 is —CH?CH—, —C?C—, —CF2—O—, —O—CF2—, —CO—O—, —O—CO—, —O—CO—O—, —S—, —CS— S—, —S—CS—, —CO—S—, —S—CO—, —S—CO—S—, —S—CS—S— or a single bond, under the condition that in —X11—Sp1-X2— no two O-atoms are adjacent to one another, no two —CH?CH— groups are adjacent to each other and no two groups selected from the group consisting of —O— CO—, —S—CO—, —O—COO—, —CO—S—, —CO—O— and —CH?CH— are adjacent to each other,
X12 is —CH?CH—, —C?C—, —O—, —CF2—O—, —O—CF2—, —CO—O—, —O—CO—, —O—CO—O—, —S—, —CS— S—, —S—CS—, —CO—S—, —S—CO—, —S—CO—S—, —S—CS—S— or a single bond, under the condition that in —X11—Sp1-X12— no two O-atoms are adjacent to one another, no two —CH?CH— groups are adjacent to each other and no two groups selected from the group consisting of —O— CO—, —S—CO—, —O—COO—, —CO—S—, —CO—O— and —CH?CH— are adjacent to each other,
MG11 has formula II*
-A*11-(Z*11-A*12)k-  II*
MG12 is selected
from the group consisting of formulae II-1 to II-26 and their mirror images
-Phe-Z-Phe-  II-1
-Phe-Z-Cyc-  II-2
-Cyc-Z-Cyc-  II-3
-Phe-Z-PheL-  II-4
-PheL-Z-Phe-  II-5
-PheL-Z-Cyc-  II-6
-PheL-Z-PheL-  II-7
-Phe-Z-Phe-Z-Phe-  II-8
-Phe-Z-Phe-Z-Cyc-  II-9
-Phe-Z-Cyc-Z-Phe-  II-10
-Cyc-Z-Phe-Z-Cyc-  II-11
-Phe-Z-Cyc-Z-Cyc-  II-12
-Cyc-Z-Cyc-Z-Cyc-  II-13
-Phe-Z-Phe-Z-PheL-  II-14
-Phe-Z-PheL-Z-Phe-  II-15
-PheL-Z-Phe-Z-Phe-  II-16
-PheL-Z-Phe-Z-PheL-  II-17
-PheL-Z-PheL-Z-Phe-  II-18
-PheL-Z-PheL-Z-PheL-  II-19
-Phe-Z-PheL-Z-Cyc-  II-20
-Phe-Z-Cyc-Z-PheL-  II-21
-Cyc-Z-Phe-Z-PheL-  II-22
-PheL-Z-Cyc-Z-PheL-  II-23
-PheL-Z-PheL-Z-Cyc-  II-24
-PheL-Z-Cyc-Z-Cyc-  II-25
-Cyc-Z-PheL-Z-Cyc-  II-26
wherein
Cyc is 1,4-cyclohexylene,
Phe is 1,4-phenylene or alkyl-1,4-phenylene,
PheL is 1,4-phenylene, which is substituted by one, two or three fluorine atoms, by one or two Cl atoms, by one Cl atom and one F atom or by one alkyl or alkoxy group having 1 to 9 C-atoms, and
Z is a single bond, —COO—, —OCO—, —O—CO—O—, —OCH2—, —CH2O—, —OCF2—, —CF2O—, —CH2CH2—, —(CH2)4—, —CF2CF2—, —CH?CH—, —CF?CF—, —CH?CH—COO—, —OCO— CH?CH— or —C?C—
Z*11 is a single bond, —COO—, —OCO—, —O—CO—O—, —OCH2—, —CH2O—, —OCF2—, —CF2O—, —CH2CH2—, —(CH2)4—, —CF2CF2—, —CH?CH—, —CF?CF—, —CH?CH—COO—, —OCO—CH?CH— or —C?C—,
A*11 present in MG11 is 1,3-phenylene, wherein optionally one or two non-adjacent CH groups each are replaced by an N-atom, and which optionally is substituted by one or more halogen atoms and/or by one or more alkyl group(s) each independently having 1 to 9 C atoms,
A*12 if present in MG11 is 1,4-phenylene, wherein one or more CH groups are optionally replaced by N, trans-1,4-cyclo-hexylene in which one or two non-adjacent CH2 groups are optionally replaced by O and/or S, 1,4-cyclohexenylene, 1,4-bicyclo-(2,2,2)-octylene, naphthalene-2,6-diyl, decahydro-naphthalene-2,6-diyl, 1,2,3,4-tetrahydro-naphthalene-2,6-diyl, cyclobutane-1,3-diyl, spiro[3.3]heptane-2,6-diyl or dispiro[3.1.3.1] decane-2,8-diyl, wherein all these groups are unsubstituted, mono-, di-, tri- or tetrasubstituted with F, Cl, CN or alkyl, alkoxy, alkylcarbonyl or alkoxycarbonyl groups with 1 to 7 C atoms, wherein one or more H atoms are optionally substituted by F or Cl, and
k is 1, 2, 3 or 4.

US Pat. No. 10,711,195

LIQUID-CRYSTALLINE MEDIUM

Merck Patent GmbH, Darms...

1. Liquid-crystalline medium comprising one or more compounds of formula A
and, in addition
one or more compounds selected from the group of compounds of formulae I and II

wherein
R01 and R02 each, independently of one another, denote a halogenated or unsubstituted alkyl radical having 1 to 15 C atoms, wherein one or more CH2 groups in these radicals may be replaced, independently of one another, by —C?C—, —CH?CH—, —CF?CF—, —CF?CH—, —CH?CF—, —(CO)O—, —O(CO)—, —(CO)—, —O— or —S— in such a way that O or S atoms are not linked directly to one another,
L01 and L02 denote H or CH3 with the proviso that one of L01 and L02 denotes H and the other of L01 and L02 denotes CH3,
denotes
L11 denotes alkyl having 1 to 6 C atoms, cycloalkyl having 3 to 6 C atoms or cycloalkenyl having 4 to 6 C atoms,
X11 denotes H, alkyl having 1 to 3 C atoms or halogen,
R11 to R14 independently of one another, denote unfluorinated alkyl or unfluorinated alkoxy, each having 1 to 15 C atoms, unfluorinated alkenyl, unfluorinated alkenyloxy or unfluorinated alkoxyalkyl, each having 2 to 15 C atoms, or cycloalkyl, alkylcycloalkyl, cycloalkenyl, alkylcycloalkenyl, alkylcyclo-alkylalkyl or alkylcycloalkenylalkyl, each having up to 15 C atoms, and alternatively one of R13 and R14 or both also denote H;
L21 denotes R21 and, in the case where Z21 and/or Z22 denote trans-CH?CH— or trans-CF?CF—, alternatively also denotes X21,
L22 denotes R22 and, in the case where Z21 and/or Z22 denote trans-CH?CH— or trans-CF?CF—, alternatively also denotes X22,
R21 and R22 independently of one another, denote H, unfluorinated alkyl or unfluorinated alkoxy having 1 to 17 C atoms or unfluorinated alkenyl, unfluorinated alkenyloxy or unfluorinated alkoxyalkyl having 2 to 15 C atoms,
X21 and X22 independently of one another, denote F or Cl, —CN, —NCS, —SF5, fluorinated alkyl or alkoxy having 1 to 7 C atoms or fluorinated alkenyl, alkenyloxy or alkoxyalkyl having 2 to 7 C atoms,
one of
Z21 and Z22 denotes trans-CH?CH—, trans-CF?CF— or —C?C— and the other, independently thereof, denotes trans-CH?CH—, trans-CF?CF— or a single bond, and

independently of one another, denote

US Pat. No. 10,711,194

LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT OR LIQUID CRYSTAL DISPLAY COMPRISING SAME

SHIJIAZHUANG CHENGZHI YON...

1. A liquid crystal composition, comprising one or more compounds represented by formulas I16-I27 and one or more compounds represented by formula II
wherein alkyl represents a linear alkyl having a carbon atom number of 1-5;
alkoxy represents a linear alkoxy having a carbon atom number of 1-5;
alkenyl represents an alkenyl having a carbon atom number of 2-5;
R3 and R4 each independently represent a linear alkyl having a carbon atom number of 1-5, a linear alkoxy having a carbon atom number of 1-5, an alkenyl having a carbon atom number of 2-5, F, Cl, CF3, OCF3, or any methylene that may be replaced with

representsandn represents 0 or 1.

US Pat. No. 10,711,193

QUANTUM DOTS AND PRODUCTION METHODS THEREOF, AND QUANTUM DOT POLYMER COMPOSITES AND ELECTRONIC DEVICES INCLUDING THE SAME

SAMSUNG ELECTRONICS CO., ...

1. A quantum dot, comprisinga core comprising a first semiconductor nanocrystal; and
a shell disposed on the core, the shell comprising a second semiconductor nanocrystal and a metal dopant,
wherein the first semiconductor nanocrystal comprises a Group II-VI compound, a Group III-V compound, or a combination thereof,
the second semiconductor nanocrystal comprises a Group II-VI compound,
the metal dopant comprises hafnium, zirconium, titanium, or a combination thereof,
wherein the shell has a varying composition in a radial direction, and
wherein the shell comprises sulfur and an amount of the sulfur increases in a radial direction toward a surface of the quantum dot.

US Pat. No. 10,711,192

LIGHTING DEVICE

Osram Oled GmbH, Regensb...

1. A lighting device comprising a phosphor having the general molecular formula:(MA)a(MB)b(TA)e(TB)f(TC)g(TD)h(XB)l(XC)m:E,whereinMA is selected from a group of monovalent metals which comprises Li, Na, K, Rb, Cs, Cu, Ag and combinations thereof,
MB is selected from a group of divalent metals which comprises Mg, Ca, Sr, Ba, Zn, Mn, Eu, Yb, Ni, Fe, Co and combinations thereof,
TA is selected from a group of monovalent metals which comprises Li, Na, Cu, Ag and combinations thereof,
TB is selected from a group of divalent metals which comprises Mg, Zn, Mn, Eu, Yb, Ni and combinations thereof,
TC is selected from a group of trivalent metals which comprises B, Al, Ga, In, Y, Fe, Cr, Sc, rare earths and combinations thereof,
TD is selected from a group of tetravalent metals which comprises Si, Ge, Sn, Mn, Ti, Zr, Hf, Ce and combinations thereof,
XB is selected from a group of elements which comprises O, S and combinations thereof,
XC=N
E=Eu, Ce, Yb and/or Mn
a+b=t
e+f+g+h=u
l+m=v
a+2b+e+2f+3g+4h?2l?3m=w
0.8?t?1
3.5?u?4
3.5?v?4
(?0.2)?w?0.2 and0?m<0.875 v and/or v?l>0.125 v.

US Pat. No. 10,711,191

PHOSPHOR, METHOD FOR PRODUCING A PHOSPHOR AND USE OF A PHOSPHOR

OSRAM Opto Semiconductors...

1. A lighting device comprising:a primary radiation source configured to emit primary radiation in a wavelength range between 300 nm and 570 nm; and
a first phosphor disposed in a beam path of the primary radiation source, the first phosphor configured to convert at least a portion of the primary radiation to secondary radiation within an orange to red wavelength range from 570 nm to 800 nm,
wherein the first phosphor has the formula:
Sr(SraM1?a)Si2Al2(N,X)6:D,A,B,E,G,L,
wherein element M is selected from the group consisting of Ca, Ba, Mg and combinations thereof,
wherein element D is one or more elements selected from the group consisting of Mn, Ce, Pr, Nd, Sm, Eu, Tb, Dy, Ho, Er, Tm, alkali metals and Yb,
wherein element A is selected from divalent metals different than those of the elements M and D,
wherein element B is selected from trivalent metals,
wherein element E is selected from monovalent metals,
wherein element G is selected from tetravalent elements,
wherein element L is selected from trivalent elements,
wherein element X is selected from 0 or halogen,
wherein a parameter a is between 0.6 and 1.0, and
wherein the first phosphor crystallizes in space groups P1, P2, P1 or P21.

US Pat. No. 10,711,189

LIGHT SOURCE UNIT AND PROJECTION DISPLAY APPARATUS

Sony Corporation, Tokyo ...

1. A light source unit comprising:a light source section; and
a fluorescent structure including a fluorescent part where light from the light source section enters,
the fluorescent part including a plurality of phosphors each having a surface that is covered with a transparent coating layer,
wherein the fluorescent structure includes:
a first substrate;
a second substrate; and
a first adhesive part and a second adhesive part that adhere the first substrate to the second substrate, wherein the fluorescent part is between the first adhesive part and the second adhesive part,
wherein the first substrate and the second substrate each include an opening to accommodate a motor, and
wherein the phosphors are not coupled to the first and second substrates.

US Pat. No. 10,711,187

FLUORIDE PHOSPHOR, METHOD OF MANUFACTURING THE SAME, AND LIGHT EMITTING DEVICE

SAMSUNG ELECTRONICS CO., ...

1. A method of manufacturing a fluoride phosphor represented by a chemical formula A3MF7:Mn4?, the method comprising:forming a first mixture by mixing a first raw material containing A2MF6 and a second raw material containing AF or AHF2;
forming a second mixture by mixing the first mixture and a sintering aid; and
firing the second mixture,
wherein in the chemical formula, A is selected from the group consisting of lithium (Li), sodium (Na), potassium (K), rubidium (Rb), cesium (Cs) and mixtures thereof, and M is selected from the group consisting of silicon (Si), titanium (Ti), zirconium (Zr), hafnium (Hf), germanium (Ge), tin (Sn) and mixtures thereof; and
the sintering aid comprises at least one of NH4F, NH4HF2, F2, and XeF2.

US Pat. No. 10,711,186

PHOSPHOR, PRODUCING METHOD THEREOF, AND LIGHT-EMITTING DEVICE EMPLOYING THE PHOSPHOR

Kabushiki Kaisha Toshiba,...

1. A phosphor:having a basic structure comprising at least one element selected from the group consisting of potassium, sodium and calcium; at least one element selected from e group consisting of silicon and titanium; and fluorine;
wherein said phosphor is a manganese-activated fluoride phosphor; and shows an IR absorption spectrum in which the intensity ratio of the peak in the range of 3570 to 3610 cm?to that in the range of 1200 to 1240 cm?1 is 0.1 or less.

US Pat. No. 10,711,185

REAGENT AND KIT FOR PERFORMING CHEMILUMINESCENT REACTION

BIO-HELIX CO., LTD., Kee...

1. A reagent for performing a luminol chemiluminescent reaction catalyzed by peroxidase, comprising:luminol or luminol derivatives;
an oxidant;
an electron mediator; and
an enhancer, which is a nitrogen-containing fused heterocyclic compound having at least two nitrogen atoms and is selected from the group consisting of imidazo[1,2-a]pyridine, a compound of Formula (Ia), and a compound of Formula (Ib):

wherein in Formula (Ia) and Formula (Ib), a, b, c and d are respectively a single bond or a double bond;
in Formula (Ia),
b is a double bond, R1 and R3 are respectively a hydrogen atom (H), —NH2, —NHR5, —N(R5)2, —OH or —SH, but R1 and R3 are not hydrogen atoms at the same time and R2 is absent when a is a single bond; or
b is a single bond, R1 is an oxygen atom (O), R2 is a hydrogen atom (H), and R3 is hydrogen atom (H), —NH2, —NHR5, —N(R5)2, —OH or —SH when a is a double bond,
where R5 is an unsubstituted alkyl group having 1 to 3 carbon atoms or an alkyl group having 1 to 3 carbon atoms, substituted with a phenyl group;
in Formula (Ib),
b is a double bond, c is a double bond, d is a single bond, R1 and R3 are respectively a hydrogen atom (H), —NH2, —NHR5, —N(R5)2, —OH or —SH, and R2 and R4 are absent when a is a single bond; or
b is a single bond when a is a double bond and d is a single bond when c is a double bond, R1 is an oxygen atom (O) or a sulfur atom (S), R2 and R3 are respectively a hydrogen atom (H), and R4 is absent; or
b is a single bond when a is a double bond and d is a double bond when c is a single bond, R1 and R3 are respectively an oxygen atom (O) or a sulfur atom (S), and R2 and R4 are respectively a hydrogen atom (H).

US Pat. No. 10,711,183

SYNTHESIS OF NANOCRYSTALS

MASSACHUSETTS INSTITUTE O...

1. A nanocrystal composition comprising:a nanocrystal, and
an outer layer including a ligand bound to the nanocrystal, wherein
the ligand includes a norbornene group and a carboxyl group.

US Pat. No. 10,711,182

PHOTOCHROMIC ARTICLES CONTAINING A POLYOXOMETALATE AND METHODS OF MAKING AND USING SAME

3M Innovative Properties ...

1. A photochromic article comprising:a structural component, wherein the structural component comprises a porous material, a plurality of cavities, or a combination thereof;
a fluid in contact with the structural component; and
a polyoxometalate complex comprising a counter cation complexed with either a polyoxometalate anion or a polyoxometalate derivative anion, wherein the polyoxometalate complex is in contact with the fluid, wherein at least a portion of the polyoxometalate complex is dissolved or dispersed in the fluid, and wherein the article is photochromic.

US Pat. No. 10,711,181

METHODS AND SYSTEMS INCORPORATING N-(PHOSPHONOALKYL)IMINODIACETIC ACID PARTICULATES

HALLIBURTON ENERGY SERVIC...

1. A method comprising:introducing a foamed treatment fluid having a continuous liquid phase and a discontinuous gas phase into a wellbore penetrating a subterranean formation, the foamed treatment fluid being substantially free of hydrofluoric acid or a hydrofluoric acid-generating compound, the foamed treatment fluid comprising:
a plurality of particulates comprising an N-(phosphonoalkyl)iminodiacetic acid, and
an acid in which the N-(phosphonoalkyl)iminodiacetic acid is substantially insoluble; and
depositing at least a portion of the plurality of particulates at one or more locations within the subterranean formation.

US Pat. No. 10,711,180

PROCESS FOR MAKING AND USING A COMPOSITION OF MATTER

Economy Mud Products Comp...

1. A process for making a ground product composition of matter, the process comprising:reacting a guar split with at least one reagent at a reaction temperature in a range of 120° F. to 180° F. to form a guar derivative;
treating the guar derivative with at least one of washing and drying to form a resultant treated derivative;
transferring the resultant treated derivative to a co-grinder operably associated with a heated vacuum system; and
co-grinding the resultant treated derivative with a powdered acid to form a ground product,wherein the heated vacuum system further comprises:a combustion burner;
a micropulsair dust collector configured for use as a dryer;
and a blower configured for pulling a vacuum.

US Pat. No. 10,711,179

METHOD FOR ENHANCING FLUID RECOVERY FROM SUBSURFACE RESERVOIRS

1. A method for enhancing the extraction of fluids from subterranean hydrocarbon-bearing, geological formations, comprising introducing a Gemini surfactant into the subterranean hydrocarbon-bearing geological formation, wherein the Gemini surfactant comprises a first simple surfactant molecule (T1Hd1) and a second simple surfactant molecule (Hd2T2), linked by a spacer moiety (A), wherein the general formula of the Gemini surfactant is (T1Hd1)-A-(Hd2T2);a. wherein the first simple surfactant molecule, (Hd1T1) comprises a hydrophobic tail T1 and a hydrophilic head Hd1 and the second surfactant molecule (Hd2T2) comprises a by tail T2 and a hydrophilic head Hd2;
b. wherein the first simple surfactant molecule (Hd1T1) is chemically abound to the spacer moiety (A) at, or near, the hydrophilic head (Hd1) of the first simple surfactant molecule, and the second simple surfactant molecule (Hd2T2) is chemically bound to the spacer moiety (A) at, or near, the hydrophilic head (Hd2) of the second simple surfactant molecule, and
c. wherein Hd1T1 is [(CH3)2N(CH2)mCH3]?[Cl]?,
Hd2T2 is [(CH3)2N(CH2)mCH3]?[Cl]?,
the spacer moiety A is (CH2)2, and where m is 7.9 or 17.

US Pat. No. 10,711,178

SECONDARY AND TERTIARY GREEN WATER FLOODING OF FRACTURED AND HETEROGENEOUS OIL RESERVOIRS AT HIGH SALINITY AND HIGH TEMPERATURE

Abu Dhabi University, Ab...

1. A method comprising:generating an aqueous extract with a ratio of 80% by volume of Ziziphus Spina Christi and 20% by volume of Aloe Vera and a salinity of 86,000 ppm;
inserting the aqueous extract into an oil reservoir; and
recovering, with the aqueous extract, 77.3% of oil trapped in the oil reservoir having a salinity of more than 86,000 ppm.

US Pat. No. 10,711,177

ENGINEERING FORMATION WETTABILITY CHARACTERISTICS

CHEVRON U.S.A. INC., San...

1. A method to select a brine composition to be injected into a formation to alter wettability at a surface of the formation to enhance recovery of hydrocarbons from the formation, the method comprising:providing a plurality of substrates representative of a formation;
providing a plurality of brine compositions;
providing a plurality of reducing agents characterized as yielding oxyanions when added to an aqueous stream;
selecting a brine composition with at least one reducing agent based on interactions between the plurality of substrates, the plurality of brine compositions, and the plurality of reducing agents, wherein selecting the brine composition with the at least one reducing agent comprises:
conducting an uncertainty analysis using various combinations of the plurality of the substrates, the plurality of the brine compositions, and the plurality of the reducing agents;
correlating results from the uncertainty analysis to determine interactions between the plurality of the reducing agents, the plurality of the brine compositions, and concentrations of the plurality of the reducing agents with wettability altering characteristics; and
using the correlated results from the uncertainty analysis to select the brine composition with the at least one reducing agent to inject into the formation to enhance recovery of the hydrocarbons from the formation.

US Pat. No. 10,711,176

METHOD, PROCESS, APPARATUS AND CHEMICALS TO PRODUCE AND INJECT PARAFFIN TREATING COMPOUNDS

1. A system for in-line mixing and injection of paraffin treatment solutions comprising:a first feed tank containing a precursor salt and selectively in communication with a first conduit;
a first positive displacement pump in line with the first conduit;
a second feed tank containing an acid and selectively in communication with a second conduit;
a second positive displacement pump in line with the second conduit;
an in-line motion mixer selectively in communication with the first conduit and second conduit, wherein the in-line motion mixer combines the precursor salt and the acid to form a carbon disulfide solution and release it into an exit conduit; and
an injection manifold which receives the carbon disulfide solution from the exit conduit and releases it into a flowline.

US Pat. No. 10,711,175

COMPOSITIONS AND METHODS FOR CONTROLLING PARAFFIN AND ASPHALTENE PROBLEMS IN WELLS

Sasol Performance Chemica...

1. A composition for use in controlling heavy hydrocarbon deposits, including both paraffins and asphaltenes, in oil and gas wells comprising:A. an ether having the general formula:
R—O—R1  I
wherein R and R1 are each alkyl groups which, independent of each other, can be linear or branched containing from about 1 to about 29 carbon atoms, said ether being present in an amount of 40 wt % to 90 wt %
B. at least one additional component selected from the group consisting of:
(i) an ester of the formula:

wherein R2-R5 are linear or branched alkyl groups having from 1 to 30 carbon atoms and n is from 0 to 20;
(ii) an alkoxylated branched alcohol having the general formula:
CH3(CxH2x)—O—(CnH2nO)y—(C2H4O)z—H  IV
wherein x is from 3 to 30, n is from 2 to 4, y is from 0 to 6 and z is from 3 to 20;
(iii) mixtures of (i) and (ii); and C. a hydrocarbon co-solvent comprising a liquid hydrocarbon containing from about 6 to about 30 carbon atoms, and from about 20 to about 90 wt % or greater naphthenics, isoparaffins, or mixtures thereof.

US Pat. No. 10,711,172

AIR CONDITIONING REFRIGERANT OIL THERMAL ADDITIVE

Alltemp Products Company ...

1. A composition comprising:an organosilane component and an orthoformate component, wherein a weight ratio of organosilane:orthoformate is approximately 1:50.

US Pat. No. 10,711,171

ABRASIVE ARTICLE INCLUDING SHAPED ABRASIVE PARTICLES

1. A shaped abrasive particle comprising a body having a first major surface, a second major surface, and a side surface joined to the first major surface and the second major surface, a first exterior corner and a second exterior corner, wherein at least one edge defined by the joining of the side surface with the first major surface comprises a first discrete stepped depression having a first depression and a second depression, and wherein the first discrete stepped depression is spaced away from the first exterior corner and the second exterior corner.

US Pat. No. 10,711,168

PROCESS FOR ASSEMBLING ELEMENTS CONTAINING BIOLOGICAL SUBSTANCES

SICPA HOLDING SA, Prilly...

1. An adhesive composition for assembling a biomedical device comprising at least two components, the adhesive composition in an uncured state comprises:an epoxy composition comprising at least one di-functional epoxy monomer;
an acrylate composition comprising at least one multi-functional acrylate monomer selected from the group consisting of (i) tri-(meth)acrylates, (ii) tetra-(meth)acrylates, and mixtures thereof;
at least one cationic photoinitiator capable of initiating curing of the epoxy composition;
at least one free radical photoinitiator capable of initiating curing of the acrylate composition;
at least one reactive diluent capable of copolymerizing with the epoxy composition; and
at least one adhesion promoter.

US Pat. No. 10,711,162

ADHESIVE AGENT

DAICEL CORPORATION, Osak...

1. An adhesive comprising:a multivalent vinyl ether compound (A) comprising at least one compound selected from the group consisting of
a compound represented by Formula (a-1):

a compound represented by Formula (a-2):

a compound represented by Formula (a-4):
anda compound represented by Formula (a-6):
andat least one of:
a compound (B) represented by Formula (b); and
a compound (C) including two or more constitutional units each represented by Formula (c), Formulae (b) and (c) expressed as follows:
Z1?X)n1  (b)
wherein Z1 represents a group corresponding to a compound selected from the group consisting of saturated or unsaturated aliphatic hydrocarbons, saturated or unsaturated alicyclic hydrocarbons, aromatic hydrocarbons, heterocyclic compounds, and compounds including two or more of them bonded to one another with or without medium of a linkage group, except for removing hydrogen atoms in a number of n1 from a structural formula of the compound; X is selected from a hydroxyl group and a carboxyl group; and n1 represents an integer of 2 or more, where n1 occurrences of X may be identical to or different from each other,

wherein Z2 represents a group corresponding to a compound selected from the group consisting of saturated or unsaturated aliphatic hydrocarbons, saturated or unsaturated alicyclic hydrocarbons, aromatic hydrocarbons, heterocyclic compounds, and compounds including two or more of them bonded to one another with or without medium of a linkage group, except for removing hydrogen atoms in a number of (n2+2) from a structural formula of the compound; X is selected from a hydroxyl group and a carboxyl group; and n2 represents an integer of 1 or more, where n2 occurrence(s) of X may be identical to or different from each other.

US Pat. No. 10,711,159

POLISHING COMPOSITIONS

FUJIFILM ELECTRONIC MATER...

1. A composition comprising:a) about 0.01 wt % to about 10 wt % of an abrasive;
b) about 0.001 wt% to about 0.1 wt % of a first surfactant comprising a phosphate;
c) about 0.001 wt% to about 0.05 wt % of a second surfactant comprising an acetylenic compound;
d) about 0.1 wt % to about 20 wt% a complexing agent;
e) about 0.001 wt % to about 5 wt% of at least one azole; and
f) water,
wherein the composition is free of poly(vinylpyrrolidone).

US Pat. No. 10,711,154

CURING AGENTS FOR HYDROPHOBIC EPOXY COMPOSITIONS

The United States of Amer...

3. The composition according to claim 2, wherein said tougheners for cured epoxies are selected from the group consisting of thermoplastics, elastomers, reactive elastomers in the range of 1% by weight to about 20% by weight.

US Pat. No. 10,711,148

COLORING COMPOSITION, INK JET RECORDING INK, INK JET RECORDING METHOD, AND INK JET PRINTER CARTRIDGE

FUJIFILM Corporation, To...

1. A coloring composition comprising:a compound represented by the following Formula (1); and
a compound represented by the following Formula (D),

in Formula (1), R1, R5, R6, and R10 each independently represent an alkyl group,
R4, R9, R11, R12, R13, R14, R15, R16, R17, R18, R19, and R20 each independently represent a hydrogen atom or a substituent,
R2, R3, R7, and R8 each independently represent a hydrogen atom, an alkyl group, or a substituent represented by the following Formula (A), and
at least one of R2, R3, R7, or R8 represents a substituent represented by the following Formula (A),

in Formula (A), X represents a substituent represented by the following Formula (X1), (X2), or (X3), and
* represents a direct bond to a benzene ring,

in Formula (X1), R401, R402, R403, R404, and R405 each independently represent a hydrogen atom or a substituent,
R401, R402, R403, R404, and R405 satisfy the following condition (i) or (ii),
* represents a direct bond to a sulfur atom,
the condition (i): at least one of R401, R402, R403, R404, or R405 represents a hydroxyl group and at least one of R401, R402, R403, R404, or R405 represents a carboxyl group, and
the condition (ii): at least two of R401, R402, R403, R404, or R405 represent a carboxyl group,

in Formula (X2), R501, R502, R503, R504, R505, R506, and R507 each independently represent a hydrogen atom or a substituent,
R501, R502, R503, R504, R505, R506, and R507 satisfy the following condition (iii) or (iv),
* represents a direct bond to a sulfur atom,
the condition (iii): at least one of R501, R502, R503, R504, R505, R506, or R507 represents a hydroxyl group and at least one of R501, R502, R503, R504, R505, R506, or R507 represents a carboxyl group, and
the condition (iv): at least two of R501, R502, R503, R504, R505, R506, or R507 represent a carboxyl group,

in Formula (X3), R601, R602, R603, R604, R605, R606, and R607 each independently represent a hydrogen atom or a substituent,
R601, R602, R603, R604, R605, R606, and R607 satisfy the following condition (v) or (iv),
* represents a direct bond to a sulfur atom,
the condition (v): at least one of R601, R602, R603, R604, R605, R606, or R607 represents a hydroxyl group and at least one of R601, R602, R603, R604, R605, R606, or R607 represents a carboxyl group, and
the condition (vi): at least two of R601, R602, R603, R604, R605, R606, or R607 represent a carboxyl group,

in Formula (D), R21, R22, and R23 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 9 carbon atoms, an alkoxy group having 1 to 9 carbon atoms, a halogen atom, a hydroxyl group, a substituted or unsubstituted carbamoyl group, a substituted or unsubstituted sulfamoyl group, a substituted or unsubstituted amino group, a nitro group, a sulfonate group, a substituted or unsubstituted alkylsulfonyl group having 1 to 9 carbon atoms, an arylsulfonyl group having 6 to 15 carbon atoms, a carboxyl group, or a carboxylate group,
m represents 0, 1, or 2,
R24, R25, and R26 each independently represent a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 18 carbon atoms, a substituted or unsubstituted alkenyl group having 2 to 18 carbon atoms, a substituted or unsubstituted aryl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted heterocyclic group,
M4 represents a hydrogen atom or a counter cation, and
M4's may be the same as or different from each other.

US Pat. No. 10,711,146

METHOD OF THREE-DIMENSIONAL PRINTING

XEROX CORPORATION, Norwa...

1. A sustainable three-dimensional printing material comprising:a filament consisting of:
a sustainable resin derived from a bio-based diacid monomer and bio-based glycol monomer;
wherein when the sustainable resin is polybutylene succinate, the weight average molecular weight of the sustainable resin is from about 10,000 grams/mole to about 500,000 grams/mole; further wherein the polybutylene succinate is produced through the reaction of bio-based succinic acid and 1,4-butane-diol as shown by the reaction scheme below:

wherein n is from about 100 to about 100,000;
a colorant; and
an optional conductive material.

US Pat. No. 10,711,145

PHOTOCURABLE INK COMPOSITION AND METHOD FOR FORMING IMAGE

FUJIFILM CORPORATION, To...

1. A photocurable ink composition comprising:a resin that includes at least one of a structural unit (1) below or a structural unit (2) below; and
at least one of a monofunctional radical-polymerizable monomer or a bifunctional radical-polymerizable monomer,
wherein a total content of the monofunctional radical-polymerizable monomer and the bifunctional radical-polymerizable monomer is 50% by mass or more relative to a total amount of the photocurable ink composition:

wherein, in the structural unit (1),
R1 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms,
two Y1 each independently represent a single bond or a divalent organic group having 1 to 20 carbon atoms,
two Z1 each independently represent a single bond, a carbonate bond, an amide bond, or a urethane bond,
two * each represent a binding site, and
provided that, in a case where one of two Z1 is a single bond, the other is not a single bond, and
wherein, in the structural unit (2),
R1 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms,
R2 represents a hydrogen atom or a hydrocarbon group having 1 to 12 carbon atoms,
X represents an ether bond or an ester bond,
Y2 represents a trivalent organic group having 1 to 20 carbon atoms,
two Z2 each independently represent a single bond, an ester bond, a carbonate bond, an amide bond, or a urethane bond,
two * each represent a binding site, and
provided that, in a case where one of two Z2 is a single bond, the other is not a single bond.

US Pat. No. 10,711,144

ANTI-SCATTERING FILM AND METHOD FOR MANUFACTURING SAME

LG Chem, Ltd., (KR)

1. An anti-scattering film comprising:a transparent film; and
a hard coating layer formed on top of the transparent film,
wherein the hard coating layer is formed of a composition which comprises a UV-curable acrylate resin, hydrophobically surface-modified inorganic nanoparticles, a photoinitiator, and a mixed solvent comprising a ketone-based solvent and an alcohol-based solvent,
wherein the surface-modified inorganic nanoparticles aggregate with each other to form surface-modified inorganic nanoparticle clusters, and only a portion of the surface-modified inorganic nanoparticle clusters are buried in the composition, so that portions which are not buried are exposed to form a plurality of protruding parts on an upper surface of the hard coating layer, and
wherein an alkyl group having 9, 11 or 12 carbon atoms is introduced into outer surfaces of the surface-modified inorganic nanoparticles.

US Pat. No. 10,711,142

ANTIREFLECTION FILM AND DISPLAY DEVICE

LG CHEM, LTD., Seoul (KR...

1. An antireflection film comprising:a hard coating layer; and a low refractive index layer formed on the hard coating layer,
wherein the antireflection film has a surface concavo-convex structure having a peak with a convex portion and a valley with a concave portion, and
wherein the sum of the volume of the convex portion of the peak equal to or higher than an average line is greater than 0 and less than 0.03 mm3 in a surface area of 1.47 mm2, and the sum of the volume of the concave portion of the valley equal to or higher than an average line is greater than 0 and less than 0.03 mm3 in a surface area of 1.47 mm2.

US Pat. No. 10,711,140

METHODS FOR SOL-GEL POLYMERIZATION IN ABSENCE OF SOLVENT AND CREATION OF TUNABLE CARBON STRUCTURE FROM SAME

Group14 Technologies, Inc...

1. A method for preparing a carbon material, comprising:a. preparing a mixture by physically blending polymer precursors, wherein the mixture comprises less than 10% solvent by weight, and the polymer precursors comprise monomers;
b. aging the mixture at a temperature for a time sufficient for the polymer precursors to react with each other and form a polymer; and
c. pyrolyzing the polymer in an inert atmosphere.

US Pat. No. 10,711,139

LEUCO POLYMERS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS

1. A leuco polymer comprising a leuco monomer and an alkene, wherein the leuco polymer has a molecular weight of at least 500 and is obtained by polymerization of the leuco monomer and one or more alkene co-monomers, wherein the leuco monomer consists of an alkene covalently bound to a leuco moiety and the leuco monomer has a maximum molar extinction coefficient at a wavelength in the range 400 to 750 nm of less than 1000 M?1 cm?1, wherein the alkene co-monomer(s) have a maximum molar extinction coefficient at a wavelength in the range 400 to 750 nm that is less than 100 M?1 cm?1;wherein the leuco moiety is a univalent or polyvalent moiety derived by removal of one or more hydrogen atoms from a structure of Formula (I):

wherein the ratio of Formula (I) to its oxidized form is at least 1:3; wherein each individual Ro, Rm and Rp group on each of rings A, B and C is independently selected from the group consisting of hydrogen, deuterium and R5; wherein each R5 is independently selected from the group consisting of halogens, nitro, alkyl, substituted alkyl, aryl, substituted aryl, alkaryl, substituted alkaryl, —C(O)R1, —C(O)OR1, —C(O)O?, —C(O)NR1R2, —OC(O)R1, —OC(O)OR1, —OC(O)NR1R2, —S(O)2R1, —S(O)2OR1, —S(O)2O?, —S(O)2NR1R2, —NR1C(O)R2, —NR1C(O)OR2, —NR1C(O)SR2, —NR1C(O)NR2R3, —OR1, —NR1R2, —P(O)2R1, —P(O)(OR1)2, —P(O)(OR1)O?, and —P(O)(O?)2; wherein at least one of the Ro and Rm groups on at least one of the three rings A, B or C is hydrogen; each Rp is independently selected from hydrogen, —OR1 and —NR1R2;
wherein G is independently selected from the group consisting of hydrogen, deuterium, C1-C16 alkoxide, phenoxide, bisphenoxide, nitrite, nitrile, alkyl amine, imidazole, arylamine, polyalkylene oxide, halides, alkylsulfide, aryl sulfide, and phosphine oxide;
wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkaryl, substituted alkaryl, and R4; R4 is an organic group composed of one or more organic monomers with said monomer molecular weights ranging from 28 to 500;
wherein any charge present is balanced with a suitable independently selected internal or external counterion; and
wherein (i) two Ro groups on different A, B and C rings combine to form a fused ring of five or more members, (ii) an Ro and Rm on the same ring combine to form a fused aliphatic ring or fused aromatic ring, or (iii) an Rm and Rp on the same ring combine to form a fused aliphatic ring or fused aromatic ring.

US Pat. No. 10,711,138

INTERMEDIATES AND PROCEDURES FOR THE SYNTHESIS OF FUNCTIONAL MATERIALS

Merck Patent GmbH, Darms...

1. A method of synthesizing a compound of formula (I),
where the following applies to the variable groups occurring:
G1, G2 are selected from reactive groups, and G1 and G2 are selected differently;
Y is S;
Z either is selected, identically or differently, from CR1 and N;
or the unit Z—Z is replaced by a divalent group selected from —S— and —Se—;
R1 is selected, identically or differently on each occurrence, from H, D, F, Cl, CN, NO2, N(R2)2, —(C?O)OR2, —O(C?O)R2, and alkyl, alkoxy or thioalkoxy groups having 1 to 20 C atoms, where the alkyl, alkoxy and thioalkoxy groups may be substituted with one or more radicals R2, and where one or more CH2 groups in the alkyl, alkoxy and thioalkoxy groups may be replaced by —R2C?CR2—, -C?C, C?O, C?S, —C(?O)O—, —OC(?O)—, —Si(R2)2—, —NR2—, —O— or —S—;
R2 is selected, identically or differently on each occurrence, from H, D, F, Cl, CN, NO2, NH2, NAr2, and alkyl, alkoxy or thioalkoxy groups having 1 to 20 C atoms, where one or more CH2 groups in the alkyl, alkoxy and thioalkoxy groups may be replaced by —HC?CH—, -C?C-, C?O, C?S, —C(?O)O—, —OC(?O)—, —NH—, —O— or —S—, and where the alkyl, alkoxy and thioalkoxy groups may be substituted with one or more radicals selected from F, Cl and CN; and
Ar is selected, identically or differently, from aryl and heteroaryl groups having 5 to 30 aromatic ring atoms, which may be substituted by one or more radicals R2 which do not comprise a group Arwherein a compound of the formula (I-Int)where T is selected from H, D, and —OH, andthe other variable groups occurring are as defined above for formula Iis used as the starting material.

US Pat. No. 10,711,136

ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM

VITROLABS INC, South San...

1. A method comprising: tanning at least a portion of an artificial dermal layer comprising a hair follicle cell, wherein said tanning comprises a vegetable tanning, a chrome tanning, an aldehyde tanning, syntan, or a bacterial dyeing, and wherein said artificial dermal layer comprises a fibroblast differentiated from a stem cell.

US Pat. No. 10,711,134

LIQUID CRYSTAL POLYESTER RESIN COMPOSITION

UENO FINE CHEMICALS INDUS...

1. A liquid crystal polyester resin composition, comprising:a liquid crystal polyester (A) consisting of repeating units represented by formulae (I) to (III),

wherein each of Ar1 and Ar2 represents one or more divalent aromatic groups, and p, q, and r are molar percentages of the respective repeating units in the liquid crystal polyester (A) and satisfy the following condition,
35?p?90
5?q?30, and
5?r?30;
a liquid crystal polyester (B) including repeating units represented by formulae (IV) and (V),

wherein
s and t are molar percentages of the respective repeating units in the liquid crystal polyester (B) and satisfy the following condition,
80/20?s/t?60/40; and
surface-treated glass fibers (C) including an epoxy resin on the surface thereof, wherein
the mass ratio of (A) to (B) [A/B] is from 90/10 to 45/55,
the content of (C) is from 10 to 130 parts by mass relative to 100 parts by mass of the total amount of (A) and (B), and
as measured in a bending test using a molded article which is a strip having a length of 127 mm, width of 12.7 mm, and thickness of 0.5 mm, the bending strength and the bending elastic modulus of the liquid crystal polyester resin composition are equal to or more than 330 MPa and equal to or more than 20 GPa, respectively.

US Pat. No. 10,711,132

USE OF AN ESTERIFIED AROMATIC POLYPHENOL DERIVATIVE FOR THE PRODUCTION OF A PHENOL-ALDEHYDE RESIN FOR REINFORCEMENT OF A RUBBER COMPOSITION

Compagnie Generale Des Et...

1. A method for the manufacture of a phenol-aldehyde resin for reinforcing a rubber composition comprising the steps of:mixing at least one aldehyde and an aromatic polyphenol derivative, wherein the aromatic polyphenol derivative is selected from the group consisting of the aromatic polyphenol derivatives (IV), (V), and mixtures thereof, the aromatic rings bearing at least two —O—Z groups in the meta position relative to one another, the two positions ortho to at least one of the —O—Z groups being unsubstituted, and each —O—Z group representing an —O—((C?O)(R1)) group with R1 representing a hydrocarbon-based radical or a substituted hydrocarbon-based radical,
andcrosslinking the aromatic polyphenol derivative and the at least one aldehyde to produce the phenol-aldehyde resin.

US Pat. No. 10,711,125

COMPOSITION COMPRISING HETEROPHASIC PROPYLENE COPOLYMER

SABIC GlOBAL TECHNOLOGIES...

1. A composition comprising:(A) a heterophasic propylene copolymer; and
(B) a nucleating composition;
wherein (A) the heterophasic propylene copolymer consists of
(a) a propylene-based matrix, wherein the propylene-based matrix consists of a propylene homopolymer and wherein the propylene-based matrix is present in an amount of 83 to 88 wt %, based on the total heterophasic propylene copolymer,
wherein the propylene-based matrix has a molecular weight distribution as Mw/Mn of 3 to 6, wherein Mw stands for the weight average molecular weight and Mn stands for the number average weight, both of which are measured according to ASTM D6474-12, and
(b) a dispersed ethylene-?-olefin copolymer, wherein the dispersed ethylene-?-olefin copolymer is present in an amount of 12 to 17 wt %, based on the total heterophasic propylene copolymer, and
wherein the sum of the total amount of propylene-based matrix and total amount of the dispersed ethylene-?-olefin copolymer in the heterophasic propylene copolymer is 100 wt %,
wherein the amount of ethylene in the ethylene-?-olefin copolymer is 40 to 60 wt %, and
wherein the heterophasic propylene copolymer has a melt flow index of 35 to 50 g/10 min as determined according to ISO1133 at 230° C. and 2.16 kg, and
wherein (B) the nucleating composition comprises
(i) a first nucleating agent, which comprises a cyclic dicarboxylate salt compound, and
(ii) a second nucleating agent, which comprises talc,
wherein the cyclic dicarboxylate salt compound has the formula (I):

US Pat. No. 10,711,115

PROCESS FOR EXTRUDING POLYPROPYLENE

1. A process for extruding polypropylene comprising, in order:a. extruding a first composition through a first extruder forming a first extrudate, wherein the first composition comprises first reactor flake polypropylene, a nucleating agent, and a first acid scavenger, wherein the nucleating agent is in an amount of at least about 50 ppm;
b. extruding a second composition through the first extruder following step a. forming a second extrudate, wherein the second composition comprises second reactor flake polypropylene and a second acid scavenger, wherein the second acid scavenger is a potassium salt of a fatty acid, wherein the second extrudate contains between about 0.01 ppm and 1 ppm of the nucleating agent, and wherein the content of all nucleating agents in the second extrudate is less than 10 ppm.

US Pat. No. 10,711,114

PPTC COMPOSITION AND DEVICE HAVING THERMAL DEGRADATION RESISTANCE

Littelfuse, Inc., Chicag...

1. A polymer positive temperature coefficient (PPTC) material, comprising:a polymer matrix, a conductive filler, and a thermal stabilizer, wherein the thermal stabilizer comprises 4% by volume antimony oxide, wherein the polymer matrix comprises ethylene tetrafluoroethylene copolymer, wherein a grain size of particles of the conductive filler is in a range of 50 nm to 100 ?m, and wherein a volume fraction of the conductive filler ranges from 5% to 9%.

US Pat. No. 10,711,109

METHOD OF MAKING A SEMIFINISHED PRODUCT

1. A method of making a semifinished product for the manufacture of a composite fiber molded part, the method comprising the steps of:a) melt-blowing from a row of orifices of a nozzle low-melting fibers of a thermoplastic;
b) forming the meltblown low-melting fibers into two layers;
c) sandwiching between the layers of the meltblown low-melting plastic fibers high-melting reinforcement fibers of the same thermoplastic but having a melting temperature higher than the melting temperature of the meltblown low-melting fibers to form a laminated semifinished product;
d) consolidating the laminated semifinished product by mechanical needling, water-jet stabilization, calendering, thermobonding with hot air, adhesion, or chemical bonding;
e) applying heat or pressure to the laminated semifinished product such that the low-melting fibers melt, impregnate the high-melting reinforcement fibers, and form a matrix in which the high-melting reinforcement fibers are embedded; and thereafter
f) forming the laminated semifinished product into a molded body.

US Pat. No. 10,711,108

CROSSLINKING MATERIALS FROM BIORENEWABLE ACONITIC ACID

International Business Ma...

1. A process comprising forming a tri-alcohol compound by reducing an aconitic acid compound.

US Pat. No. 10,711,103

DCPD-DERIVED POLYETHER AND METHOD OF PRODUCING THE SAME

NATIONAL CHUNG SAN INSTIT...

1. A dicyclopentdiene (DCPD)-derived polyether expressed by structural formula (I) below,
where R is,

where n=10-100;
wherein the dicyclopentdiene (DCPD)-derived polyether is made by the steps of:
(1) allowing a compound expressed by structural formula (A) below

to react with 4,4?-difluorobenzophenone by alkaline catalysis to obtain polymer (B)

(2) allowing polymer (B) to react with 9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (DOPO) and phenol by acid catalysis to obtain DCPD-derived polyether expressed by structural formula (I-a) below,

where n=10-100; and
(3) allowing the polyether expressed by structural formula (I-a) to react with methacrylic anhydride by alkaline catalysis to obtain the dicyclopentdiene (DCPD)-derived polyether, wherein the DCPD-derived polyether has a glass transition temperature around 290° C.

US Pat. No. 10,711,102

METHOD FOR ISOLATING A PHENYLENE ETHER OLIGOMER COMPOSITION AND PHENYLENE ETHER OLIGOMER COMPOSITION

SABIC GIOBAL TECHNOLOGIES...

1. A method for isolating a phenylene ether oligomer composition, the method comprising,feeding a solution comprising a solvent and a phenylene ether oligomer into a thin film evaporator comprising a cylindrical heating chamber and a rotor comprising one or more rotor blades, wherein an edge of the one or more rotor blades and an interior surface of the cylindrical heating chamber are separated by a distance of 0.5 to 3.5 millimeters;
forming a film comprising the phenylene ether oligomer and the solvent on the interior surface of the cylindrical heating chamber; and
heating the cylindrical heating chamber to devolatilize the solvent from the film to provide a phenylene ether oligomer composition having an intrinsic viscosity of 0.03 to 0.13 deciliter per gram and a zero shear melt viscosity of greater than 10,000 centipoise at 200° C. and comprising:
a phenylene ether oligomer having an external amine content of less than 1.5 weight percent; and
a residual solvent in an amount of 0 to 10,000 parts per million by weight (ppm), based on the weight of the phenylene ether oligomer composition.

US Pat. No. 10,711,101

ISOTACTIC POLYETHERS AND BIMETALLIC CATALYSTS, METHODS OF MAKING SAME, AND USES THEREOF

Cornell University, Itha...

1. A polymer comprising the structure:
wherein CSG is a chain shuttling group and PE is an isotactic polyether group, and i is from 1 to 10,
the isotactic polyether group comprises at least 2 stereoregular blocks having the following structure:

 wherein R1 is H or C1 to C20 aliphatic group, R4 is H or C1 to C20 aliphatic group,

 R2 is H or a C1 to C20 aliphatic group, R3 is H or a C1 to C20 aliphatic group, n is independently at each occurrence in the polyether group 5 to 500, x and y are independently at each occurrence in the polyether group 5 to 500, and z is greater than or equal to 1, and
the mr-triad+rm-triad is greater than or equal to 2 times the rr-triad, and the Mn of the polymer is from 500 to 500,000 g/mol.

US Pat. No. 10,711,100

DIHYDROXY COMPOUND

MITSUBISHI GAS CHEMICAL C...

1. A dihydroxy compound comprising a dihydroxy compound represented by the following formula (1), whereinthe total weight of a compound represented by the following formula (A), a compound represented by the following formula (B), and a compound represented by the following formula (C) in the dihydroxy compound is 1 ppm or more and 1,500 ppm or less, based on 100 parts by weight of the dihydroxy compound represented by the formula (1):
wherein X represents an alkylene group containing 1 to 4 carbon atoms,

US Pat. No. 10,711,099

OPTICAL USE POLYCARBONATE RESIN COMPOSITION METHOD FOR PRODUCING SAME, AND SPECTACLE LENS AND CAMERA LENS CONTAINING SAME

MITSUBISHI GAS CHEMICAL C...

1. An optical polycarbonate resin composition, comprising: a polycarbonate resin (A) comprising a structural unit represented by formula (1) below and having an intrinsic viscosity of 0.320 to 0.630 dL/g; and polycarbonate resin (B) comprising a structural unit represented by formula (2) below and having an intrinsic viscosity of 0.423 to 0.600 dL/g, wherein the resin composition comprises the polycarbonate resin (B) in an amount of 45 to 75% by mass

US Pat. No. 10,711,097

POLYLACTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND POLYLACTIDE STEREOCOMPLEX

NATIONAL UNIVERSITY CORPO...

1. A polylactic acid derivative expressed by a following general formula (1):where one of X1-X5 is an aldehyde group, one of the other four is an alkoxy group, and the other three are hydrogen atoms, and wherein n represents the number of lactide repeating units in the polylactic acid derivative.

US Pat. No. 10,711,096

AQUEOUS MONOMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

Elevance Renewable Scienc...

1. A method of forming a polymer, the method comprising:(a) providing a composition comprising: water and a compound of formula (I)

wherein:
X1 is C12-20 alkylene, optionally substituted one or more times with substituents selected independently from —OH and C1-6 oxyalkyl;
R1 and R2 are independently —OH, —O—R4, or —O?Z+;
R4 is C1-6 alkyl or C2-24 heteroalkyl, each of which is optionally substituted one or more times by —OH; and
Z+ is a positively charged counterion;
provided that at least one of R1 and R2 is not —OH; and
(b) reacting one or more compounds of formula (I) with one or more monomers to form a polymer.

US Pat. No. 10,711,095

SYSTEMS AND METHODS FOR PRODUCING SUPERABSORBENT POLYMERS

Novomer, Inc., Rochester...

1. A production system for superabsorbent polymers from ethylene oxide and carbon monoxide, comprising:a ?-propiolactone production system, comprising:
a first reactor comprising:
at least one inlet to receive carbon monoxide, ethylene oxide, carbonylation catalyst, and solvent; and
at least one outlet for a first ?-propiolactone stream comprising ?-propiolactone, solvent, and carbonylation catalyst;
a carbonylation catalyst recycling system configured to separate at least a portion of the carbonylation catalyst from the first ?-propiolactone stream to produce a second ?-propiolactone stream; and
a superabsorbent polymer production system, comprising:
a second reactor comprising:
at least one inlet to receive the second ?-propiolactone stream, a crosslinking agent, and a sodium-containing component; and
at least one outlet for a superabsorbent polymer stream comprising superabsorbent polymer.

US Pat. No. 10,711,094

CONJUGATED POLYMER NANOPARTICLES, METHODS OF USING, AND METHODS OF MAKING

KING ABDULLAH UNIVERSITY ...

1. A composition comprising conjugated polymer nanoparticles with a diameter in the range of 2-5 nm as measured by Transmission Electron Microscopy (TEM), the nanoparticles comprising a polymer including the following structure:wherein R1 is H or an aliphatic group, R2 is H or an aliphatic group, R3 is H or an aliphatic group, and n is an integer between 1 and 10,000.

US Pat. No. 10,711,093

ION EXCHANGE SEPARATION MEMBRANE, ELECTROCHEMICAL CELL INCLUDING SAME, FLOW CELL AND FUEL CELL, AND MANUFACTURING METHOD THEREOF

LG CHEM, LTD., Seoul (KR...

1. An ion exchange polymer membrane having an ion channel provided with an ion transferring group, comprising:a bonding structure formed by at least one ion transferring group comprising —NH3+OH?or —SO3?X, wherein X is a monovalent cation, and at least one compound of Chemical Formula 1:

wherein, in Chemical Formula 1,
R1 and R2 are each hydrogen, an alkyl group or a sulfonic acid group;
L is a direct bond, —O—, —S—, —NH— or —SO2—;
a1 and a3 are each 1 or 2;
a2 and a4 are each an integer of 0 to 4; and
1?a1+a2?5 and 1?a3+a4?5;wherein when the at least one ion transferring group comprises —SO3?X, the bonding structure includes at least one structure represented by the following Chemical Formulae 3 to 7:
wherein in Chemical Formulae 3 to 7:
R3 to R6 are each hydrogen, an alkyl group or a sulfonic acid group;
L1 and L2 are each a direct bond, —O—, —S—, —NH— or —SO2—;
b1 and b3 are each 0 or 1;
b2 and b4 are each an integer of 0 to 4;
0?b1+b2?4 and 0?b3+b4?4;
c1 and c2 are each an integer of 0 to 3;
c3 is 1 or 2, c4 is an integer of 0 to 4 and 1?c3+c4?5;
c5 is 0 or 1, c6 is an integer of 0 to 4 and 0?c5+c6?4; and
represents a bonding site; andwherein when the at least one ion transferring group comprises —NH3+OH?, the bonding structure includes at least one structure represented by the following Chemical Formulae 8 to 12:
wherein in Chemical Formulae 8 to 12:
R3 to R6 are each hydrogen, an alkyl group or a sulfonic acid group;
L1 and L2 are each a direct bond, —O—, —S—, —NH— or —SO2—;
d1, d3 and d5 are each 1 or 2;
d2 and d4 are each an integer of 0 to 3;
d6 is an integer of 0 to 4;
1?d1+d2?4, 1?d3+d4?4 and 1?d5+d6?5;
e1, e3, e5 and d7 are each 1 or 2;
e2 and e4 are each an integer of 0 to 2;
e6 is an integer of 0 to 4;
e8 is an integer of 0 to 3; and
1?e1+e2?3, 1?e3+e4?3, 1?e5+e6?5 and 1?e7+e8?4.

US Pat. No. 10,711,092

GOLD CATALYZED POLYMERIZATION REACTIONS OF UNSATURATED SUBSTRATES

The University of Souther...

1. A method of polymerizing an unsaturated substrate with an arene, comprising use of a gold (Au) catalyst for polymerization and synthesis of a polymer via polyhydroarylation of at least one multifunctional monomer.

US Pat. No. 10,711,090

THERMAL INSULATION

MATERIA, INC., Pasadena,...

1. A method of coating at least a portion of at least one surface of an object with a thermal insulation material, comprising:combining a resin composition comprising a cyclic olefin composition with a catalyst composition comprising at least one metal carbene olefin metathesis catalyst, thereby forming a ROMP composition,
wherein the cyclic olefin composition comprises 10.0 mol % to 80.0 mol % of at least one cyclic olefin containing multiunsaturation, and up to 90.0 mol % of at least one cyclic olefin containing monounsaturation,
wherein the at least one cyclic olefin containing multiunsaturation may be substituted or unsubstituted;
wherein the at least one cyclic olefin containing monounsaturation may be substituted or unsubstituted;
contacting the ROMP composition with at least a portion of at least one surface of the object; and
subjecting the ROMP composition to conditions effective to promote a ROMP reaction of the cyclic olefin composition in the presence of the at least one metal carbene olefin metathesis catalyst, wherein the thermal insulation material is a ROMP polymer or a ROMP polymer composite.

US Pat. No. 10,711,089

UV EPOXY RESIN INSTILLATION MOLDING METHOD AND APPLICATION THEREOF

CollTech (Dongguan) Bondi...

1. A method for instillation molding of a UV epoxy resin, comprising the following steps:the UV epoxy resin preparation step: adding at least two photosensitizers to a single component epoxy resin and uniformly mixing them to obtain the UV epoxy resin, wherein the photosensitizer with the highest content in said UV epoxy resin is a photosensitive curing agent for curing said UV epoxy resin, and the rest photosensitizers are photosensitive viscosity regulating agents for regulating the viscosity of said UV epoxy resin to be suitable for instillation molding; and
instillation step: dividing the instillation molding of the UV epoxy resin into N procedures performed in one work station, wherein zero, one or more photosensitive viscosity regulating agents are initiated in each procedure, so that said UV epoxy resin reaches a viscosity suitable for respective instillation procedure and is subsequently instillation molded; and
curing step: initiating said photosensitive curing agent to finally cure said UV epoxy resin
wherein the main absorption peaks of any two of the photosensitive viscosity regulating agents in said UV epoxy resin are separated from each other, and that the main absorption peak of any one of the photosensitive viscosity regulating agents and the main absorption peak of said photosensitive curing agent in said UV epoxy resin are separated from each other, and
wherein said photosensitive viscosity regulating agent is initiated by irradiation using monochromatic sources having a spectral range of emission wavelength corresponding to the main absorption peak of said photosensitive viscosity regulating agent.

US Pat. No. 10,711,087

PROCESSES FOR PRODUCING VISCOUS EPOXY SYRUPS

TESA SE, Norderstedt (DE...

1. Process for producing an epoxy adhesive comprising:providing an at least one liquid multifunctional epoxy;
adding to the at least one liquid multifunctional epoxy an initiator selected from the group consisting of an electron-poor monoisocyanate, a photoinitiator, and a thermal initiator;
mixing the at least one liquid multifunctional epoxy and the initiator;
cationically polymerizing the at least one liquid multifunctional epoxy, thereby forming an epoxy syrup comprising an at least one uncrosslinked polyepoxy; and
mixing the epoxy syrup with further components to form an epoxy adhesive,wherein:a viscosity of the epoxy syrup is at least twice as high as a viscosity of the at least one liquid multifunctional epoxy before the addition of the initiator; and
the cationic polymerization is stopped upon reaching a desired viscosity by the addition of an initiator scavenger.

US Pat. No. 10,711,085

CROSSLINKING AGENT AND FLUORINE-CONTAINING AROMATIC COMPOUND

NICHIAS CORPORATION, Tok...

1. Compounds respectively represented by the following formulas:

US Pat. No. 10,711,084

IN-CHAIN FUNCTIONALIZED ELASTOMER, RUBBER COMPOSITION AND PNEUMATIC TIRE

1. A functionalized elastomer, wherein the functionalized elastomer is a copolymer of a first monomer and a second monomer, the first monomer selected from the group consisting of conjugated diene monomers and vinyl aromatic monomers, and the second monomer of formula 1wherein R1=C1-C8 alkyl, aryl, substituted aryl, or —SiR3 where R3 are independently C1-C8 alkyl; R2=C1-C8 alkyl, aryl, or substituted aryl, or —SiR3; and n=0-3.

US Pat. No. 10,711,083

ADHESIVE

JAPAN SCIENCE AND TECHNOL...

1. An organic polymer comprising:a main chain formed by a water-soluble polymer unit;
a hydrophilic organic group and a self-assembling group bonded to the water-soluble polymer unit; and
units represented by the following formula (I):

wherein R1 represents a hydrogen atom or a methyl group; R2 represents a hydrocarbon group having 1 to 6 carbon atoms; L1 represents —O— or —NH—; X represents a hydroxy group or an amino group optionally forming an ammonium salt R3 represents a hydrogen atom or a methyl group; R4 represents a hydrocarbon group having 3 to 20 carbon atoms; L2 represents —O— or —NH—; L3 represents a single bond or —CO—; A represents an amino acid residue or oligopeptide which contains at least one amino acid selected from the group consisting of alanine, leucine, isoleucine and valine as a constituent amino acid; R5 represents a hydrogen atom or a methyl group; R6 represents a hydrocarbon group having 4 to 10 carbon atoms; L4 represents —O— or —NH—; m, n and o represent the abundance ratios of the units, and each of m and n represents a numerical value greater than 0, o represents a numeral value not less than 0, and m:n:o satisfies (2 to 20):1:(0 to 3).

US Pat. No. 10,711,082

NEAR INFRARED ABSORBING COLORANT POLYMER, COMPOSITION, FILM, OPTICAL FILTER, PATTERN FORMING METHOD, AND DEVICE

FUJIFILM Corporation, To...

1. A near infrared absorbing colorant polymer having a maximal absorption in a wavelength range of 700 to 1200 nm, comprising:a curable group, and
at least one near infrared absorbing colorant structure,
wherein the at least one near infrared absorbing colorant structure comprises a compound derived from a compound represented by the following Formula (PP),

in Formula (PP), R1a and R1b each independently represent an alkyl group, an aryl group, or a heteroaryl group, R2 and R3 each independently represent a hydrogen atom or a substituent, R2 and R3 may be bonded to each other to form a ring, R4's each independently represent a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, —BR4AR4B, or a metal atom, R4 may form a covalent bond or a coordinate bond with at least one selected from the group consisting of R1a, R1b, and R3, and R4A and R4B each independently represent a hydrogen atom or a substituent.

US Pat. No. 10,711,081

VINYL ALCOHOL-VINYL ACETATE COPOLYMER

TOKUSHIMA UNIVERSITY, To...

1. A method for producing a vinyl alcohol-vinyl acetate copolymer comprising a unit of vinyl alcohol and a unit of vinyl acetate, wherein the vinyl alcohol-vinyl acetate copolymer has a randomness value R of 0.5 or higher, and wherein the randomness value R is obtained using the following equation (1):
where LO represents a mean chain length of the unit of vinyl alcohol and LA represents a mean chain length of the unit of vinyl acetate,
the method comprising the step of:
transesterification of polyvinyl acetate or a raw material vinyl alcohol-vinyl acetate copolymer using a dianionic zincate complex represented by the following formula (2):
t-BunR4-nZnMm  (2)
where n represents an integer of 1 to 4, m represents 1 or 2, Rs may be the same as or different from one another when n represents 1 or 2 and each represent a C1-C8 alkyl, alkenyl, aryl, or arylalkyl group, and M represents lithium or magnesium.

US Pat. No. 10,711,078

POLYMERIZABLE COMPOSITION, PROCESS FOR PRODUCING ORGANIC GLASS USING THE COMPOSITION, AND ORGANIC GLASS

MITSUI CHEMICALS, INC., ...

1. A polymerizable composition comprising:a compound (A) including two or more allyloxycarbonyl groups represented by Formula (1);
a polymerization initiator (B) which is at least one kind selected from the group consisting of a peroxyketal-based radical polymerization initiator, a peroxy monocarbonate-based radical polymerization initiator, and a peroxyester-based radical polymerization initiator; and
a photochromic compound (C) which is at least one kind selected from a naphthopyran compound group,

wherein, in the formula, n is an integer of 2 to 6, R1 represents a hydrogen atom or a methyl group, and a plurality of R1's existing together may be identical to or different from each other, and
X is a divalent to hexavalent organic group a derived from a linear or branched aliphatic polyol having 3 to 12 carbon atoms which optionally have an oxygen atom, a divalent to hexavalent organic group b derived from a cyclic aliphatic polyol having 5 to 16 carbon atoms which optionally have an oxygen atom, or a divalent to hexavalent organic group c derived from an aromatic compound having 6 to 12 carbon atoms, and the organic group a or the organic group b is bonded to an allyloxycarbonyl group via an ether group derived from a hydroxyl group included in these organic groups, so as to form an allyl carbonate group.

US Pat. No. 10,711,076

MOBILE VACUUM DISTILLATION UNIT FOR TRANSPORT OF ARTICLES CONTAINING RELEASABLE VOLATILE ORGANIC COMPOUNDS

GM Global Technology Oper...

1. A mobile vacuum distillation unit comprising:a transportable support platform;
a shell that defines an enclosed interior space, the shell being mounted to the transportable support platform;
a vacuum distillation vessel housed within the enclosed interior space of the shell, the vacuum distillation vessel having a casing that defines a vacuum distillation chamber, the casing also defining an outlet of the vacuum distillation vessel, wherein polymer-containing articles that contain releasable volatile organic compounds are housed within the vacuum distillation chamber of the vacuum distillation vessel;
a condensate storage tank housed within the enclosed interior space of the shell, the condensate storage tank having a tank wall that defines an internal cavity;
a condenser housed within the enclosed interior space of the shell, the condenser being fluidly coupled to the outlet of the vacuum distillation vessel and to an inlet of the condensate storage tank and being configured to condense volatile organic compound (VOC) vapor emissions received from the vacuum distillation chamber into a liquid condensate and to deliver the liquid condensate into the internal cavity of the condensate storage tank; and
a vacuum pump system in fluid communication with the vacuum distillation chamber of the vacuum distillation vessel, the vacuum pump system being operable to create a partial vacuum within the vacuum distillation chamber and to draw the VOC vapor emissions from the vacuum distillation chamber into the condenser.

US Pat. No. 10,711,075

METHOD OF PREPARING RUBBER COMPOSITION INCLUDING SYNDIOTACTIC 1,2-POLYBUTADIENE

Korea Kumho Petrochemical...

1. A method of preparing a rubber composition, comprising:(a) reacting a conjugated diene-based monomer with one or more of compounds represented by the following Chemical Formulas 1 and 2 in the presence of a first catalyst;
(b) adding a conjugated diene-based monomer to a product of the step (a) and inducing a reaction; and
(c) adding a second catalyst and a conjugated diene-based monomer to a product of the step (b) and inducing a reaction:
(R1)m—Z1?C?C?nZ2—(R2)o  
(R1)m—Z1-A1?C?C?nA2-Z2—(R2)o  
wherein R1 and R2 each are a C1 to C20 alkyl, aryl, or alkoxy group, —NR?R?, —SiR?R?R??, or hydrogen, wherein R?, R?, and R?? each are a C1 to C20 alkyl, aryl, or alkoxy group, or hydrogen,
m and o each are an integer of 0 to 3,
Z1 and Z2 each are silicon, tin, nitrogen, oxygen, sulfur, phosphorus, carbon, or hydrogen,
A1 and A2 each are a C1 to C20 alkylene or arylene group, and
n is an integer of 1 to 20.

US Pat. No. 10,711,054

TRISPECIFIC BINDING MOLECULES FOR TREATING HBV INFECTION AND ASSOCIATED CONDITIONS

DEUTSCHES KREBSFORSCHUNGS...

1. A binding molecule comprising three binding specificities, the binding molecule comprising:(a) a first binding specificity for a Hepatitis B virus (HBV) surface antigen selected from HBV small surface antigen, HBV medium surface antigen and HBV large surface antigen, the first binding specificity comprising three binding sites;
(b) a second binding specificity for CD3 and
(c) a third binding specificity for CD28, wherein the second and third binding specificity comprises one binding site and each of the binding sites of the first, second and third binding specificities comprises a set of six complementarity determining regions (CDRs), where said set of six CDRs consists of a first set of three CDRs and a second set of three CDRs, wherein said first and said second set is each comprised in an immunoglobulin domain.

US Pat. No. 10,711,040

LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF

XELLIA PHARMACEUTICALS AP...

1. A polymyxin represented by formula (I):
wherein
R1 is an aliphatic linear or branched C6-C10 acyl group, or

R5 is —CH(CH3)2, —CH2CH(CH3)2, —CH(CH3)CH2CH3, or —CH2C6H5;
R6 is —CH(CH3)2, —CH2CH(CH3)2, or —CH(CH3)CH2CH3;
each of R2, R3, R4, R7 and R8 is either —(CH2)xCH2NH2 or —(CH2)xCH2N(CH2SO3M)2;
wherein x is 0 or 1;
wherein M is a cation; and
wherein one of R2, R3, R4, R7 and R8 is —(CH2)xCH2N(CH2SO3M)2, and the remaining four of R2, R3, R4, R7 and R8 are —(CH2)xCH2NH2.

US Pat. No. 10,711,039

MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE WITH C-TERMINAL NAPHTHYLALANINE

Palatin Technologies, Inc...

1. A cyclic peptide of the formula:including all enantiomers, stereoisomers or diastereoisomers thereof, or a pharmaceutically acceptable salt of any of the foregoing,wherein:
R4 is —(CH2)w—R14;
R7 is —(CH2)w—R16;
R9 is
—(CH2)x—C(?O)—NH—(CH2)y—,
—(CH2)x—NH—C(?O)—(CH2)y—,
—(CH2)x—C(?O)—(CH2)z—C(?O)—(CH2)y—,
—(CH2)x—C(?O)—NH—C(?O)—(CH2)y—,
—(CH2)x—NH—C(?O)—NH—(CH2)y—,
—(CH2)x—NH—C(?O)—(CH2)z—C(?O)—NH—(CH2)y—, or
—(CH2)x—S—S—(CH2)y—;
R11 is H or a C1 to C7 acyl group, wherein the C1 to C17 comprises a linear or branched alkyl, cycloalkyl, alkylcycloalkyl, aryl or alkylaryl;
R14 is independently in each instance —N(R19a)(R19b), —NH—(CH2)z—N(R19a)(R19b), —NH—C(?NH)—N(R19a)(R19b), —NH—C(?O)—N(R19a)(R19b), —O(R19a), —(R19a)(R19b), —S(?O)2(R19a), —C(?O)—O(R19a),
wherein any ring in R14 is optionally substituted with one or more ring substituents, and when one or more substituents are present, are the same or different and independently hydroxyl, halogen, sulfonamide, alkyl, —O-alkyl, aryl, —O-aryl, —C(?O)—OH, or —C(?O)—N(R19a)(R19b);R16 is —H, —N(R19a)(R19b), —NH—(CH2)z—N(R19a)(R19b), —NH—C(?NH)—N(R19a)(R19b), —NH—C(?O)—N(R19a)(R19b), —O(R19a), a linear or branched C1 to C17 alkyl chain, —C(?O)—N(R19a)(R19b), —S(?O)2(R19a),
wherein any ring is optionally substituted with one or more optional ring substituents, and when one or more substituents are present, are the same or different and independently hydroxyl, halogen, sulfonamide, alkyl, —O-alkyl, aryl, aralkyl, O-aralkyl, or —O-aryl;R18 is —OH, —N(R19a)(R19b), —N(R19a)(CH2)w (C1-C7)cycloalkyl, or —O—(CH2)w—(C1-C7)cycloalkyl;
R19a and R19b are each independently H or a C1 to C4 linear or branched alkyl chain;
R20 is naphthyl, optionally substituted with one or more substituents independently selected from halo, (C1-C10)alkyl-halo, (C1-C10)alkyl, (C1-C10)alkoxy, (C1-C10)alkylthio, aryl, aryloxy, nitro, nitrile, sulfonamide, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, and alkoxy-carbonyl;
R21a, R21b and R21c are independently in each instance hydrogen, halo, (C1-C10)alkyl-halo, (C1-C10)alkyl, (C1-C10)alkoxy, (C1-C10)alkylthio, aryl, aryloxy, nitro, nitrile, sulfonamide, amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, or alkoxy-carbonyl;
R22 is H or a C1 to C9 linear or branched alkyl, cycloalkyl, alkylcycloalkyl, aryl or alkylaryl;
w is in each instance independently 0 to 5;
x is 1 to 5;
y is 1 to 5; and
z is in each instance independently 1 to 5.

US Pat. No. 10,711,036

MALT1 INHIBITORS AND USES THEREOF

Cornell University, Itha...

1. A compound of Formula (I):or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:R3 is hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R4 is hydrogen, halogen, or optionally substituted alkyl;
RN is hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group;
or RN and either R3 or R4 are joined to form an optionally substituted heterocyclic ring, or R3 and R4 are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;
R5 is hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R6 is hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
or R5 and R6 are joined to form an optionally substituted carbocyclic or optionally substituted heterocyclic ring;
R8 is optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, —C(?O)R8b, —C(?O)N(R8a)2, —S(?O)2R8a, or of formula
wherein each instance of RA is independently hydrogen, halogen, optionally substituted alkyl, optionally substituted carbocyclyl, cyano, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted acyl;each occurrence of R8a and R8b is independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, an oxygen protecting group when attached to an oxygen atom, or a nitrogen protecting group when attached to a nitrogen atom, or two R8a are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring;
L1 is a bond, an amino acid, or a dipeptide;
each of Rc and Rd is independently hydrogen, optionally substituted alkyl, optionally substituted acyl, or a nitrogen protecting group;
RA1 is hydrogen, optionally substituted alkyl, optionally substituted acyl, optionally substituted sulfonyl, or a nitrogen protecting group; and
each of RA2, RA3, and RA4 is independently hydrogen, unsubstituted methyl, methyl substituted with one or more halogen, optionally substituted C2-10 alkyl, —C(?O)Rf, —C(?O)NH(Rf), —C(?O)N(Rf)2, optionally substituted sulfonyl, or a nitrogen protecting group selected from the group consisting of formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitrophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide, (N?-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethyl carbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate, 1,1-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), 1,1-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-1-(4-biphenylyl)ethyl carbamate (Bpoc), 1-(3,5-di-t-butylphenyl)-1-methylethyl carbamate (t-Bumeoc), 2-(2?- and 4?-pyridyl)ethyl carbamate (Pyoc), 2-(N,N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC or Boc), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc), 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxyacylvinyl carbamate, o-(N,N-dimethylcarboxamido)benzyl carbamate, 1,1-dimethyl-3-(N,N-dimethylcarboxamido)propyl carbamate, 1,1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p?-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1-methylcyclohexyl carbamate, 1-methyl-1-cyclopropylmethyl carbamate, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate, 1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethyl carbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-trimethylbenzyl carbamate, p-toluenesulfonamide (Ts), benzenesulfonamide, 2,3,6-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc), methanesulfonamide (Ms), ?-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4?,8?-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, phenacylsulfonamide, phenothiazinyl-(10)-acyl derivative, N?-p-toluenesulfonylaminoacyl derivative, N?-phenylaminothioacyl derivative, N-benzoylphenylalanyl derivative, N-acetylmethionine derivative, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole, N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE), 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm), N-2-picolylamino N?-oxide, N-1,1-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N—(N?,N?-dimethylaminomethylene)amine, N,N?-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-1-cyclohexenyl)amine, N-borane derivative, N-diphenylborinic acid derivative, N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys), wherein each occurrence of Rf is independently hydrogen, optionally substituted alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted acyl, or a nitrogen protecting group when attached to a nitrogen atom, or two Rf are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring;
or any two of RA1, RA2, RA3, and RA4 are joined to form an optionally substituted heterocyclic or optionally substituted heteroaryl ring;provided the compound is not of formula:

US Pat. No. 10,711,033

BRANCHED CHAIN-CONTAINING AROMATIC COMPOUND

AJINOMOTO CO., INC., Tok...

1. A branched chain-containing aromatic compound adduct which has a carboxyl group,wherein
said carboxyl group is protected by a branched chain-containing aromatic compound selected from the group consisting of:
2,4-di(2?,3?-dihydrophytyloxy)benzyl alcohol;
3,5-di(2?,3?-dihydrophytyloxy)benzyl alcohol;
4-(2?,3?-dihydrophytyloxy)benzyl alcohol;
1-[(2-chloro-5-(2?,3?-dihydrophytyloxy)phenyl)]-1-phenylmethanamine;
3,4,5-tri(2?,3?-dihydrophytyloxy)benzyl alcohol;
3,4,5-tri(2?,3?-dihydrophytyloxy)benzylamine;
4-(2?,3?-dihydrophytyloxy)benzylamine;
2-[3?,4?,5?-tri(2?,3?-dihydrophytyloxy)benzyloxy]-4-methoxybenzyl alcohol;
4-(2?,3?-dihydrophytyloxy)-2-methoxybenzyl alcohol;
4-(2?,3?-dihydrophytyloxy)-2-methoxybenzylamine;
4-(2?,3?-dihydrophytyloxy)-2-methylbenzyl alcohol;
4-(2?,3?-dihydrophytyloxy)-2-methylbenzylamine;
2,2,4,8,10,10-hexamethyl-5-dodecanoic acid (4-hydroxymethyl)phenylamide;
4-(3,7,11-trimethyldodecyloxy)benzyl alcohol;
2-(3,7,11-trimethyldodecyloxy)-9-phenylfluoren-9-ol;
a compound represented by the formula:

wherein n16 is 23 or 34;
a compound represented by the formula:

wherein n17 is 23 or 34;
a compound represented by the formula:

wherein n18 is 5 to 7; and
a compound represented by the formula:

US Pat. No. 10,711,032

STEROIDS AND PROTEIN-CONJUGATES THEREOF

Regeneron Pharmaceuticals...

1. A compound of Formula (A):
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof,
wherein:
R1 and R2 together form

wherein R4 is alkyl, aryl, arylalkyl, or an N-containing heterocycloalkyl, wherein the alkyl, aryl, arylalkyl, and N-containing heterocycloalkyl are, independently in each instance, optionally substituted with —NRaRb;
R3 is

 wherein RP is halo, t is an integer from 0 to 2;
R5 is, independently in each instance, —OH, halo, alkyl, or arylalkyl;
Ra and Rb are, independently in each instance, —H or alkyl
n is an integer from 0-19.

US Pat. No. 10,711,028

ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF

Lakewood Amedex, Inc., S...

1. A method of treating a bladder infection in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound having the formula:or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,711,027

DNA POLYMERASE BETA INHIBITORS

The Johns Hopkins Univers...

1. A compound of formula (I):
wherein:
X is selected from the group consisting of alkyl, alkoxyl, O?, and S?;
R is selected from the group consisting of —CH3 and

R? is selected from the group consisting of —NR6R7 and
with the proviso that if R is —CH3, then R? is —NR6R7;R1 and R2 are each independently selected from the group consisting of hydrogen and —C(?O)-alkyl;
R3 and R4 are each independently selected from the group consisting of hydrogen or C1-C6 alkyl;
R5, R6 and R7 are each independently selected from the group consisting of substituted or unsubstituted aryl, heteroaryl, arylalkyl, heteroarylalkyl, multicyclic aliphatic ring systems, multicylic aromatic ring systems, fused aliphatic ring systems, fused aromatic ring systems, and combinations thereof;
each R8 is independently selected from the group consisting of halogen, hydroxyl, alkyl, alkenyl, alkynyl, alkoxyl, sulfhydryl, sulfide, and carboxyl;
n is an integer selected from the group consisting of 0, 1, 2, 3, 4, and 5;
p is an integer selected from the group consisting of 0 and 1; and pharmaceutically acceptable salts thereof.

US Pat. No. 10,711,024

STEVIOL GLYCOSIDE COMPOUNDS, COMPOSITIONS FOR ORAL INGESTION OR USE, AND METHOD FOR ENHANCING STEVIOL GLYCOSIDE SOLUBILITY

Cargill, Incorporated, W...

1. Compound 1, 2, 3, or 4 according to the following structures:

US Pat. No. 10,711,023

SOPHOROLIPID COMPOUND AND COMPOSITION COMPRISING SAME

Saraya Co., Ltd., Osaka-...

1. A sophorolipid compound represented by Formula (I):wherein: R1 represents a hydrogen atom or methyl group; R3 and R4 are the same or different, and each represents a hydrogen atom or acetyl group; one of five R5 is a saturated or unsaturated fatty acid residue that may have hydroxy, and the remaining four R5 are hydrogen atoms; R2 represents a C9-18 alkylene group, or C9-18 alkenylene group having 1 to 3 double bonds; and R6 represents hydroxy, or may form a single bond together with one of five R7 in the compound represented by Formula (II):wherein: R1? represents a hydrogen atom or methyl group; R3? and R4? are the same or different, and each represents a hydrogen atom or acetyl group; R2? represents a C9-18 alkylene group, or C9-18 alkenylene group having 1 to 3 double bonds; and one of R7 forms a single bond together with R6 in the compound represented by Formula (I) and the remaining four R7 are hydrogen atoms.

US Pat. No. 10,711,020

TRICYCLIC SULFONES AS ROR? MODULATORS

Bristol-Myers Squibb Comp...

1. A method of treating inflammatory bowel disease, Crohn's disease and ulcerative colitis in a subject, the method comprising administering to the subject a therapeutically-effective amount of a compound of the formula
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

US Pat. No. 10,711,019

PHOTOINITIATORS FUNCTIONED AS BOTH INITIATORS AND NANOFILLERS

Agency for Science, Techn...

1. A photoinitiator compound comprising:a polyhedral oligomeric silsesquioxane (POSS) moiety and a photoinitiator moiety, wherein the photoinitiator compound has a structure according to formula (I): [R—SiO1.5]n (I), wherein n is 6, 8, 10 or 12 and R is independently selected from the group consisting of H, linear or branched (hetero)alkyl, linear or branched (hetero)alkenyl, (hetero)aryl, (hetero)alkyl aryl, (hetero)aryl alkyl, and the photoinitiator moiety, wherein only one R is the photoinitiator and the photoinitiator compound is a nanoparticle, formula (II):

wherein m is an integer ranging from 1 to 20 and R1-R5 are independently selected from the group consisting of H, linear or branched (hetero)alkyl, linear or branched (hetero)alkenyl, (hetero)aryl, (hetero)alkyl aryl ,and (hetero)aryl alkyl.

US Pat. No. 10,711,017

FLUORINATED CYCLOALKENE FUNCTIONALIZED SILICAS

United States of America ...

1. A fluorinated cyclopentene moiety having a general chemical formula:wherein R1 is selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocycle; wherein Y is selected from the group consisting of F, OR2, SR2, and NR2R5 wherein R2 is selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocyclic; wherein R5 is selected from the group consisting of H, substituted or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl, and heterocyclic; and wherein at least one of R1 or R2 includes a reactive functional group selected from the group consisting of a hydrosilylation reaction product of the alkene or the alkyne, with a silane.

US Pat. No. 10,711,016

FUNCTIONALIZED ALUMINUM REAGENTS

1. A functionalized aluminum reagent of formula 1wherein R is a linear or branched alkane group containing 1 to 8 carbon atoms, and R1 is phenylene, or a linear or branched alkane diyl group containing 2 to 10 carbon atoms, or a combination of one or more phenylene groups and one or more linear or branched alkane diyl groups containing 1 to 10 carbon atoms; Q is of formula 2
wherein R3 and R4 are independently phenyl or a linear or branched alkyl group containing 1 to 10 carbon atoms, or R3 and R4 taken together with the nitrogen atom represent a nitrogen containing heterocyclic group containing from 4 to 12 carbon atoms; wherein the functionalized aluminum reagent of formula 1 is selected from the group consisting of
wherein TMS is a trimethylsilyl group.

US Pat. No. 10,711,015

NITROGEN-CONTAINING COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME

LG CHEM, LTD., Seoul (KR...

1. A compound represented by the following Chemical Formula 1:
in Chemical Formula 1,
p is 2, and structures in the parenthesis are different from each other,
L1 and L2 are the same as or different from each other, and are each independently a direct bond; —SiR101R102—; —SO2—; —O—; —NR103—; —C(?O)O—; a substituted or unsubstituted alkylene group; a substituted or unsubstituted cycloalkylene group; a substituted or unsubstituted arylene group; or a substituted or unsubstituted divalent heterocyclic group,
R1 and R2 are the same as or different from each other, and are each independently hydrogen; deuterium; a halogen group; a cyano group; a nitro group; a carbonyl group; a carboxyl group (—COOH); an ether group; a hydroxy group; —C(?O)NR104R105; —C(?O)OR106; a substituted or unsubstituted alkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted alkoxy group; a substituted or unsubstituted aryloxy group; a substituted or unsubstituted alkenyl group; a substituted or unsubstituted silyl group; a substituted or unsubstituted amine group; a substituted or unsubstituted alkylamine group; a substituted or unsubstituted arylamine group; a substituted or unsubstituted aryl group; or a substituted or unsubstituted heterocyclic group, or adjacent groups are optionally bonded to each other to form a ring,
m is an integer of 0 to 4, and when m is 2 or more, R1's are the same as or different from each other,
n is an integer of 0 to 5, and when n is 2 or more, R2's are the same as or different from each other,
X1 and X2 are the same as or different from each other, and are each independently a halogen group; a cyano group; a hydroxy group; an ether group; an ester group; a substituted or unsubstituted alkyl group; a substituted or unsubstituted alkynyl group; a substituted or unsubstituted alkoxy group; a substituted or unsubstituted aryloxy group; a substituted or unsubstituted aryl group; or a substituted or unsubstituted heterocyclic group, or X1 and X2 are bonded to each other to form a substituted or unsubstituted ring, and
R101 to R106 are the same as or different from each other, and are each independently hydrogen; deuterium; a substituted or unsubstituted alkyl group; a substituted or unsubstituted fluoroalkyl group; a substituted or unsubstituted aryl group; or a substituted or unsubstituted heterocyclic group.

US Pat. No. 10,711,013

ANDROGEN RECEPTOR MODULATING COMPOUNDS

ORION CORPORATION, Espoo...

1. A pharmaceutical dosage form comprising:a compound of formula (VI):
whereinR1 is halogen;
R2 is cyano;
R3 is hydrogen, halogen, or methyl;
R4 is hydrogen;
R5 is methyl;
ring A is any one of the following groups or tautomers thereof:

R8 is hydrogen, C1-7 alkyl, or hydroxy C1-7 alkyl; and
R9 is hydrogen, halogen, or C1-7 alkyl, or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient.

US Pat. No. 10,711,012

PYRIDINIUM OXAZOLE DYAD SCAFFOLD AND A PROCESS FOR PREPARATION THEREOF

1. A Pyridinium oxazole dyad scaffold of formula (I);
Wherein; R1, R2 and R3 are same or different and each is independently selected from the group consisting of H, alkyl groups, alkenyl groups, aryl groups, heteroaryl groups, electron donating as well as electron withdrawing substituents;
X is selected from the group consisting of —CRR?, O, S and —NR wherein R and R? are same or different and each is independently selected from the group consisting of H, alkyl, benzyl, and aryl; further R and R? may form a cyclic ring having 4 to 6 carbon atoms.

US Pat. No. 10,711,010

HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

LES LABORATORIES SERVIER,...

1. A method of treating multiple myeloma in a subject in need thereof, comprising administration of a compound of formula (I):
alone or in combination with one or more pharmaceutically excipients, wherein:
A represents the group

wherein 1 is linked to the oxygen atom and 2 is linked to the phenyl ring,
R1 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)alkoxy group, a —S—(C1-C6)alkyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a hydroxy(C1-C6)alkyl group, a cyano group, —NR11R11?, -Cy6, or a halogen atom,
R2, R3, R4 and R5 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a hydroxy(C1-C6)alkyl group, a linear or branched (C1-C6)alkoxy group, a —S—(C1-C6)alkyl group, a cyano group, a nitro group, -alkyl(C0-C6)—NR9R9?, —O-alkyl(C1-C6)—NR9R9?, —O-alkyl(C1-C6)—R10, —C(O)—OR9, —O—C(O)—R9, —C(O)—NR9R9?, —NR9—C(O)—R9?, —NR9—C(O)—OR9?, -alkyl(C1-C6)—NR9—C(O)—R9?, —SO2—NR9R9?, —SO2-alkyl(C1-C6),
or the substituents of one of the pairs (R2, R3), (R3, R4), (R4, R5), when grafted onto two adjacent carbon atoms, together with the carbon atoms carrying them, form an aromatic or non-aromatic ring having from 5 to 7 ring members, which ring may contain from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, wherein the resulting ring may be substituted by a group selected from the group consisting of a linear or branched (C1-C6)alkyl group, —NR11R11?, -alkyl(C0-C6)-Cy1, and oxo,
R6 and R7 independently of one another represent a hydrogen atom, a halogen atom, a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, a linear or branched (C1-C6)polyhaloalkyl, a hydroxy group, a linear or branched (C1-C6)alkoxy group, a —S—(C1-C6)alkyl group, a cyano group, a nitro group, -alkyl(C0-C9)—NR9R9?, —O-alkyl(C1-C6)—NR9R9?, —O-Cy1, -alkyl(C0-C6)-Cy1, -alkenyl(C2-C6)-Cy1, -alkynyl(C2-C6)-Cy1, —O-alkyl(C1-C6)—R10, —C(O)—OR9, —O—C(O)—R9, —C(O)—NR9R9?, —NR9—C(O)—R9?, —NR9—C(O)—OR9?, -alkyl(C1-C6)—NR9—C(O)—R9?, —SO2—NR9R9?, —SO2-alkyl(C1-C6),
or the substituents of the pair (R6, R7), when grafted onto two adjacent carbon atoms, together with the carbon atoms carrying them, form an aromatic or non-aromatic ring having from 5 to 7 ring members, which ring may contain from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, wherein the resulting ring may be substituted by a group selected from the group consisting of a linear or branched (C1-C6)alkyl group, —NR11R11?, -alkyl(C0-C6)-Cy1, and oxo,
R8 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C2-C6)alkenyl group, a linear or branched (C2-C6)alkynyl group, -Cy3, -alkyl(C1-C6)-Cy3, -alkenyl(C2-C6)-Cy3, -alkynyl(C2-C6)-Cy3, -Cy3-Cy4, -alkynyl(C2-C6)—O-Cy3, -Cy3-alkyl(C0-C6)—O-alkyl(C0-C6)-Cy4, a halogen atom, a cyano group, —C(O)R12, or —C(O)—NR12R12?,
R9 and R9? independently of one another represent a hydrogen atom, a linear or branched (C1-C6)alkyl group, -alkyl(C0-C6)-Cy1,
or the substituents of the pair (R9, R9?), together with the nitrogen atom carrying them, form an aromatic or non-aromatic ring having from 5 to 7 ring members, which ring may contain, in addition to the nitrogen atom, from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, wherein the nitrogen may be substituted by a hydrogen atom or a linear or branched (C1-C6)alkyl group and wherein one or more of the carbon atoms of the possible substituents, may be deuterated,
R10 represents -Cy1, -Cy1-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)—O-alkyl(C0-C6)-Cy2, -Cy1-alkyl(C0-C6)—NR9-alkyl(C0-C6)-Cy2, -Cy1-Cy2-O-alkyl(C0-C6)-Cy5, —C(O)—NR9R9?, —NR9R9?, —OR9, —NR9—C(O)—R9—O-alkyl(C1-C6)—OR9, —SO2—R9, —C(O)—OR9, or —NH—C(O)—NH—R7,
R11, R11?, R12 and R12?, independently of one another represent a hydrogen atom or an optionally substituted linear or branched (C1-C6)alkyl group,
R13 represents a hydrogen atom, a hydroxy group, or a hydroxy(C1-C6)alkyl group,
Ra represents a hydrogen atom or a linear or branched (C1-C6)alkyl group,
Rb represents a —O—C(O)—O—Rc group, a —O—C(O)—NRcRc? group, or a —O—P(O)(ORc)2 group,
Rc and Rc? independently of one another represent a hydrogen atom, a linear or branched (C1-C8)alkyl group, a cycloalkyl group, a (C1-C6)alkoxy(C1-C6)alkyl group, or a (C1-C6)alkoxycarbonyl(C1-C6)alkyl group,
or the substituents of the pair (Rc, Rc?), together with the nitrogen atom carrying them, form a non-aromatic ring having from 5 to 7 ring members, which ring may contain, in addition to the nitrogen atom, from 1 to 3 heteroatoms selected from oxygen and nitrogen, wherein the nitrogen may be substituted by a linear or branched (C1-C6)alkyl group,
Cy1, Cy2, Cy3, Cy4, Cy5 and Cy6, independently of one another, represent a cycloalkyl group, a heterocycloalkyl group, an aryl group or a heteroaryl group,
n is an integer equal to 0 or 1,
wherein:
“aryl” means a phenyl, naphthyl, biphenyl, indanyl or indenyl group,
“heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen,
“cycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members,
“heterocycloalkyl” means any mono- or bi-cyclic non-aromatic carbocyclic group containing from 3 to 10 ring members, and containing from 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen, which may include fused, bridged or spiro ring systems,
wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the alkyl, alkenyl, alkynyl, alkoxy groups, may be substituted by from 1 to 4 groups selected from optionally substituted linear or branched (C1-C6)alkyl, optionally substituted linear or branched (C2-C6)alkenyl group, optionally substituted linear or branched (C2-C6)alkynyl group, optionally substituted linear or branched (C1-C6)alkoxy, optionally substituted (C1-C6)alkyl-S—, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, —C(O)—OR?, —O—C(O)—R?, —C(O)—NR?R?, —NR?R?, —(C?NR?)—OR?, linear or branched (C1-C6)polyhaloalkyl, trifluoromethoxy, or halogen, wherein R? and R?, independently of one another, represent a hydrogen atom or an optionally substituted linear or branched (C1-C6)alkyl group, and wherein one or more of the carbon atoms of the preceding possible substituents, may be deuterated,
its enantiomers, diastereoisomers and atropisomers, or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,711,009

METHOD OF PREPARING D-GLUCARO-1,4:6,3-DILACTONE

Hyundai Motor Company, S...

1. A method of preparing d-glucaro-1,4:6,3-dilactone, comprising:preparing an admixture comprising an organic acid or a salt thereof and a solvent component, wherein the organic acid is prepared by adding glucose, potassium hydroxide (KOH) and noble metal catalyst to a solvent and reacting an oxidation;
contacting the admixture with an ion exchange resin;
separating the ion exchange resin from the admixture;
preparing a composition comprising 1,4-dioxane and the admixture from which the ion exchange resin has been separated, and
freezing and drying the composition to prepare particles of the d-glucaro-1,4:6,3-dilactone,
wherein the admixture comprises an amount of about 20 wt % to 40 wt % of the organic acid or the salt thereof based on the total weight of the admixture,
wherein the oxidation reaction proceeds at a pH of about 3 to 4,
wherein the organic acid comprises a glucaric acid in which a potassium cation (K+) is present in the form of a salt at only one end,
wherein the composition is frozen and dried at a temperature of about ?70° C. or less for about 12 hr to 20 hr.

US Pat. No. 10,711,008

INDOLINE ANALOGS AND USES THEREOF

Oncternal Therapeutics, I...

1. A compound having Formula (VII):
or a stereoisomer, a pharmaceutically acceptable salt, or solvate thereof, wherein A is selected from the group consisting of —OH, D, H, F, and —NH2; wherein R1, R2, R3, and R4 are independently selected from the group consisting of H, Cl, —CN, —CF3, C1-6 alkyl, C1-6 alkoxy, —C(?O)NH2, —NO2, —NH2, and —OH; and wherein G is selected from the group consisting of:

US Pat. No. 10,711,007

SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)

Prelude Therapeutics Inco...

7. A pharmaceutical composition comprising a compound claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

US Pat. No. 10,711,006

SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF

HANGZHOU HERTZ PHARMACEUT...

1. A compound, having a structure of Formula II or Formula II?:
or their optical isomers, or pharmaceutically acceptable salts or solvates;
where each Rg is independently H, halogen, —CF2H, —CF3, —CN, C1-C3 alkyl, or C1-C3 alkoxy;
n is selected from 0, 1 and 2;
Rd is selected from
Re is selected from H, CH3, C2-C6 alkyl, C1-C6 azaalkyl, and C1-C6 oxaalkyl, wherein CH3, C2-C6 alkyl, C1-C6 azaalkyl and C1-C6 oxaalkyl are further substituted with amino, hydroxyl, and C1-C3 alkyl;Y1, Y2, Y3 and Y4 are independently selected from C(Rf) and N, and at least one of Y1, Y2, Y3 and Y4 is N, wherein Rf is selected from H, halogen, C1-C3 alkyl, —CF3, and —CF2H.

US Pat. No. 10,711,005

COMPOUND I AND COMPOUND II AS WELL AS PREPARATION METHODS THEREFOR AND APPLICATION THEREOF

SHENZHEN UNIVERSITY, She...

1. A compound of formula I:

US Pat. No. 10,711,004

OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

Genentech, Inc., South S...

1. A compound of formula (I):
wherein:
(i) A is selected from

 

(ii) X is selected from a bond, C1-4 alkylene, —O—, —S—, —SO2—, and —N(R1)—, wherein R1 is selected from H and C1-6 alkyl;
(iii) B is selected from:
(a) substituted and unsubstituted C4-6 cycloalkyl wherein, when substituted, the bond to the oxadiazole moiety and the bond to the substituent are on other than adjacent ring carbon atoms;
(b) substituted and unsubstituted fused bicyclic bound to the oxadiazole moiety by a carbon-carbon bond; and
(c) substituted and unsubstituted fused tricyclic;
(iv) E is a five membered or a six membered heteroaryl ring wherein one ring carbon atom is optionally substituted with oxo;
(v) G is a six membered heteroaryl ring having one ring carbon atom substituted with oxo;
(vi) one of Y1, Y2, Y3 and Y4 is —C(O)—, one to three of Y1, Y2, Y3, Y4, Y5 and Y6 are nitrogen, and the other of Y1, Y2, Y3, Y4, Y5 and Y6 are carbon;
(vii) one or two of Z1, Z2, Z3, Z4 and Z5 are nitrogen and the other of Z1, Z2, Z3, Z4 and Z5 are carbon;
(viii) each R2 is independently selected from H, deuterium, —C1-4 alkyl, —C1-4 haloalkyl, —CN, halo, C1-4 haloalkoxy, C1-4 alkoxy, —OH, —SO2—C1-4alkyl, —C1-4CN, C1-4 aldehyde, C1-4 ketone, and —NR14R15, and p is 0, 1 or 2, wherein R14 and R15 are independently selected from H, substituted and unsubstituted —C1-4 alkyl, substituted and unsubstituted —C(O)—C1-4 alkyl, substituted and unsubstituted C3-6 cycloalkyl, substituted and unsubstituted 3- to 6-membered heterocycloalkyl, substituted and unsubstituted —C1-4 heteroalkyl, and substituted and unsubstituted —C1-4 alkyl-C(O)NR16R17 wherein R16 and R17 are independently selected from H and C1-4 alkyl; and
(ix) R3 is selected from H, —C1-4 alkyl, —C1-4 haloalkyl, —CN, and halo, and q is 0 or 1; or a pharmaceutical salt thereof.

US Pat. No. 10,711,003

TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A HETEROBIARYL MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR

Bristol-Myers Squibb Comp...

1. A compound having a structure according to formula (Ia-01):

US Pat. No. 10,711,002

PURINE COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER

1. A compound of formula
or a pharmaceutically acceptable salt or solvate thereof; wherein
each Ra is H, or a straight or branched alkyl;
Rb is H or a lower straight or branched alkyl;
Rc is H or a lower straight or branched alkyl;
R1 is an optionally substituted selenium-containing heterocycle, an optionally substituted bridged bicycloalkyl or an optionally substituted cycloalkyl, wherein said optional substituent is an alkyl group, wherein said selenium-containing heterocycle is a 5 to 6 membered saturated monocyclic ring consisting of one or two selenium (Se) atoms as the heteroatoms; and
R2 is H or alkyl.

US Pat. No. 10,711,001

MACROCYLIC LIGANDS WITH PICOLINATE GROUP(S), COMPLEXES THEREOF AND ALSO MEDICAL USES THEREOF

GUERBET, Villepinte (FR)...

1. A compound of general formula (I) or a pharmaceutically acceptable salt of general formula (I)
in which:
R1, R2, R3, R4, R5 and R6 represent, independently of each other, one of the following:
H, a (C1-C20)alkyl group or a (C1-C20)alkylene-(C6-C00)aryl group, wherein said alkyl, alkylene and aryl groups optionally are substituted with one or more organic acid functions;
X1, X2 and X3 represent, independently of each other, one of the following:
H, —C(O)N(Re)(Rd), a (C1-C20)alkyl, a (C2-C20)alkenyl, a (C2-C20)alkynyl, or a (C6-C10)aryl, with Re and Rd being, independently of each other, H or a (C1-C20)alkyl group, wherein said alkyl, alkenyl and alkynyl groups optionally comprise one or more heteroatoms and/or one or more (C6-C10)arylenes in their chains and, wherein said alkyl, alkenyl and alkynyl groups optionally are substituted with a (C6-C10)aryl,
wherein said alkyl, alkenyl, alkynyl and aryl groups optionally are substituted with one or more organic acid functions;
Y1, Y2 and Y3 represent, independently of each other, a C(O)OH group or a group of formula (II), with at least one of Y1, Y2, and Y3, being a group of formula (II):

in which:
the radicals Ri represent, independently of each other, one of the following:
H, a halogen, N3, a (C1-C20)alkyl, a (C2-C20)alkenyl, a (C2-C20)alkynyl, or a (C6-C10)aryl, wherein said alkyl, alkenyl and alkynyl groups optionally comprise one or more heteroatoms and/or one or more (C6-C10)arylenes in their chains and, wherein said alkyl, alkenyl, and alkynyl groups optionally are substituted with a (C6-C10)aryl;
wherein said alkyl, alkenyl, alkynyl and aryl groups optionally are substituted with one or more organic acid functions.

US Pat. No. 10,711,000

AUTOTAXIN INHIBITORS AND USES THEREOF

FRONTHERA U.S. PHARMACEUT...

1. A compound of Formula (I?), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
wherein:
X1 is CR13;
X2 is CR14;
X3 is N or CR15;
W is

Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
Ring C is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
L is —O—, —S—, or —NR19—;
R11 is L1-R20;
L1 is absent or C1-C6 alkylene optionally substituted with deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, or —C(?O)NRcRd;
R20 is halogen, —CN, —OR21, —SR21, —S(?O)R22, —S(?O)2R22, —NO2, —NR23R24, —NR21S(?O)2R22, —S(?O)2NR23R24, —C(?O)R22, —OC(?O)R22, —C(?O)C(?O)R22, —C(?O)OR21, —C(?O)NR21OR21, —OC(?O)OR21, —C(?O)NR23R24, —OC(?O)NR23R24, —NR21C(?O)NR23R24—NR21S(?O)2NR23R24, —NR21C(?O)R22, —NR21C(?)OR21, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R1;
each R21 is independently hydrogen, —CN, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R1a;
R22 is hydrogen, —CN, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R1b;
R23 and R24 are independently hydrogen, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R1c;
or R23 and R24 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R1d;
each R12 is independently deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, —C(?O)NRcRd, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R2;
or two R12 on the same carbon are taken together to form an oxo;
R13 is hydrogen, deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, —C(?O)NRcRd, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R3;
R14 is deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, —C(?O)NRcRd, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R4;
R15 is hydrogen, deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, —C(?O)NRcRd, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R5;
or R14 and R15 are taken together to form a cycloalkyl or heterocycloalkyl; wherein the cycloalkyl and heterocycloalkyl are independently optionally substituted with one, two, or three R6;
R16 is hydrogen, deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, —C(?O)NRcRd, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R7;
each R17 is independently deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)Ra, —C(?O)ORa, —C(?O)NRcRd, —NRaC(?O)Rb, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R8;
or two R17 on the same carbon are taken together to form an oxo;
each R18 is independently deuterium, halogen, —CN, —ORa, —NRcRd, —C(?O)Ra, —C(?O)ORa, —C(?O)NRcRd, —NRaC(?O)Rb, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three R9;
or two R18 on the same carbon are taken together to form an oxo;
R19 is hydrogen, —S(?O)Rb, —S(?O)2Rb, —S(?O)2NRcRd, —C(?O)Rb, —C(?O)ORa, —C(?O)NRcRd, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 heteroalkyl, cycloalkyl, or heterocycloalkyl;
each R1a, R1b, R1c, and R1d are independently oxo, halogen, —CN, —ORa, —S(?O)2Rb, —NRcRd, —S(?O)2NRcRd, —C(?O)Rb, —OC(?O)Rb, —C(?O)ORa, —OC(?O)ORa, —C(?O)NRcRd, —OC(?O)NRcRd, —NRaC(?O)NRcRd, —NRaC(?O)Rb, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, or phenyl;
each R1 is independently oxo, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, —C(?O)Ra, —C(?O)NRcRd, —S(?O)2Rb, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, or phenyl; wherein the alkyl, cycloalkyl, heterocycloalkyl, and phenyl are independently optionally substituted with one, two, or three halogen, —OH, —NH2, C1-C6 alkyl, or phenyl;
each R2, R3, R4, R5, R6, R7, R8, and R9 are independently oxo, halogen, —CN, —ORa, —NRcRd, —C(?O)ORa, —C(?O)Ra, —C(?O)NReRd, —S(?O)2Rb, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, or phenyl; wherein the alkyl, cycloalkyl, heterocycloalkyl, and phenyl are independently optionally substituted with one, two, or three halogen, —OH, —NH2, C1-C6 alkyl, or phenyl;
each Ra is independently hydrogen, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three halogen, —OH, —NH2, or C1-C6 alkyl;
each Rb is independently C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three halogen, —OH, —NH2, or C1-C6 alkyl;
each Rc and Rd are independently hydrogen, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl are independently optionally substituted with one, two, or three halogen, —OH, —NH2, or C1-C6 alkyl;
or Rc and Rd are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three halogen, —OH, —NH2, or C1-C6 alkyl;
n is 0-3;
m is 0-3; and
p is 0-3.

US Pat. No. 10,710,998

COMPOUND AND PROCESS

VERONA PHARMA PLC, Cardi...

1. A nitrile compound or a salt thereof, which nitrile compound is a compound of formula (A):
wherein:
R1 and R2 are the same or different and each is independently a C1-C6 alkyl group or a C2-C7 acyl group, or R1 and R2 together form a C1-C6 alkylene group;
R3 and R4 are the same or different and each is independently hydrogen, halogen or a C1-C6 alkyl group;
R5 and R6 are the same or different and each is independently hydrogen, halogen or a C1-C6 alkyl group;
X is CHR7, O or NR7, and R7 is hydrogen or a C1-C6 alkyl group; and
Ar is a C6-C10 aryl group substituted with from 0 to 4 substituents, each of which substituents is independently halogen or a C1-C6 alkyl group.

US Pat. No. 10,710,997

ISOQUINOLINE AMIDE AND ISOQUINOLINE AMIDE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION

Vanderbilt University, N...

1. A compound having a structure of the following formula:
wherein the variables are substituted or unsubstituted and:
X is N,;
X1 is N;
X2 is CH, or N;
Y is CH, CD, C-alkyl;
R1 is H, alkyl, alkenyl, cycloalkyl, halogen, CF3, alkoxy, OH, CN, Oalkyl, CH2F, CHF2, or together with R2 forms a 4-7 membered ring optionally substituted with one or more R;
R2 is optionally substituted with one or more R, and is chosen from cycloaklyl, heterocycloalkyl, aryl, heteroaryl, or together with R1 forms a 4-7 membered ring optionally substituted with one or more R;
R is independently H, alkyl, alkene, hydroxyl, alkoxy, CF3, ?O, O-Me, O-alkyl, O-cycloalkyl, SO2-alkyl, hydroxyl, amino, aminoalkoxy, halogen, SO2, SO2-Me, CONH2, CN, cycloalkyl, heterocycloalkyl, aryl, heteroaryl;
R3 is H, alkyl, alkenyl, aryl, heteroaryl, alkoxy, hydroxyl, amino, aminoalkoxy, or halogen;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,996

PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF

SHANGHAI INSTITUTE OF MAT...

1. A pyrido-azacyclic compound, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, wherein the compound has a structure represented by the following formula I:
wherein,
represents a single bond;
R1 and R2 are each independently selected from hydrogen and halogen;
X is absent or is O;
Y is O;
n is 0, 1, 2 or 3; m is 0 or 1;
R3 is absent, or is hydrogen, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C6-C10 aryl, a substituted or unsubstituted 5- or 6-membered saturated or unsaturated heterocyclic group containing 1 to 2 heteroatoms selected from N, O and S, a substituted or unsubstituted 5- or 6-membered saturated or unsaturated heterocyclic carbonyl group containing 1 to 2 heteroatoms selected from N, O and S,
or a substituted or unsubstituted 5- or 6-membered heteroaromatic ring group containing 1 to 2 heteroatoms selected from N, O and S, wherein, the number of the substituents may be 1 or 2 and the substituents are each independently selected from halogen, —CN, —CF3, —NO2, hydroxyl, C1-C6 alkyl, amino substituted by C1-C6 alkyl, C1-C6 alkoxy, benzyl, C1-C6 alkoxy substituted by halogen, C1-C6 alkylsulfonyl and an unsubstituted or C1-C6 alkyl-substituted 5- or 6-membered saturated or unsaturated heterocyclic group or heteroaromatic ring group containing 1 to 2 heteroatoms selected from N and O;R6 is absent, or is selected from hydrogen and C1-C6 alkyl;
R7 is absent, or is selected from hydrogen and C1-C6 alkyl;
Z is phenylacetamido or any of the following structures:

in the above formulas II, III, IV, V and VI, R4 is selected from hydrogen, C1-C6 alkyl and C5-C10 aryl or heteroaryl; R5 and R5? are each independently selected from hydrogen, halogen and C1-C6 alkoxy;
Ring B forms one structure of the following formulas with pyridine:

US Pat. No. 10,710,995

INHIBITORS OF ?-HYDROXYLASE FOR TREATMENT OF CANCER

Rhode Island Hospital, P...

1. A method for treating a cancer, wherein said cancer is selected from Pancreatic Cancer, neuroendocrine pancreatic cancer, Cholangiocarcinoma, Lung cancer, Colon Cancer, Breast Cancer, Prostatic Cancer, and Glioblastoma where asparatyl (asparaginyl) beta-hydroxylase (ASPH) is overexpressed, comprising administering to a subject in need thereof a therapeutically efficient amount of a compound of Formula Ia or Ib:or a pharmaceutically acceptable salt thereof, whereinAr1 is substituted or unsubstituted C6-C20 aryl or heteroaryl that is 5-6 membered monocyclic or 8-12 membered bicyclic aromatic ring containing 1-3 heteroatoms selected from the group consisting of O, N and S, each substituted with one or more substituents selected from the group consisting of halo, CN, NO2, NO, N3, ORa, NRaRb, C(O)Ra, C(O)ORa, C(O)NRaRb, NRbC(O)Ra, —S(O)bRa, —S(O)bNRaRb, and RS1;
X is C(O), C(S), or S(O)2;
W1 is a single bond, O, CR50R51, or NR52 when X is CO and W1 is a single bond, CR50R51, or NR52 when X is SO2; and
each of R50,R51, R52, and R53 independently is selected from the group consisting of hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C6-C20 aryl, substituted or unsubstituted C7-C26 arylalkyl, substituted or unsubstituted substituted or unsubstituted 5 to 12-membered heteroaryl that is 5-6 membered monocyclic or 8-12 membered bicyclic aromatic ring containing 1-3 heteroatoms selected from the group consisting of O, N and S, and substituted or unsubstituted 6-26 membered heteroarylalkyl, each substituted with one or more substituents selected from the group consisting of halo, CN, NO2, NO, N3, ORa, NRaRb, C(O)Ra, C(O)ORa, C(O)NRaRb, NRbC(O)Ra, —S(O)bRa, —S(O)bNRaRb, or RS1;
wherein RS1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, or 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of O, N and S, b is 0, 1, or 2;
each of Ra and Rb, independently is H or RS2, and RS2 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, or 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of O, N and S; and
each of RS1 and RS2, is optionally substituted with one or more substituents selected from the group consisting of halo, OH, oxo, C(O)OH, C(O)O—C1-C6 alkyl, CN, C1-C6 alkyl, C1-C6 alkoxyl, amino, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C3-C8 cycloalkyl, C6-C10 aryl, and 5- or 6-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of O, N and S, and wherein said compound inhibits ASPH enzyme activity.

US Pat. No. 10,710,994

OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS

Genentech, Inc., South S...

1. A compound of formula I,
or a pharmaceutically acceptable salt thereof,
wherein:
A is selected from:

X is; a bond; C1-4 alkylene; —O—; —S—; —SO2—; or —N(Ra)—;
n is: 0, 1, 2 or 3;
Ra is H or C1-6 alkyl which may be unsubstituted or substituted one or more times with halo;
R1 is: H; or C1-6alkyl; and
each R2 is independently: H; D; —C1-4 alkyl; —C1-4 haloalkyl; C1-4 alkoxy; —CN, halo; halo-C1-4alkoxy; —OH; —SO2—C1-4alkyl; —C1-4CN, C1-4 aldehyde; C1-4 ketone; benzylamino; or NR14R15—;
each R3 is independently: H; D: —C1-4 alkyl; —C1-4 haloalkyl; —CN; NR14R15; or halo;
R4 is: substituted or unsubstituted phenyl; substituted or unsubstituted heteroaryl; or substituted or unsubstituted naphthyl;
or R1 and R4 may together form an unsubstituted or substituted C3-6cylcoalkyl fused to a substituted or unsubstituted phenyl; substituted or unsubstituted heteroaryl; or substituted or unsubstituted naphthyl,
p is 0, 1 or 2;
q is 0 or 1;
R14 and R15 are each independently: H; substituted or unsubstituted —C1-4 alkyl; substituted or unsubstituted —C(O)—C1-4 alkyl; substituted or unsubstituted C3-6 cycloalkyl; substituted or unsubstituted 3- to 6-membered heterocycloalkyl; substituted or unsubstituted —C1-4 heteroalkyl; —C(O)NR16R17; substituted or unsubstituted alkyl-C(O)NR16R17; substituted or unsubstituted phenyl; or substituted or unsubstituted benzyl;
or R14 and R15 together with the atoms to which they are attached may form a 4-, 5-, 6- or 7-membered ring that optionally includes one additional heteroatom selected from O, N and S; and
R16 and R17 each are independently H and C1-4 alkyl.

US Pat. No. 10,710,993

BENZOFURAN PYRAZOLE AMINE KINASE INHIBITOR

HANGZHOU REX PHARMACEUTIC...

1. A compound having the following general structural formula (I) or a pharmaceutically acceptable salt thereof:
Wherein R1 is selected from

R0, R8 and R9 are each independently selected from one or more of the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, acyl, amido, sulfo group, sulfanilamido, hydroxyl, aryl and heterocyclyl;
R2, R3, R4, R5, R6, R7, R10 and R11 are each independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, halogenated C1-6 alkyl, C1-6 alkoxy, halogenated C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, cyano and amino;
R13 is selected from one or more of the group consisting of hydrogen, C1-6 alkoxy, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-6 alkynyl, amido, boryl, amino, hydroxyl, cyano, carbonyl, carboxy, aryl and heterocyclyl;
R12 and R14 are each independently selected from one or more of the group consisting of hydrogen, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C3-6 cycloalkyl, amino, amido, hydroxyl, carbonyl, ureido, sulfuryl, sulfamido, phosphoroso, boryl, aryl and heterocyclyl;
R10 and R11 each substitute at the pyrimidine of the parent nucleus, or R10 and R11 are linked to each other to form a 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring fused with the pyrimidine of the parent nucleus;
the heterocyclyl is a 3-12 membered heterocyclic ring containing one or more of N and O atoms;
m is selected from any integer from 0 to 3; p is selected from any integer from 0 to 6; andn is 1 or 2.

US Pat. No. 10,710,991

PROCESS FOR THE PREPARATION OF THIETANE DERIVATIVES

Syngenta Participations A...

1. A process for preparing a compound of formula X
comprising
i. reacting a compound of formula VII

with triphenylphosphoranyldiene-acetonitrile or (Cyanomethyl)diethoxyphosphine oxide to give a compound of formula VIII

ii. reducing the compound of formula VIII with a suitable reducing agent to give a compound of formula X.

US Pat. No. 10,710,990

METHOD FOR PRODUCING GLYCERIC ACID ESTER

KAO CORPORATION, Tokyo (...

1. A method of producing a compound represented by the following formula (II), comprising a step of oxidatively esterifying Compound A, Compound A being represented by the following formula (I), with Compound B, Compound B being selected from an organic nitroxyl radical, an N-hydroxy form thereof, and a salt containing an oxo ammonium cation of them, and an oxidizing agent, and in the presence of a pyridine having an alkyl substituent, wherein the molar ratio of Compound B to Compound A (B:A) used in the oxidative esterification is in the range from 0.0001:1 through 0.1:1:
wherein, in the formula (I), R1 and R2 each independently represent a hydrogen atom or a monovalent hydrocarbon group, or R1 and R2 are bonded to each other to form a divalent hydrocarbon group for constituting a ring structure; and

wherein, in the formula (II), R1 and R2 each independently represent a hydrogen atom or a monovalent hydrocarbon group, or R1 and R2 are bonded to each other to form a divalent hydrocarbon group for constituting a ring structure.

US Pat. No. 10,710,988

PIPERAZINE DERIVATIVE

Astellas Pharma Inc., Ch...

9. A pharmaceutical composition, comprising a compound or salt thereof according to claim 8 and a pharmaceutically acceptable excipient.

US Pat. No. 10,710,987

HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION

Epizyme, Inc., Cambridge...

1. A method of preparing a solid crystalline form of a N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide monohydrochloride, wherein the solid crystalline form exhibits an X-ray powder diffraction pattern having two or more peaks expressed in degrees 2-theta (+/?0.2), selected from the group consisting of 8.438, 10.083, 10.18, 10.74, 10.940, 11.22, 12.0, 13.116, 13.318, 13.418, 13.541, 13.762, 13.899, 16.443, 16.583, 17.026, 17.124, 17.219, 17.53, 17.78, 18.032, 18.32, 18.340, 18.419, 18.66, 19.399, 20.182, 20.199, 20.421, 20.500, 20.839, 21.14, 21.84, 21.917, 21.958, 22.22, 22.499, 23.238, 23.46, 23.725, 24.159, 24.363, 24.7, 24.958, 25.498, 26.222, 26.596, 26.863, 27.72, 30.30, 30.557, and 30.879, comprising the step of combining N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide with hydrochloric acid.

US Pat. No. 10,710,986

PD-1/PD-L1 INHIBITORS

Gilead Sciences, Inc., F...

1. A compound which is:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,985

INDOLIN-2-ONE DERIVATIVES

Hoffmann-La Roche Inc., ...

1. A compound of formula (I)
wherein
A is phenyl or a five or six membered heteroaryl group, containing one or two N atoms, selected from

or the amide group —C(O)—NR1R2 may form together with two neighboring carbon atoms from the group A an additional fused ring, selected from
R1 and R2 are independently selected from hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, —(CH2)2-lower alkoxy, oxetanyl, cycloalkyl, or CH2-cycloalkyl, which cycloalkyl rings are optionally substituted by halogen;or R1 and R2 may form together with the N atom to which they are attached the group
andR3 is hydrogen or lower alkyl;or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,984

N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N-[(PYRIDINYLAMINO)-PROPANYL]ARYLCARBOXAMIDES

Boehringer Ingelheim Inte...

1. A compound selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,983

2,4-DIAMINO-PYRIMIDINE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS

Rigel Pharmaceuticals, In...

1. A compound having a formula 1or salt thereof, wherein:ring A is cycloaliphatic;
ring B is selected from

R1 is (C1-C10)alkyl, (C3-C10)cycloalkyl, aryl, or heteroaryl; and
R2 and R3 are independently hydrogen or (C1-C6)alkyl.

US Pat. No. 10,710,981

ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

BEIJING INNOCARE PHARMA T...

1. A compound of Formula II, or its stable isotope derivatives, stereoisomers, pharmaceutically acceptable salts thereof:wherein,R1 is H or —NHR3;
R3 is H, C1-6 alkyl or 4-6 membered heterocyclyl, wherein alkyl and heterocyclyl are optionally substituted by halogen, —OR5, C1-6 alkyl, C3-6 cycloalkyl or 4-6 membered heterocyclyl;
X is absent or is C1-6 alkylene;
Y is absent or is C3-6 cycloalkylene or 4-6 membered heterocyclylene;
Z is cyano,

bond a is a double bond or a triple bond;
in the case where bond a is a double bond, Ra, Rb and Rc are each independently H, cyano, halogen or C1-6 alkyl, wherein alkyl is optionally substituted by —OC1-2 alkyl, —N(C1-2 alkyl)2 or 4-6 membered heterocyclyl;
in the case where bond a is a triple bond, Ra and Rc are absent, and Rb is H, C1-6 alkyl, C3-6 cycloalkyl, or 3-6 membered heterocyclyl, wherein alkyl, cycloalkyl and heterocyclyl are optionally substituted by —OC1-2 alkyl or —N(C1-2 alkyl)2;
Ga, Gb, Gc, and Gd are each independently selected from the group consisting of H, halogen, cyano, C1-6 alkyl, —OR5, and —C(O)NR6R7; and
R5, R6 and R7 are each independently H or C1-6 alkyl.

US Pat. No. 10,710,979

EGFR KINASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF

ZHEJIANG BOSSAN PHARMACEU...

1. A compound of the following formula (I):
wherein:
X, Y are each independently selected from the group consisting of N, CH; with the proviso that X and Y are not CH at the same time;
R is selected from the group consisting of: unsubstituted 5-7 membered heterocycles, 5-7 membered heterocycles substituted by 1-5 substituents, C1-C6 alkyl-(unsubstituted 5-7 membered heterocycles), C1-C6 alkyl-(5-7 membered heterocycles substituted by 1-5 substituents), —NH-(unsubstituted 5-7 membered heterocycles), —NH-(5-7 membered heterocycles substituted by 1-5 substituents), —N(CH3)-(unsubstituted 5-7 membered heterocycles), —N(CH3)-(5-7 membered heterocycles substituted by 1-5 substituents), wherein the heterocycle contains at least one heteroatom selected from the group consisting of N, O and S; the substitution means one or more hydrogen atoms on the group are replaced by R1 substituents;
wherein the R1 is selected from the group consisting of: unsubstituted or halogenated C1-C6 alkyl, C3-C8 cycloalkyl, unsubstituted or halogenated C1-C6 alkoxy, C3-C8 cycloalkyloxy, —C(O)—R2, C2-C8 alkylacyl, C2-C8 alkoxyacyl, —S(O)2—R2, —SOR2;
the R2 is selected from the group consisting of unsubstituted or halogenated C1-C6 alkyl, unsubstituted or halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, C3-C8cycloalkoxy, —CH2—OAc, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2.

US Pat. No. 10,710,978

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

DANA-FARBER CANCER INSTIT...

1. A compound of the following formula:
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein:

is

X1 is N or CH;
X2 is N or CR6;
R1 is H, (C1-C3) alkyl, (C1-C3) alkoxy, NO2, halogen, O—(C3-C7) cycloalkyl, or O-benzyl;
R2 is H, (C1-C2) alkyl, (C2-C4) alkenyl, (C2-C4) alkynyl, (C1-C2) alkoxy, (CH2)0-2-heterocycloalkyl, halogen, NO2, CN, NR9C(O)R10, NR9R10, S(O)mNR9R10, NHS(O)m—(C3-C7) cycloalkyl, or (CH2)0-2-heteroaryl wherein the heteroaryl comprises a 5- to 6-membered ring and is optionally substituted with one or more substituents selected from halogen, (C1-C3) alkyl, and (C1-C3) alkoxy, wherein the alkyl, alkenyl, or alkynyl is optionally substituted with one or more substituents selected from NH2, NH(C1-C3) alkyl, and N((C1-C3) alkyl)2;
R3 is H, halogen, (C1-C3) alkyl, (C1-C3) alkoxy, NO2, C(O)NR11R12, NR11(O)R12, C(O)OR11, S(O)mR12, S(O)mNR11R12, NHS(O)m—(C3-C7) cycloalkyl, CN, or a 5- to 6-membered heteroaryl optionally substituted with one or more substituents selected from halogen, (C1-C3) alkyl, and (C1-C3) alkoxy, wherein the alkyl is optionally substituted with one or more substituents selected from NH2, NH(C1-C3) alkyl, and N((C1-C3) alkyl)2;
R4 is H, (C1-C3) alkyl, (C1-C3) alkoxy, NO2, halogen, O—(C3-C7) cycloalkyl, or O-benzyl;
R6 is H, halogen, (C1-C3) alkyl, (C1-C3) alkoxy, NO2, C(O)NR11R12, NR11C(O)R12, C(O)OR11, S(O)mR12, S(O)mNR11R12, NHS(O)m—(C3-C7) cycloalkyl, CN, or a 5- to 6-membered heteroaryl optionally substituted with one or more substituents selected from halogen, (C1-C3) alkyl, and (C1-C3) alkoxy, wherein the alkyl is optionally substituted with one or more substituents selected from NH2, NH(C1-C3) alkyl, and N((C1-C3) alkyl)2; or
R2 and R3, together with the atoms to which they are attached, form a 6-membered heterocycloalkyl optionally substituted with one or more R7, or a 5- to 6-membered heteroaryl optionally substituted with one or more R7; or
R2 and R6, together with the atoms to which they are attached, form a 6-membered heterocycloalkyl optionally substituted with one or more R7, or a 5- to 6-membered heteroaryl optionally substituted with one or more R7; or
R3 and R4, together with the atoms to which they are attached, form a 5- to 6-membered heteroaryl optionally substituted with one or more R8; or
R1 and R6, together with the atoms to which they are attached, form a 5- to 6-membered heteroaryl optionally substituted with one or more R8;
each R7 is independently (C1-C3) alkyl, (C1-C3) alkoxy, or halogen, or two R7, together with the carbon atom to which they are attached, form C(O);
each R8 is independently (C1-C3) alkyl, (C1-C3) alkoxy, or halogen, or two R8, together with the carbon atom to which they are attached, form C(O);
R9 and R10 are each independently H, (C1-C4) alkyl, (CH2)0-2-aryl, (CH2)0-2-heteroaryl, (CH2)0-2—(C3-C7) cycloalkyl, or (CH2)0-2-heterocycloalkyl;
R11 and R12 are each independently H, (C1-C4) alkyl, (C3-C7) cycloalkyl, or heterocycloalkyl;
each R5 is independently (C1-C4) alkyl, C(O)NR14R15, CN, OH, or halogen;
R14 and R15 are each independently H or (C1-C4) alkyl;
m is 0, 1, or 2; and
n is 1, 2, or 3
wherein at least one of R1, R2, R3, R4, and R6 is not H; and
provided that
when R2 is S(O)2NR9R10 or F, then R4 and R1 are not simultaneously H, and
when R2 is S(O)2NR9R10, then R4 or R1 is not Cl.

US Pat. No. 10,710,977

METHOD FOR PRODUCING GEOMETRICAL ISOMER OF OXIMINO COMPOUND

Nissan Chemical Corporati...

1. A process for stereoselectively producing an oximino compound which produces the E-isomer of an oximino compound represented by the following formula (E)-1:
or the Z-isomer of an oximino compound represented by the following formula (Z)-1:

from a mixture of geometrical isomers of an oximino compound represented by the following formula (EZ)-1:

produces the Z-isomer of the oximino compound represented by the formula (Z)-1 from the E-isomer of the oximino compound represented by the formula (E)-1, or produces the E-isomer of the oximino compound represented by the formula (E)-1 from the Z-isomer of the oximino compound represented by the formula (Z)-1, the method comprising:
(i) mixing a mixture of the geometrical isomers represented by the formula (EZ)-1 or the Z-isomer of the oximino compound represented by the formula (Z)-1 as a starting material with at most 0.1 equivalent of an acidic compound, relative to the starting material, in a solvent to produce the E-isomer of the oximino compound represented by the formula (E)-1, or
(ii) mixing a mixture of the geometrical isomers represented by the formula (EZ)-1 or the E-isomer of the oximino compound represented by the formula (E)-1 as a starting material with at least 0.7 equivalent of an acidic compound, relative to the starting material, in a solvent to produce the Z-isomer of the oximino compound represented by the formula (Z)-1.

US Pat. No. 10,710,976

COMPOUNDS, COMPOSITIONS AND METHODS

Cerecor Inc., Rockville,...

1. A crystalline Form II of Compound Iwherein Form II is obtained by converting Form I of Compound 1 having an X-ray powder diffraction pattern as shown in FIG. 1B to Form II having an X-ray powder diffraction pattern substantially as shown in FIG. 1A.

US Pat. No. 10,710,975

OXOPIPERAZINE DERIVATIVES

Inthera Bioscience AG, W...

1. A compound of formula (Ia)or a pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, wherein:R1 is selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, and C1-3 alkyl substituted by cycloalkyl, aryl, or heteroaryl, wherein the cycloalkyl, aryl, or the heteroaryl is optionally substituted by halogen, C1-4 alkyl, or C3-5 cycloalkyl;
R2 is selected from H, C(O)R14, C(O)NR15R15, C(O)OR15, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-5 alkyl-OR8, C1-3 alkanediyl-O—C1-3 alkanediyl-O—C1-3 alkanediyl, C1-5 alkyl-NHCOR13, and C1-3 alkyl substituted by cycloalkyl, aryl, or heteroaryl, wherein the cycloalkyl, aryl, or the heteroaryl is optionally substituted by halogen, C1-4 alkyl, or C3-5 cycloalkyl; with the proviso that when R2 is C(O)NR15R15, both R15 can form a ring wherein the ring contains the N of NR15R15 and optionally one further heteroatom selected from O and N, wherein if the one further heteroatom is N, the ring is optionally substituted by R8;
R3 and R7 are each independently selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, and C4-7 cycloalkenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl is optionally substituted by halogen, OR8, or NR8R11; or R3 and R7 are each independently C1-3 alkyl substituted by aryl or heteroaryl, wherein the aryl or the heteroaryl is optionally substituted by halogen, C1-4 alkyl, or C3-5 cycloalkyl;
R4 is selected from C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, and C1-3 alkyl substituted by cycloalkyl, aryl, or heteroaryl, wherein the cycloalkyl, aryl, or the heteroaryl is optionally substituted by halogen, C1-4 alkyl, or C3-5 cycloalkyl;
R5 is selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, OR8, C1-3 alkyl-OR8, and SR8; and wherein R5 can form a ring with any part of X or Y, wherein the ring optionally contains a carbonyl group;
R6 is selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, and C4-7 cycloalkenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl is optionally substituted by halogen, OR8, or NR8R11; or R6 is C1-3 alkyl substituted by C(O)NR8R11; or R6 is C1-3 alkyl substituted by aryl or heteroaryl, wherein the aryl or the heteroaryl is optionally substituted by halogen, C1-4 alkyl, or C3-5 cycloalkyl; and wherein R6 can form a ring with any part of X; or R6 is imidazolidinone;
R8 and R11 are each independently selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, and C4-7 cycloalkenyl;
X is selected from a bond, C1-7 alkanediyl, C2-7 alkenediyl, C2-7 alkynediyl, C3-9 cycloalkanediyl, C4-6 cycloalkenediyl, —O—, C1-3 alkanediyl-O—, —O—C1-7 alkanediyl, —O—C3-9 cycloalkanediyl, C1-3 alkanediyl-O—C1-7 alkanediyl, C1-7 heteroalkanediyl, and —S—C1-7 alkanediyl; and wherein X can form a ring or a polycyclic system with any part of R5, R6, or Y, wherein the ring optionally contains a carbonyl group;
Y is selected from H, C(O)NR10R12, C(O)OR10, R10NC(O)NR10R12, OC(O)R10, OC(O)NR10R12, S(O)nR8 wherein n is 0, 1 or 2, SO2NR10R12, NR10SO2R10, NR10R12, HNCOR8, CN, C3-7-cycloalkyl optionally containing a heteroatom in the ring selected from O and N, wherein if the heteroatom is N it is optionally substituted by R8, S-aryl, O-aryl, S-heteroaryl, and O-heteroaryl, wherein the S-aryl, O-aryl, S-heteroaryl, or O-heteroaryl is optionally substituted by one or more R9 or R14; or Y is aryl or heteroaryl, wherein the aryl or heteroaryl is optionally substituted by one or more of R8; and wherein Y can form a ring with any part of X or R5, wherein the ring optionally contains a carbonyl group; with the proviso that when Y is C(O)NR10R12 or NR10R12, R10 and R12 can form a ring wherein the ring contains the N of NR10R12 and optionally one further heteroatom selected from O and N, wherein if the one further heteroatom is N, the ring is optionally substituted by R8;
R9 is selected from H, halogen, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, C3-5 cycloalkyl, C1-5 alkyl-OR8, C1-5 alkyl-SR8, C1-5 alkyl-NR8R11, C1-5 alkyl-C(O)OR8, C1-5 alkyl-C(O)NR8R11, C1-5 alkyl-C(O)R10, CN, C(O)R8, C(O)NR8R11, C(O)OR8, NR8C(O)NR8R11R, OC(O)NR8R11, SO2NR8R11, NR8SO2R8, OR8, NR8R11, and S(O)nR8 wherein n is 0, 1 or 2;
R10 and R12 are each independently selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, C1-3 alkanediyl-O—C1-3 alkanediyl-O—C1-3 alkanediyl, C1-3 alkyl-aryl, and C1-3 alkyl-heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkanediyl, aryl, or heteroaryl is optionally substituted by halogen, OR8, or NR8R11;
R13 is C1-5 alkyl substituted by a bicyclic ring optionally containing at least one heteroatom and a carbonyl group;
R14 is selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, and C1-3 alkyl substituted by aryl or heteroaryl, wherein the aryl or the heteroaryl is optionally substituted by halogen, C1-4 alkyl, or C3-5 cycloalkyl; and
each R15 is independently selected from H, C1-7 alkyl, C2-7 alkenyl, C2-7 alkynyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, OR8, and C1-3 alkyl-OR8.

US Pat. No. 10,710,973

METHOD OF PRODUCING BERAPROST

Lung Biotechnology PBC, ...

1. A method of synthesizing a substantially pure salt of beraprost stereoisomer comprising converting an R1 group in a substantially pure ester compound of the following formula:into a cation to form the substantially pure salt of beraprost stereoisomer, wherein R1 is initially a C1-12 alkyl, each of R2 and R3 is H, and each of R4 and R5 is CH3.

US Pat. No. 10,710,972

METHOD FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN DERIVATIVES

Bayer CropScience Aktieng...

1. Method for preparing substituted 2,3-dihydro-1-benzofuran derivative of formula (I):in whichR1 is Cl (Ia), Br (Ib) or methyl (Ic),
comprising reacting an aniline of the formula (II)
in whichR1 is Cl, Br or methyl in the presence of one or more organic nitrite and organic or inorganic acids in one or more organic solvents to give a diazonium salt of formula (III),
in whichR1 is Cl, Br or methyl,
X? is a counterion of a organic or inorganic acid, which further reacts by heating to give one or more compounds of formula (I).

US Pat. No. 10,710,970

METHODS FOR PRODUCING 5-(HALOMETHYL)FURFURAL

MICROMIDAS, INC., West S...

1. A method for producing 5-(halomethyl)furfural, comprising: combining feedstock, acid, and salt to produce 5-(halomethyl)furfural, wherein:the feedstock comprises glucose, fructose, sucrose, starch, inulin, cellulose, hemicellulose, cellulosic oligomers, or cellobiose, or any combinations thereof;
the acid comprises halogen-containing mineral acid or halogen-containing organic acid, or any combinations thereof;
the acid is continuously added at a rate to maintain an average [H+] greater than 0 M and less than or equal to 8 M; and
the salt comprises inorganic salt or organic salt, or any combinations thereof,
wherein the combination of the feedstock, acid and salt has a [X?] of at least 8 M, wherein X? is halo.

US Pat. No. 10,710,969

PROCESS FOR PREPARING 2-EXO-(2-METHYLBENZYLOXY)-1-METHYL-4-ISOPROPYL-7-OXABICYCLO[2.2.1]HEPTANE

BASF AGRO B.V., Arnhem (...

1. A process for preparing (±)-2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane of the formula (I)
any one of its individual enantiomers or any non-racemic mixture thereof comprising the steps of
(a) reacting (±)-2-exo-hydroxy-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane of the formula (II)

any one of its individual enantiomers or any non-racemic mixture thereof with a 2-Methylbenzyl compound of the formula (III)

wherein X is a halogen in the presence of at least one alkali metal hydroxide capable of forming water under the reaction conditions, and at least one inert organic solvent, and
(b) simultaneously removing water from the reaction mixture by azeotropic distillation.

US Pat. No. 10,710,968

RADIOLABELED ERLOTINIB ANALOGS AND USES THEREOF

Hadasit Medical Research ...

1. A radiolabeled compound represented by general Formula Ia or Ib:
wherein:
the dashed line in Formula Ib denotes an optional unsaturated bond;
R1-R21, Ra and Rb are each hydrogen;
Rc and Rd are each absent, in case the dashed line denotes an unsaturated bond, or are each hydrogen; and
Y1 and Y2 are each independently selected from hydrogen, alkyl, cycloalkyl, alkoxy, hydroxyl, a substituted or unsubstituted, saturated or unsaturated hydrocarbon chain of 1 to 20 carbon atoms, optionally interrupted by one or more heteroatoms, a radioactive halogen, and Q,
wherein Q is a chemical moiety comprising a radioactive halogen,
provided that at least one of Y1 and Y2 is said radioactive halogen or said Q.

US Pat. No. 10,710,967

PYRIMIDINE DERIVATIVE

ASKA PHARMACEUTICAL CO., ...

1. A compound represented by the following general formula (1):
wherein, X represents carbonyl group, or sulfonyl group; R1 represents hydrogen atom, a halogen atom, an alkyl group, an alkanoyl group, cyano group, or carboxyl group; R2 represents an alkyl group, a cyclic carbon group which may have a substituent, or a heterocyclic group which may have a substituent; R3 represents hydrogen atom, or 1 to 3 substituents substituting on the benzene ring (these substituents are selected from the group consisting of a halogen atom, an alkyl group (this alkyl group may be substituted with a halogen atom), and an alkoxy group (this alkoxy group may be substituted with a halogen atom)); R4 and R5 independently represent hydrogen atom, a halogen atom, or an alkyl group; and R6 represents an alkyl group (this alkyl group may be substituted with hydroxy group, a halogen atom, or an alkoxy group), or an alkoxy group, or a salt thereof.

US Pat. No. 10,710,966

SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF

Pfizer Inc., New York, N...

1. A method of treating a subject having a desmoid tumor comprising administering to the subject a pharmaceutical composition, comprising a crystalline form of a hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide of Formula (I)
wherein the crystalline form is Form A characterized by an XRPD pattern having peaks at 8.8±0.2, 9.8±0.2, and 23.3±0.2 degrees two theta, and a pharmaceutically acceptable carrier.

US Pat. No. 10,710,965

PYRIDINE COMPOUND AND USE THEREOF

Nippon Soda Co., Ltd., T...

1. A pyridine compound represented by formula (I), an N-oxide compound thereof, or a tautomer or salt thereof,
in formula (I), R1 represents a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group, an unsubstituted or G1-substituted C2-6 alkenyl group, an unsubstituted or G1-substituted C1-6 alkoxycarbonyl group, an unsubstituted or G1-substituted C1-6 alkylthio group, an unsubstituted or G1-substituted C1-6 alkylaminocarbonyl group, an unsubstituted or G2-substituted C6-10 aryl group, a cyano group or a halogeno group,
in formula (I), R2 represents a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group, an unsubstituted or G1-substituted C2-6 alkenyl group, an unsubstituted or G2-substituted C3-8 cycloalkyl group, a formyloxy group, an unsubstituted or G1-substituted C1-6 alkylcarbonyloxy group, an unsubstituted or G2-substituted C6-10 aryl group, an (unsubstituted or G1-substituted C1-6 alkoxyimino)-C1-6 alkyl group, an unsubstituted or G2-substituted 3- to 10-membered heterocyclyl C1-6 alkyl group, a cyano group or a halogeno group,
in formula (I), R3 represents a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group, an unsubstituted or G1-substituted C2-6 alkenyl group, an unsubstituted or G2-substituted C3-8 cycloalkyl group, an unsubstituted or G1-substituted C1-6 alkoxy group, an unsubstituted or G1-substituted C1-6 alkylcarbonyl group, an unsubstituted or G1-substituted C1-6 alkoxycarbonyl group, a carboxyl group, a formyl group, a formyloxy group, an unsubstituted or G1-substituted C1-6 alkylcarbonyloxy group, an unsubstituted or G2-substituted C6-10 aryl group, an unsubstituted or G2-substituted 3- to 10-membered heterocyclyl group, an (unsubstituted or G1-substituted C1-6 alkoxyimino)-C1-6 alkyl group, an unsubstituted or G1-substituted mono C1-6 alkylamino group, an unsubstituted or G1-substituted di C1-6 alkylamino group, a cyano group or a halogeno group,
in formula (I), R4 represents a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group, an unsubstituted or G1-substituted C2-6 alkenyl group, an unsubstituted or G1-substituted C2-6 alkynyl group, an unsubstituted or G2-substituted C3-8 cycloalkyl group, an unsubstituted or G2-substituted C6-10 aryl C1-6 alkyl group, an unsubstituted or G2-substituted 3- to 10-membered heterocyclyl C1-6 alkyl group, a formyl group, an unsubstituted or G1-substituted C1-6 alkylcarbonyl group, an unsubstituted or G2-substituted C3-8 cycloalkylcarbonyl group, an unsubstituted or G1-substituted C2-6 alkenylcarbonyl group, an unsubstituted or G2-substituted C6-10 arylcarbonyl group, an unsubstituted or G1-substituted C1-6 alkoxycarbonyl group, an unsubstituted or G1-substituted C2-6 alkenyloxycarbonyl group, an unsubstituted or G1-substituted C1-6 alkylsulfonyl group, an unsubstituted or G1-substituted C1-6 alkylaminocarbonyl group, an unsubstituted or G1-substituted (C1-6 alkylthio) carbonyl group, an unsubstituted or G1-substituted C1-6 alkylamino (thiocarbonyl) group or an organic group represented by formula (II),

in formula (II), * represents bonding site,
in formula (II), each Ga independently represents a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group, an unsubstituted or G1-substituted C2-6 alkenyl group, an unsubstituted or G1-substituted C2-6 alkynyl group, an unsubstituted or G2-substituted C3-8 cycloalkyl group, or an unsubstituted or G2-substituted C6-10 aryl group,
in formula (II), Gb represents a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group, an unsubstituted or G1-substituted C2-6 alkenyl group, an unsubstituted or G1-substituted C2-6 alkynyl group, an unsubstituted or G2-substituted C3-8 cycloalkyl group, an unsubstituted or G2-substituted C6-10 aryl group, or an unsubstituted or G2-substituted 3- to 10-membered heterocyclyl group,
in formula (II), T represents an oxygen atom, an oxycarbonyl group, a carbonyloxy group, an oxycarbonyloxy group, a sulfur atom, a (thio) carbonyl group, a carbonyl (thio) group, a (thio) carbonyloxy group, an oxycarbonyl (thio) group or a divalent group represented by —O—C(?O)—N(Gb)-,
in formula (I), A represents an oxygen atom or a divalent organic group represented by formula (III),

in formula (III), * represents bonding site,
in formula (III), R5 and R6 each independently represent a hydrogen atom, an unsubstituted or G1-substituted C1-6 alkyl group, an unsubstituted or G1-substituted C1-6 alkoxy group, an unsubstituted or G2-substituted C6-10 aryloxy group, an unsubstituted or G1-substituted alkoxycarbonyloxy group, a halogeno group, a hydroxyl group, R5 and R6 may bond to form a 3- to 6-membered ring together with the carbon atom to which R5 and R6 are bonded,
in formula (I), Cy represents an unsubstituted or G2-substituted C6-10 aryl group, a G2-substituted C3-8 cycloalkyl group, an unsubstituted or G2-substituted 3- to 10-membered heterocyclyl group or a 13-membered heteroaryl group,
G1 represents a hydroxyl group, a C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkoxy group, a C1-6 alkoxycarbonyl group, a formyloxy group, a C1-6 alkylcarbonyloxy group, a C1-6 alkoxycarbonyloxy group, a mono C1-6 alkoxycarbonylamino group, a cyano group, an amino group or a halogeno group, when there are two or more G1-substituted groups, such G's may be the same as or different from each other,
G2 represents an unsubstituted or G21-substituted C1-8 alkyl group, an unsubstituted or G1-substituted C2-6 alkenyl group, an unsubstituted or G1-substituted C2-6 alkynyl group, a hydroxyl group, an unsubstituted or G1-substituted C1-6 alkoxy group, a formyl group, an unsubstituted or G1-substituted C1-6 alkylcarbonyl group, an unsubstituted or G1-substituted C1-6 alkoxycarbonyl group, a formyloxy group, an unsubstituted or G1-substituted C1-6 alkylcarbonyloxy group, a formylamino group, an unsubstituted or G21-substituted mono C1-6 alkylcarbonylamino group, an unsubstituted or G1-substituted N—(C1-6 alkylcarbonyl)-N—(C1-6 alkyl) amino group, an unsubstituted or G1-substituted N—(C1-6 alkylcarbonyl)-N—(C1-6 alkoxycarbonyl) amino group, an unsubstituted or G1-substituted C1-6 alkoxycarbonyloxy group, an unsubstituted or G21-substituted mono C1-6 alkoxycarbonylamino group, an unsubstituted or G22-substituted C3-8 cycloalkyl group, an unsubstituted or G22-substituted C3-8 cycloalkenyl group, an unsubstituted or G1-substituted C 3-8 cycloalkylcarbonylaminocarbonyl group, an unsubstituted or G22-substituted C6-10 aryl group, an unsubstituted or G22-substituted C6-10 aryl C2-6 alkynyl group, an unsubstituted or G22-substituted C6-10 aryloxy group, an unsubstituted or G22-substituted 3- to 10-membered heterocyclyl group, a 13-membered heteroaryl group, an unsubstituted or G22-substituted 3- to 10-membered heterocyclyloxy group, a mercapto group, an unsubstituted or G1-substituted C1-6 alkylthio group, an unsubstituted or G1-substituted C1-6 alkylsulfinyl group, an unsubstituted or G1-substituted C1-6 alkylsulfonyl group, a pentafluorosulfanyl group, an unsubstituted or G22-substituted unsubstituted C6-10 arylthio group, an unsubstituted or G22-substituted C6-10 arylsulfinyl group, an unsubstituted or G22-substituted C6-10 arylsulfonyl group, an unsubstituted or G22-substituted monovalent C6-10 arylamino group, a dihydroboryl group, a nitro group, a cyano group, a halogeno group, an unsubstituted or G1-substituted C1-6 alkylene group, an unsubstituted or G1-substituted C1-6 alkylene monooxy group, an unsubstituted or G21-substituted C1-6 alkylenedioxy group, a group represented by —CRa?NRb,
here, Ra represents a hydrogen atom, a C1-6 alkyl group, an unsubstituted or G21-substituted mono C1-6 alkylcarbonylamino group, or an unsubstituted or G22-substituted mono C 3-8 cycloalkylcarbonylamino group, Rb represents an unsubstituted or G21-substituted C1-6 alkoxy group, an unsubstituted or G22-substituted C3-8 cycloalkoxy group, an unsubstituted or G22-substituted phenoxy group, an unsubstituted or G21-substituted mono C1-6 alkylamino group, or an unsubstituted or G21-substituted di C1-6 alkylamino group, when there are two or more G2-substituted groups, such G2s may be the same as or different from each other,
G21 represents a C1-6 alkoxy group, a C1-6 haloalkoxy group, a mono C1-6 alkylamino group, a di C1-6 alkylamino group, a mono (C1-6 alkoxy C1-6 alkylcarbonyl) amino group, an unsubstituted or G211-substituted C6-10 aryl group, an unsubstituted or G211-substituted C6-10 aryloxy group, an unsubstituted or G211-substituted 3- to 10-membered heterocyclyl group, an unsubstituted or G211-substituted 3- to 10-membered heterocyclyloxy group or a halogeno group, when there are two or more G21-substituted groups, such G21s may be the same as or different from each other,
G211 represents a C1-6 alkyl group, a C1-6 haloalkyl group, a C1-6 alkoxy group, a C1-6 haloalkoxy group or a halogeno group, when there are two or more G211-substituted groups, such G211s may be the same as or different from each other,
G22 represents an unsubstituted or hydroxyl-substituted C1-6 alkyl group, a C1-6 haloalkyl group, a C2-6 alkenyl group, a C2-6 haloalkenyl group, a C2-6 alkynyl group, a C1-6 alkoxy group, a C1-6 haloalkoxy group, a C1-6 alkylcarbonyl group, a mono C1-6 alkylamino group, a di C1-6 alkylamino group, a C1-6 alkylaminocarbonyl group, a C1-6 alkylthio group, a C1-6 haloalkylthio group, a C1-6 alkylsulfinyl group, a C1-6 haloalkylsulfinyl group, a C1-6 alkylsulfonyl group, a C1-6 haloalkylsulfonyl group, an unsubstituted or G221-substituted C3-8 cycloalkyl group, an unsubstituted or G221-substituted C3-8 cycloalkyl C1-6 alkyl group, an unsubstituted or G221-substituted C 6-10 aryl group, an unsubstituted or G221-substituted 3- to 10-membered heterocyclyl group, an unsubstituted or G221-substituted 3- to 10-membered heterocyclylcarbonyl group, a pentafluorosulfanyl group, a nitro group, a cyano group, a halogeno group, an oxo group, an unsubstituted or G211-substituted C1-6 alkylenedioxy group or a group represented by —CRc?NORd, here, Rc represents a C1-6 alkyl group, Rd represents an unsubstituted or G221-substituted C3-8 cycloalkyl group, when there are two or more G22-substituted groups, such G22s may be the same as or different from each other,
G221 represents a C1-6 alkyl group, a C1-6 haloalkyl group, a C1-6 alkoxy group, a C1-6 haloalkoxy group, a mono C1-6 alkylamino group, a di C1-6 alkylamino group, a C6-10 aryl group or a halogeno group, when there are two or more G221-substituted groups, such G221's may be the same as or different from each other.

US Pat. No. 10,710,964

ORGANIC ELECTROLYTE COMPOUNDS FOR REDOX-FLOW BATTERIES

FUNDACION CENTRO DE INVES...

1. A redox organic electrolyte comprising a compound selected from:
wherein in the compound of formula (i):
R1-R6 are independently selected from the group consisting of hydrogen; C1-C6 alkyl, optionally substituted with at least one halogen and/or optionally having at least one of O- and N-atom in the alkyl chain; CO2H; OH; NR15R16 and SO3?M+;
provided that at least one of R1-R6 is SO3?M+ and
wherein M+ is a cation selected from the group consisting of ammonium cation, phosphonium cation, imidazolium cation and mixtures thereof;
wherein in the compound of formula (iii):
R7-R14 are independently selected from the group consisting of hydrogen; C1-C6 alkyl, optionally substituted with at least one halogen and/or optionally having at least one of O- and N-atom in the alkyl chain; CO2H; OH; NR15R16 and SO3?M+;
provided that two of R7-R14 are SO2?M+ and
wherein:
R15 and R16 are independently selected from the group consisting of H and C1-C6 alkyl; and
M+ is a cation selected from the group consisting of ammonium cation, phosphonium cation, imidazolium cation and mixtures thereof.

US Pat. No. 10,710,962

ZWITTERIONIC REAGENTS

Siemens Healthcare Diagno...

1. A zwitterion-containing compound for labeling an analyte, analyte analog, or binding partner for an analyte having the structure of formula (II):
wherein,
L1 and L3, are independently selected at each occurrence from divalent C1-20 alkyl, alkenyl, alkynyl, aryl, or aralkyl groups, each optionally substituted with up to 20 heteroatoms;
L2 is a bond or a divalent C1-4 alkyl, alkenyl, or alkynyl group, optionally substituted with up to 10 heteroatoms;
Z is an anion-containing group selected from the group consisting of carboxylate (—COO?), sulfonate (SO3?), sulfate (—OSO3?), phosphate (—OP(O)(OR)(O?), and oxide (—O?1), where R is a C1-12 alkyl, alkenyl, alkynyl, aryl, or aralkyl, optionally substituted with up to 20 heteroatoms;
Y1 is a reactive functional group for forming covalent linkages with an analyte, analyte analog, or binding partner for an analyte, said functional group comprising a electrophilic group, nucleophilic group, or a photoreactive group;
G is a fluorescent label or biotin; and
R1 is a C1-20 alkyl, alkenyl, alkynyl, aryl, or aralkyl, optionally substituted with up to 20 heteroatoms.

US Pat. No. 10,710,961

METHOD FOR PREPARING INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE

Daewoong Pharmaceutical C...

1. A method for preparing a compound represented by the following Chemical Formula 1, comprising the steps of:1) reacting a compound represented by the following Chemical Formula 1-1 with a compound represented by the following Chemical Formula 1-2 to prepare a compound represented by the following Chemical Formula 1-3;
2) reacting a compound represented by the following Chemical Formula 1-3 with acetic anhydride in the presence of any one base selected from the group consisting of potassium carbonate, potassium hydrogen carbonate, sodium carbonate, sodium hydrogen carbonate, and cesium carbonate to prepare a compound represented by the following Chemical Formula 1-4;
3) reacting a compound represented by the following Chemical Formula 1-4 in the presence of a base to prepare a compound represented by the following Chemical Formula 1-5; and
4) reacting a compound represented by the following Chemical Formula 1-5 with dimethyl sulfate in the presence of a base to prepare a compound represented by the following Chemical Formula 1:

US Pat. No. 10,710,960

CARBON SULFUR MATERIAL AND METHOD FOR PRODUCING SAME

National Institute of Adv...

1. A sulfur material comprising carbon, hydrogen, sulfur, oxygen, and nitrogen as constituent elements, and having a peak of 2473±0.5 eV in an S K-edge X-ray absorption fine structure spectrum, the peak being of highest intensity in the spectrum, wherein the sulfur material has a carbon content of 30 to 45 wt %, a sulfur content of 55 to 70 wt %, a hydrogen content of 0.01 to 1 wt %, an oxygen content of 0.01 to 1 wt %, and a nitrogen content of 0.01 to 1 wt %.

US Pat. No. 10,710,959

SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT

NOVIRA THERAPEUTICS, INC....

1. A compoundselected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,710,957

MOTUPORAMINE DERIVATIVES AS ANTIMICROBIAL AGENTS AND ANTIBIOTIC ENHANCERS AGAINST RESISTANT GRAM-NEGATIVE BACTERIA

University of Central Flo...

1. A method of treating a microbe infection in a subject in need of treatment, comprising administering an effective amount of one or more compounds of the following formula:where n=10-13; X=CH; Y=CH2 or N; a=2-8; b=0-8; R1=H or alkyl or alkylamino or alkyl-N-alkylamino or alkylpolyamino; alkylalcohol or alkyl-O-alkylamino or polyether; alkylamide and R2=H or Me; or a pharmaceutically acceptable salt thereof;or a pharmaceutically acceptable salt thereof;and optionally co-administering an antibiotic.

US Pat. No. 10,710,956

PROCESS FOR THE PREPARATION OF ACRYLATE ESTERS FROM ALKYL LACTATES

REGENTS OF THE UNIVERSITY...

1. A process for the preparation of an alkyl 2-(propionyloxy)propanoate of formula I:
or a salt thereof, the process comprising contacting an alkyl lactate of formula II:

or a salt thereof, with carbon monoxide, ethylene, a phosphine reagent, and a palladium compound under conditions sufficient to form an alkyl 2-(propionyloxy)propanoate of formula I;
wherein R1 is selected from H, C1-C12 alkyl, and C6-C20 aryl, where alkyl and aryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CN, —NH2, —NHCH3, —N(CH3)2, —NHS(O)2CH3, —NO2, —OH, —OCH3, —OCH2CH3, —OCH2CH2OCH3, —OCH2CH2OH, —OCH2CH2N(CH3)2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —S(O)2CH3, and —S(O)3H;
the palladium compound is selected from Pd(OAc)2, Pd(OTs)2(MeCN)2, Pd(OCOCF3)2, Pd(BF4)2(MeCN)2, Pd(BArF4)2(MeCN)2, Pd(PF6)2(MeCN)2, PdX2 where X is Cl, Br, or I, and Pd(OTf)2(MeCN)2; and
the phosphine reagent is selected from the group consisting of triphenylphosphine, P(t-Bu)3, P(o-Tol)3, dppf, and dppe.

US Pat. No. 10,710,954

CONVERSION OF WOOD BASED HEMICELLULOSE PREHYDROLYSATE SUCCINIC ACID USING A HETEROGENEOUS ACID CATALAYST IN A BIPHASIC SYSTEM

1. A method of synthesizing succinic acid comprising:mixing a source of aqueous xylose with an organic solvent having low water solubility at a ratio of 1:1 to 1:5, wherein the organic solvent is selected from the group consisting of toluene, chloroform and ethyl acetate;
adding a suitable acid, thereby converting the xylose to furfural;
recovering an organic solvent phase comprising the furfural; and
adding hydrogen peroxide to the organic solvent phase comprising the furfural at a ratio of hydrogen peroxide to furfural of 1:1 to 1:5 in the presence of a macroreticular ion exchange catalyst having high acidic strength, said furfural transferring from the organic solvent phase to an aqueous phase comprising hydrogen peroxide and converting to succinic acid in the aqueous phase.

US Pat. No. 10,710,951

PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE

SHIN POONG PHARMACEUTICAL...

1. A verbenone derivative represented by a following Formula 1 or a pharmaceutically acceptable salt thereof:
wherein R1, R2, R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, a C1-C3 alkyl group, a C1-C3 alkoxy group, an amino group, a C1-C3 alkylamine group, a C1-C3 alkyldiamine group, a C5-C8 aromatic ring, a C5-C8 cyclic ring, or a C5-C8 heteroaromatic ring;
X, Y and Z are each independently a carbon atom, N atom, O atom or S atom; and
denotes a double bond or a single bond.

US Pat. No. 10,710,948

PROCESSES FOR PREPARING (R)-1-(5-CHLORO-[1,1?-BIPHENYL] -2-YL)-2,2,2-TRIFLUOROETHANOL AND 1-(5-CHLORO-[1,1?-BIPHENYL]-2-YL)-2,2,2-TRIFLUOROETHANONE

Roivant Sciences GmbH, B...

1. A process of preparing a compound of Formula A:comprising reducing a compound of Formula B:in the presence of a chiral catalyst.

US Pat. No. 10,710,947

METHOD FOR IMPROVING THE MANUFACTURE OF ETHYLENE GLYCOL

Scientific Design Company...

1. A method for improving the manufacture of an existing ethylene glycol manufacturing process comprising:(a) supplying a pipe reactor feedstream comprising ethylene oxide and water to a non-catalytic glycol reactor;
(b) reacting the ethylene oxide and water in the non-catalytic glycol reactor to produce a product stream;
(c) modifying the supply of the pipe reactor feedstream as follows:
providing a catalytic hydration feedstream containing ethylene oxide and water;
combining the catalytic hydration feedstream with a recirculation split stream to form a first reactor inlet stream;
supplying the first reactor inlet stream to an inlet of a first adiabatic reactor, the inlet of the first adiabatic reactor being at a first inlet temperature;
reacting the ethylene oxide and water contained in the first reactor inlet stream in the presence of a first ion exchange resin catalyst in the first adiabatic reactor to produce an effluent stream containing water, ethylene glycol, and unreacted ethylene oxide;
further combining the effluent stream with a recirculation supply stream to form a combined stream containing water, ethylene glycol and unreacted ethylene oxide;
supplying the combined stream to an inlet of a second adiabatic reactor, the inlet of the second adiabatic reactor being at a second inlet temperature;
reacting ethylene oxide and water contained in the combined stream in the presence of a second ion exchange resin catalyst in the second adiabatic reactor to produce a second reactor effluent stream containing water, ethylene glycol, and unreacted ethylene oxide;
compressing the second reactor effluent stream;
dividing the second reactor effluent stream into a recirculation stream and a forward stream;
dividing the recirculation stream into the split recirculation stream and the supply recirculation stream; and
supplying the forward stream as the pipe reactor feedstream to a non-catalytic pipe reactor to produce a product stream wherein a total concentration of diethyelene glycol (DEG), triethylene glycol (TEG) and higher glycols in the product stream is greater than the total concentration of DEG, TEG and higher glycols in the forward stream.

US Pat. No. 10,710,944

METHOD OF PREPARING BUTADIENE

LG CHEM, LTD., Seoul (KR...

1. A method of preparing butadiene, comprising:subjecting reaction raw materials containing butene, oxygen (O2), steam, and butane to an oxidative dehydrogenation reaction to produce oxidative dehydrogenation reaction products comprising butadiene, n-butane, butene, oxygen, water and COx;
separating water from the oxidative dehydrogenation reaction products by cooling;
compressing and cooling with a refrigerant the oxidative dehydrogenation reaction products from which water is separated to produce a first stream comprising oxidative dehydrogenation reaction products containing uncondensed hydrocarbons and a second stream comprising crude hydrocarbons including butadiene, n-butane and butene,
wherein the refrigerant used in the compressing and cooling is one or more selected from the group consisting of: cooling water, ethylene glycol, an aqueous solution of ethylene glycol having a concentration of 20 to 100% by weight, propylene glycol, an aqueous solution of propylene glycol having a concentration of 30 to 100% by weight, and a propylene-based solvent;
subjecting the first stream to absorption separation under conditions wherein a noncombustible diluent gas is fed, thereby separating COx, O2;
(i) purifying the second stream to separate butadiene therefrom; or ii) degasifying the second stream to additionally separate COx and O2, and then purifying the second stream to separate butadiene therefrom,
recycling a gas comprising n-butane remaining after butadiene is separated in the purifying step into the oxidative dehydrogenation reaction in a third stream; and
mixing a fourth stream containing butene remaining after butadiene is separated in the purifying step with butene supplied as raw material to the oxidative dehydrogenation reaction.

US Pat. No. 10,710,943

PROCESSES FOR ISOMERIZING HYDROCARBONS

UOP LLC, Des Plaines, IL...

1. A process for isomerizing a hydrocarbon feed stream comprising at least one of C4 to C7 hydrocarbons, the process comprising:drying the hydrocarbon feed stream in a drying zone configured to remove water from the hydrocarbon feed stream and provide a dried hydrocarbon feed stream;
absorbing chlorides from a gaseous stream with the dried hydrocarbon feed stream in a vessel comprising an absorbing section configured to provide a chloride rich hydrocarbon feed stream and a chloride lean vapor, wherein a temperature of the dried hydrocarbon feed stream at an inlet of the vessel is substantially equal to a temperature of the dried hydrocarbon feed stream at the drying zone;
isomerizing the chloride rich hydrocarbon feed stream with an isomerization catalyst in an isomerization reaction zone under isomerization conditions to produce an isomerized effluent stream; and,
stabilizing the isomerized effluent stream in a stabilizing zone to provide a stabilizer off-gas stream comprising chlorides and a liquid isomerate stream, wherein at least a portion of the stabilizer off-gas stream comprises the gaseous stream.

US Pat. No. 10,710,942

METHOD OF CO-PROCESSING FLUIDIZED CATALYTIC CRACKING NAPHTHA AND PYROLYSIS GASOLINE

SABIC GLOBAL TECHNOLOGIES...

1. An integrated process for forming a combined feedstock stream comprising a pyrolysis gasoline stream and a full range cracked naphtha stream to produce a plurality of olefin streams and a plurality of aromatic hydrocarbon streams, comprising:catalytically cracking a first hydrocarbon feedstock and separating the catalytically cracked first hydrocarbon feedstock to form a full range cracked naphtha stream and a first light olefins stream wherein the first light olefins stream comprises ethylene, propylene, butadiene and/or any combination thereof;
steam cracking a second hydrocarbon feedstock and separating the steam cracked second hydrocarbon feedstock to form a heavy pyrolysis oil stream, a pyrolysis gasoline stream and a second light olefins stream wherein the second light olefins stream comprises ethylene, propylene, butadiene and/or any combination thereof;
mixing at least a portion of the full range cracked naphtha stream and at least a portion of the pyrolysis gasoline stream to form a combined stream;
hydro-processing the combined stream and separating the hydro-processed effluent stream to form a hydro-processed combined stream and a light pyrolysis oil stream;
splitting the hydro-processed combined stream into:
a C5/C6 stream; and
a first aromatic rich stream comprising aromatic C6 molecules, aromatic C7 molecules, aromatic C8 molecules, aromatic C9 molecules and/or any combination thereof; and
splitting the first aromatic rich stream into:
a second aromatic rich stream; and
a heavy oil stream.

US Pat. No. 10,710,941

DIAMONDOID FUELS

The United States of Amer...

1. A diamondoid fuel, consisting of:a structure selected from one of i, ii, iii, iv:



andwhere R, R?, R?, and R?? are one of:
i) two hydrogens or two alkyl groups with 1 to 20 carbons, an allyl group, and a cyclopropyl group;
ii) one hydrogen or one alkyl group with 1 to 20 carbons, two allyl groups, and a cyclopropyl group; or
iii) one hydrogen or one alkyl group with 1 to 20 carbons, two cyclopropyl groups, and an allyl group.

US Pat. No. 10,710,940

TURBULENT FLUIDIZED-BED REACTOR, DEVICE, AND METHOD USING OXYGEN-CONTAINING COMPOUND FOR MANUFACTURING PROPENE AND C4 HYDROCARBON

DALIAN INSTITUTE OF CHEMI...

1. A turbulent fluidized-bed reactor for preparing propylene and C4 hydrocarbons from oxygen-containing compounds, comprising:a reactor shell, one or more reactor feed distributors, a first reactor gas-solid separator, a second reactor gas-solid separator, a reactor heat extractor, a product gas outlet and a reactor stripper, wherein the lower part of the turbulent fluidized-bed reactor is a reaction zone, the upper part of the turbulent fluidized-bed reactor is a settling zone, the one or more reactor feed distributors are disposed in the reaction zone, the reactor heat extractor is disposed in the reaction zone, the first reactor gas-solid separator and the second reactor gas-solid separator are placed in the settling zone or outside the reactor shell, the first reactor gas-solid separator is equipped with a regenerated catalyst inlet, the catalyst outlet of the first reactor gas-solid separator is located at the bottom of the reaction zone, the gas outlet of the first reactor gas-solid separator is located in the settling zone, the inlet of the second reactor gas-solid separator is located in the settling zone, the catalyst outlet of the second reactor gas-solid separator is placed in the reaction zone, the gas outlet of the second reactor gas-solid separator is connected to the product gas outlet, the reactor stripper passes through the reactor shell from outside to inside at the bottom of the turbulent fluidized-bed reactor and is opened in the reaction zone of the turbulent fluidized-bed reactor, a reactor stripping gas inlet is arranged at the bottom of the reactor stripper, and a spent catalyst outlet is arranged at the bottom of the reactor stripper.

US Pat. No. 10,710,939

COATED INORGANIC MATERIALS AND METHODS FOR FORMING THE COATED INORGANIC MATERIALS

GreenTechnologies, LLC, ...

1. A method of preparing a fertilizer composition comprising:contacting a first inorganic fertilizer material, the first inorganic fertilizer material comprising a plurality of granules of one or more inorganic fertilizer selected from the group consisting of ammonium nitrate, potassium nitrate, calcium nitrate, calcium ammonium nitrate, calcium chloride, calcium carbonate, urea, potassium sulfate, diammonium phosphate, monoammonium phosphate, ammonium sulfate, rock phosphate, potassium chloride, potassium carbonate, magnesium sulfate, and potassium magnesium sulfate, and a combination thereof;
with ammonium sulfate, calcium nitrate, and water;
and mixing, wherein in said contacting and mixing, the ammonium sulfate and calcium nitrate react, to produce, on said first inorganic fertilizer material, a coating comprising calcium sulfate dihydrate and ammonium nitrate;
and drying;
to prepare the fertilizer composition.

US Pat. No. 10,710,937

EXTRACTION OF AMINO ACIDS AND PHOSPHORUS FROM BIOLOGICAL MATERIALS

The United States of Amer...

1. A method for separating phosphorus and protein from biological materials, comprising:conducting an acid extraction by mixing together (a) a sugar or a sugar-containing mixture, (b) an inoculum, and (c) a biological material to create a fermentation mixture, then conducting a fermentation process to acidify the fermentation mixture, to produce an acidic supernatant and an acidic precipitate;
separating the acidic supernatant from the acidic precipitate;
conducting a protein extraction by adding an alkaline solution to the acidic precipitate and mixing the alkaline solution with the acidic precipitate to produce a basic supernatant and a basic precipitate;
separating the basic supernatant from the basic precipitate; and
recovering an amount of phosphorus from the acidic supernatant and recovering an amount of protein from the basic supernatant.